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ABSTRACT 
Sheena Hailin Wang: Novel Delivery Systems for Nasal Administration of  
Anthrax Vaccine 
(Under the direction of Dr. Anthony J. Hickey, Ph.D., D.Sc.) 
 
There is current biodefense interest in protection against Anthrax. The inhaled form of 
anthrax is difficult to diagnose and can be fatal without prompt antibiotic intervention. 
Prophylactic vaccination has become a critical measure for protection of individuals at risk of 
exposure. This thesis makes the efforts to develop a new generation of stable, effective and 
affordable anthrax vaccine. 
This project studies the immune response elicited by rPA with a mast cell activator, 
Compound 48/80 as adjuvant. The vaccine formulation was prepared in a dry powder form 
by spray-freeze-drying (SFD) under optimized conditions to produce particles with a target 
size of 25µm median diameter, suitable for rabbit nasal delivery. Physicochemical properties 
of the powder vaccines were characterized in order to assess the powder delivery and storage 
potentials. Structural stability of PA after the SFD process and storage were confirmed by 
two spectroscopic techniques (CD and ATR-FTIR), while functional stability of both the 
antigen and adjuvant were monitored via cell-based assays. Animal studies were performed 
to evaluate the in vivo efficacy of the powder vaccines in rabbits using a Unitdose powder 
device. Results showed that C48/80 is an effective mucosal adjuvant in rabbits. SFD powder 
formulations freshly prepared or stored for over two years at room temperature were able to 
elicit a significant serum anti-body and functional titer comparable to IM injection.  
iv 
 
An in-situ formed hydrogel delivery was proposed as a compliment to the moisture 
sensitive dry powder formulation, which would offer flexibility in terms of dosing. The 
hydrogel precursor, a small peptide derivative, was prepared and purified. In vitro 
experiments demonstrated hydrogel formation in the presence of reconstituted powder 
formulation. Rheology studies showed instant hydrogel formation and in vivo mucoadhesive 
behavior is expected given successful enzymatic conversion. In vitro release studies have 
shown that the formulation is suitable for nasal delivery of soluble antigen rPA. Powder 
hydrogel combined formulation is feasible as nasal product. Initial animal study has been 
conducted, yet future work is needed to identify optimal conditions for the hydrogel-powder 
combined formulation.  
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1 INTRODUCTION 
 
1.1 Anthrax and its Current Vaccine Status 
1.1.1 Anthrax history and epidemiology  
Anthrax is a deadly zoonotic disease caused by a spore forming, rod shaped gram 
positive bacterium, Bacillus anthracis. Anthrax infection occurs mainly in herbivores, such 
as sheep, goat, cattle, and horses. Anthrax spores can be found in soil, or wool, hair, animal 
hides, bone and the carcasses of infected animals, which are responsible for the spread of 
infection to herbivores and other animals as well as humans
1
. Human infections are often 
consequences of contact with infected animals or contaminated animal products 
1, 2
. 
Cutaneous infection is the most common form in human. Spore deposition through inhalation 
is less common, but has the highest mortality rate. Most gastrointestinal infection is a result 
from ingestion of contaminated meat, which is more common in the developing world. 
Human-to human infection is rare, but might be possible through skin contacts. Once anthrax 
spores enter the host, they can be taken up by antigen presenting cells such as macrophages
3
 
or dendritic cells
4, 5
. Spores will then be transported to local and regional lymph nodes where 
the spores germinate into vegetative form and start to multiply, which eventually fill the 
blood with bacteria and cause severe septicemia, followed by shock and death. Figure 1.1 is 
a schematic illustration of anthrax infection in the human. The name „anthrax‟ was derived 
from a Greek word for „coal‟, in reference to the black skin lesions seen in the cutaneous 
infection cases.  
2 
 
Anthrax is one of the oldest recorded diseases (Figure 1.2). First descriptions of 
Anthrax can be dated back to ancient times (circa 1500 BCE), where Anthrax was mentioned 
in the Bible as the fifth (death of live stock) and sixth (boils) Egyptian plagues. Inhalation 
anthrax has been indicated as the cause of the famous Plague of Athens (430-427 BCE)
6
. The 
great Roman poet Virgil (70-19 BCE) gave the most vivid description of the terrifying 
disease in ancient times
7
. Anthrax continued to bring major devastation to both the animals 
and humans throughout the Middle Ages. An epidemic in the 18
th
 century destroyed almost 
half of the sheep in Europe
7
. Human infections through inhalation of  anthrax spores became 
recognized as wool sorter‟s disease in Victorian England8. In the 19th century when the 
industrial revolution brought about the great change and improvement in medicine, anthrax 
bacillus was discovered and studied extensively. The French scientist Louis Pasteur and 
German scientist Robert Koch made great contributions to the initial discovery and 
understanding of the life cycle of anthrax bacillus and its disease transmission. The first live 
attenuated vaccine was developed and tested on livestock by Pasteur in 1881
9
. With 
increased knowledge and raised awareness of Anthrax, actions have been taken to reduce the 
risk of its transmission. It is believed that improved animal husbandry and processing of 
animal products together with subsequent vaccine development and usage have lead to the 
decrease in anthrax incidence in the 20
th
 century. However a report in 1958 showed that 
worldwide presence of anthrax is still significant, with an annual occurrence of 20,000-
100,000 in the first half of the 20
th
 century, while Anthrax incidence was reduced to 
approximately 2000 cases yearly during the second half, finding the majority of these cases 
being in Asia and Africa.  
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Most of the US human cases in recent decades have been sporadic and are limited to 
natural causes, namely from exposure to imported wool (CDC, 1988) or animal hide (CDC, 
2006) (Figure 1.3). However, the 2001 Anthrax attack on the east coast of US was a 
reminder of the severity of this ancient disease. The intentional distribution of Anthrax 
through the US postal system in fall of 2001 has resulted in 11 confirmed inhalational 
anthrax cases (5 fatalities), 7 confirmed cutaneous and 4 suspected cutaneous cases. This 
marks the largest outbreak of inhalational anthrax in US history. This intentional distribution 
of Anthrax spores brought back the need for research on anthrax protection especially in the 
biodefense field. The unique characteristics of Bacillus anthracis, in particular the stability, 
ease of dispersion (aerosolization) of anthrax spores and the high morbidity and mortality 
rates that resulted from spore exposure have made the aerosol spore form of the bacterium a 
leading bioweapon threat.  
1.1.2 Bacillus anthracis  
Anthrax is about 1-1.5µm in diameter, 3-10µm long
10
 which is in the perfect size 
range for inhalation and lung deposition. The bacterium is normally dormant in its spore 
form in soil. Endospores are formed by vegetative cells in a very complex process called 
sporulation, which involves the activation of as many as 200 genes upon environmental 
trigger, e.g. when water or an essential nutrient is limiting, or when the vegetative cell is 
exposed to oxygen
11
. The entire sporulation process can be finished in a matter of hours. 
Several protective layers are formed around the central spore cell (Figure 1.4). Composition 
in different layers such as highly cross-linked keratin, peptidoglycan and the formation of  
calcium dipicolinate by endospore contribute to their high resistance to UV radiation, 
chemical agents, extremely high temperatures, dessication, and other normally harmful 
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environments
1
. Endospores can survive in the dormant form for many years, even decades or 
centuries. When the environment becomes suitable for germination, the spore can change 
back to a vegetative cell and reestablish rapid growth in a matter of hours (Table 1.1). 
Anthrax spores can enter the mammalian host through skin contact, inhalation and ingestion. 
It has been suggested that macrophages play a very important role in spore germination and 
dissemination in all three cases 
3, 12
. However, it is not known how the germinated spores 
circumvent the phagolysosome, and subsequently, escape from the macrophage. 
Nevertheless, an intracellular step appears to be essential to initiate the infection of this 
extracellular pathogen. Capsules and toxins are then produced during multiplication of the 
vegetative cell killing the host. 
1.1.2.1 Capsule 
The capsule is a special cell surface feature, possessed by B. anthracis and a few 
other bacteria
13
. In addition to the cytoplasmic membrane and peptidoglycan found in all 
bacteria, this capsule made of polymer of γ-D-glutamic acid (PGGA) is the outermost 
element of the vegetative cell wall. This monotonous linear polymer is very weakly 
immunogenic and enables the bacteria to avoid phagocytosis by host immune defense, and 
this evasion leads to severe septicemia. This polymer is highly pathogenic and considered 
one of the primary virulence factors. 
1.1.2.2 Anthrax toxins 
Anthrax toxins are the other major virulence factors that play a key role in anthrax 
pathogenesis. Figure 1.5 is a schematic illustration of the mechanisms of action of anthrax 
toxins. They are composed of three proteins, protective antigen (PA), lethal factor (LF); and 
edema factor (EF). PA is known for its ability to elicit a protective immune response against 
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anthrax. PA itself is not toxic, it acts in binary combinations with EF (PA+EF, EdTx edema 
toxin) and LF (PA+LF, LeTx, lethal toxin) to shuttle them into the cell. Lethal factor (LF) is 
a Zinc dependent metalloprotease that cleaves N-terminus of mitrogen activated protein 
kinase kinase (MAPKK), and induces cell lysis through subsequent signaling cascade, which 
ultimately leads to tissue damage and shock. Edema factor (EF) is adenylate cyclase that 
converts intracellular adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP), this increase in cAMP concentration can cause edema. The synergistic effects of the 
proteins will ultimately lead to tissue death and shock. Interestingly, the ability of LeTx to 
inhibit MAPKK has been explored as an antitumor agent
14, 15
. 
1.1.2.3 Protective antigen and mechanism of translocation  
Protective antigen (PA) has a molecular weight of 83kDa and contains 735 amino 
acids. PA folds into four functional domains all required for protein translocation process. 
Domain 1 (residues1–249) contains the proteolytic activation site. Upon cleavage by cellular 
proteases, e.g. membrane endoprotease from the furin family, N-terminal fragment of 20 kDa 
(PA20) is released, leaving the receptor-bound portion PA called PA63. Domain 2 (residues 
250–487) is involved in membrane insertion and pore formation through formation of a β-
barrel structure. Domain 3 (residues 488–594) is the smallest of the four domains, which has 
been implicated in monomer-monomer interaction between PA63 in the formation of the 
oligomer. Domain 4 (residues 595–735) is required for binding to the cellular receptor. 
The translocation process starts when PA binds to cellular receptor, followed by the 
proteolytic cleavage of PA20. Once the steric hindrance from PA20 is removed, the 
remaining PA63 assembles into a heptamer with the formation of pre-pore. The heptamer 
formation is achieved by significant conformation changes of the monomer structure and 
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leads to exposure of the binding sites for EF and LF. Binding of EF and LF occurs 
simultaneously, and rapidly, during heptamerization process. The whole complex then 
becomes associated with lipid rafts, and is rapidly endocytosed through clathrin-dependent 
pathway
16
. Once in the acidic environment of the endosome, domain 2 of PA63 undergoes 
the greatest conformational change to form β-barrel made from both non-polar and polar 
residues. In order to get through the much smaller lumen (15 Å across) of the PA63 pore
17
, 
EF and LF  also undergo a series of unfolding and folding events driven by the hydrophobic 
interaction with the phenylalanine clamp of PA63, proton and protein gradient. The first 250 
residues of EF and LF share great sequence homology, with an irregular alternating sequence 
of basic, acidic, and hydrophobic residues. This crucial design of the amino acid sequence of 
both EF and LF has allowed the interplay between the phenylalanine clamp and protonation 
state of the protein. The amazing pore forming ability and translocation ability of anthrax 
toxins has been utilized as a general delivery system for macromolecules. Ballard et al. 
prepared a heterologous fusion protein of N-terminal of LF (LFn; 255 amino acids) and a 
CTL epitope from an intracellular pathogen, Listeria monocytogenes, The delivery of the 
fusion protein in the presence of PA was able to elicit a functional immune response which 
resulted in a reduction of colony forming units in spleen and liver upon challenge with L. 
monocytogenes comparing to nonimmunized control mice
18
. Similarly, Gaur, R and 
colleagues successfully delivered and expressed plasmid DNA into the cytosol of 
mammalian cells using fusion protein containing LFn and DNA binding domain of 
GAL4DBD
18, 19
.  
1.1.3 Clinical aspects of anthrax (symptoms and treatments) 
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Anthrax spores can enter body through broken skin, or mucous membranes. There are 
three clinical manifestations of Anthrax. Cutaneous anthrax has incubation time of 1-12 days. 
The infection begins as a papule lesion, progresses through a vesicular stage to a depressed 
black necrotic ulcer (eschar). Despite the horrid looking, cutaneous anthrax infection is 
normally painless. In most cases cutaneous anthrax can be self-limiting, without antibiotic 
treatment the fatality rate is about 5%-20% due to systemic dissemination of the bacteria, 
antibiotic treatment can reduce the rate to less than 1%. Gastrointestinal anthrax occurs due 
to ingestion of contaminated meat. Incubation time for gastrointestinal anthrax is usually 1-7 
days. Two forms of GI Infection have been reported. When infection is concentrated in 
pharyngeal region, clinical symptoms include oropharyngeal ulcerations with cervical 
adenopathy and fever. Alternatively, symptoms for intestinal infection include severe 
abdominal pain, fever, bloody vomiting or diarrhea, with shock and death occurring within 2-
5 days of onset. GI infection is difficult to diagnose and the mortality rate is high with an 
estimated 25-60% fatality.  
Typical symptoms for inhalational anthrax often appear to be biphasic. It starts with 
„flu-like‟ symptoms after 1-7 days of incubation (range up to 43 days) following exposure. 
Initial prodrome includes cough, myalgia, fatigue, and fever, with temporary improvement in 
some patients after 2-4 days. Then disease rapidly deteriorates leading to respiratory distress 
followed by shock and death in less than 24 hours. Inhalation anthrax is difficult to diagnose 
and can be fatal without prompt antibiotic treatment, with 85%- 97% mortality. Even with 
antibiotic treatment, the fatality rate is about 75% (45% in 2001), making this the worst form 
of anthrax infection.  
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Ciprofloxacin and doxycycline are considered first line agents in the treatment of 
anthrax. Cutaneous anthrax may be treated orally with Ciprofloxacin 500mg BID, or 
doxcycline 100mg BID for 7-10 days, or up to 60 days when concurrent aerosol exposure is 
suspected. For more severe forms of infection including inhalational, gastrointestinal, 
oropharyngeal anthrax, and cutaneous anthrax with signs of systemic involvement, initial 
high doses of intravenous antibiotics (ciprofloxacin 400mg every 12 hours or doxycycline 
100mg every 12 hours) are required which might be switched to oral administration later. 
Since antibiotics are only effective on vegetative cells, the total duration of treatment was to 
last up to 60 days due to potential persistence of the spores. Multidrug approaches with one 
or two additional antimicrobials in combination with either of the first line agents have been 
recommended for severe forms of anthrax. The selection of agents with reported in-vitro 
activity includes rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, 
clincamycin, clarithromycin. Aggressive supportive care with corticosteroids has also been 
suggested as adjunct therapy for inhalational anthrax with extensive edema, respiratory 
compromise, and meningitis
1
.  
Furthermore, alternative approaches utilizing a protective immune response to 
anthrax have been explored in animal models to improve the outcome of exposure. Studies in 
animal models such as the monkey have shown that post-exposure vaccination with PA-
based vaccines in combination with antibiotic treatments can be superior in terms of survival 
and long-term protection compared to antibiotic alone or vaccination alone
20, 21
. Conversely, 
passive administration of antibody may be very valuable in case of limited vaccine supply, or 
immunocompromised patients. In recent years, many efforts have been devoted to identifying 
and developing anti-anthrax human monoclonal antibodies. Anti-PA monoclonal antibodies 
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(mAbs) have demonstrated promising therapeutic effect against anthrax in a number of 
animal models such as mice
22, 23
, guinea pigs
22, 24
 and rabbit
25, 26
. However, in the case of pre-
existing vaccination with PA-based vaccine, anti-LF mAbs present a promising alternative 
approach
27, 28
. Both in-vitro cell line studies and in-vivo animal studies demonstrated that 
anti-LF mAbs are superior when compare to anti-PA mAbs in multiples ways. This approach 
can offer protection with delayed administration
27
, with the potential of extended protection 
at a lower concentration
28
, and most importantly without interfering with the development of 
an anti-PA response
29
.  
1.1.4 Anthrax vaccines  
1.1.4.1 Current development of next generation anthrax vaccines 
Anthrax is an acute infectious disease caused by spores of Bacillus anthracis bacteria. 
The inhaled form of anthrax is difficult to diagnose and can be fatal without prompt 
antibiotic intervention. Prophylactic vaccination has become a critical measure for protection 
of individuals at risk of exposure. In U.S. current licensed vaccines for human use are 
prepared from the sterile culture supernatant fraction of B. anthracis which is adsorbed on 
aluminum hydroxide (AVA: BioThrax) for intramuscular (IM) injection, while in U.K. the 
supernatant is precipitated with aluminum phosphate (AVP) for subcutaneous (SC) injection. 
These vaccines contain varying amounts of natural PA with unknown amounts of LF and EF 
and follows a complex six-dose primary vaccination schedule which requires annual booster 
vaccination to maintain immunity
30
. Although these vaccines are considered effective, they 
are difficult to produce and come with significant lot-to-lot variations. The undefined amount 
of LF and EF present in these vaccines may well be the source of frequent local injection-site 
reactions and complaints about reactogenicity after repeated vaccination
31
. With advances in 
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molecular biology techniques, many efforts have been made to develop second generation 
anthrax vaccines with purified antigen based on PA. Following the 2001 attack, fears about 
possible intentional use of anthrax spores against the general population have led to an 
increased need for more effective and tolerable anthrax vaccines with capable of eliciting a 
rapid and durable response, which will be suitable for mass vaccination in response to an 
outbreak as well as for vaccination in the developing world where anthrax epidemics are 
common. Current anthrax vaccine strategies to develop next generation products include the 
following approaches (summarized from recent review papers
32-34
): 1) incorporation of well-
defined and controlled components into the vaccine through recombinant protein technology, 
2) addition of effective adjuvants to elicit rapid and prolonged humoral response, 3) 
alternative routes of delivery including transdermal, intranasal and oral delivery of vaccines, 
4) use of plasmid and viral DNA vectors in a DNA prime/protein boost regimen with a goal 
to elicit more intense and longer-lasting memory response, 5) addition of capsular antigen 
and spore components to broaden the coverage of protection, 6) application of live attenuated 
bacilli or live attenuated strain of B. anthracis in spore form to augment the immune 
response.  
1.1.4.2 Anthrax vaccine based on recombinant PA 
PA has been a major target for protective immunity against anthrax which is mainly 
antibody-based. It is known that anti-PA antibody specific immunity not only has anti-spore 
activity (to promote phagocytic uptake and suppress germination)
35
, but can also prevent PA 
from binding to its cellular receptor and subsequently binding lethal factor (LF) and edema 
factor (EF)
36
. Purified recombinant PA has been utilized as the antigen component in second 
generation vaccines. Studies have shown that the rPA based-vaccine is capable of eliciting a 
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comparable functional antibody response (toxin-neutralizing titer) as to current licensed 
vaccine AVA
37, 38
.  Others have demonstrated administration of rPA can provide complete 
protection against aerosol challenge in murine models as well as in rabbits 
39, 40
. Most 
positively, rPA-based vaccine has been employed in clinical trials to evaluate safety and 
efficacy
38, 41, 42
. However, like AVA vaccine some results with rPA-based vaccine also 
indicate the requirement for annual boost to ensure long-lasting protection. Nevertheless, rPA 
based vaccines with the addition of effective adjuvant such as CpG seem to afford a more 
rapid and long-lasting immune response
43, 44
 which warrants further investigation.  
1.1.5 Animal models  
Since anthrax is a rare disease in human, and clinical trials are difficult to consider, it 
is very important to identify and use animal models that correlate survival and 
immunological responses.  
1.1.5.1 Animal model for anthrax disease 
Significant differences exist between species in respect to the susceptibility/resistance 
to toxins and/or to infection. The mouse is the most widely used animal model and offers 
many advantages such as immunological reagent availability, low cost of purchase and 
housing. Mice are sensitive to toxemia which makes them good candidates for antibody 
response. However mice are quite susceptible to encapsulated non-toxinogenic strains which 
might be due to the absence of highly bacteriacidal enzyme sPLA2-IIA (secretory 
phospholipase A2 group IIA, a s specific member of the 10-member family of secreted 
phospholipase A2)
45
 in host cutaneous and pulmonary tissues. As a result they are very 
difficult to protect with PA-based vaccines against fully virulent strains. Partial protection 
was observed when mice were vaccinated with rPA, with a highly significant correlation 
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between toxin neutralizing antibody tier and survival after intranasal change with Aims strain 
B
46
. A rat model Fisher 344 is particularly sensitive to lethal toxin (LeTx), and thus is more 
useful in testing the efficacy of anti-toxin therapeutics. Guinea pigs are susceptible to both 
infection and the effects of anthrax toxins. Correlation between neutralizing antibody titer 
and survival has been reported. However, variable protection against different strains of 
anthrax was observed in guinea pigs vaccinated with AVA vaccines in comparison to 
rabbits
47
.  Conversely, the pathophysiology of inhalational anthrax in rabbits and non-human 
primates, mainly monkeys are considered very similar to infection in humans. Both rabbits 
and monkeys are very sensitive to anthrax toxins. Consequently, the level of antibody 
response can be correlated for protection against inhalational anthrax. Both models are 
considered suitable alternatives/substitutes for human efficacy trials, even though each model 
demonstrates significant difference from human infection. For example, rabbits are rather 
resistant to infection aspect of anthrax exposure which have been related to the enhanced 
bacterialcidal activity of highly positively charged sPLA2-IIA enzyme
48
.  While in the case 
of monkeys, concurrent infection with virus and parasites are very common, which can 
interfere with the disease development of anthrax and ultimately may lead to modified 
immune response.  
1.2. Mucosal Immune Response through Nasal Mucosa 
1.2.1. Rational for nasal vaccine delivery 
Due to the available mucosal surface, which is highly vasculaturized and lacks 
significant quantities of metabolizing enzymes, the nasal route has been employed for both 
local and systemic drug delivery and CNS targeted drug delivery. The nasal mucosa is also 
part of mucosal immune defense system replete with immune cells in nasopharynx-
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associated lymphoid tissue (NALT) which makes it an ideal site for antigen delivery. 
Vaccination via the mucosal sites, known to be routes of entry for pathogens, may be more 
protective than immunization by parenteral route. Unlike vaccination by injection, nasal 
vaccination has the potential to induce mucosal immunity (mucosal antibodies such as 
secretory IgA and T cell responses) in addition to systemic immunity (serum derived IgG, 
systemic cytotoxic T lymphocytes) 
39, 49-53
, which helps clear the pathogen at mucosal surface 
preventing access to the systemic circulation. Nasal vaccination has been exploited as route 
of administration against a variety of infectious or non-infectious diseases as summarized 
from recent papers
54-56
 (Table 1.2). Moreover, the nasal mucosa is topically accessible and 
may be suited to mass vaccination in developing countries or in the case of an outbreak. As a 
result, vaccination via the nasal mucosa has been widely studied in animal models and 
clinically
57, 58
. Recently, Flumist
TM
 an intranasal (IN) influenza vaccine was approved by the 
FDA and has been widely used for prevention of seasonal flu, as well as the recent outbreak 
of swine flu. Finally, it has been reported that nasal mucosal immunization elicited antibody 
responses covering the entire upper airway mucosa with regional secretions (saliva, nasal 
secretions)
59, 60
, which would offer broader defense against mucosal pathogens such as 
inhalational anthrax where the entire respiratory tract is involved. 
1.2.2. Mucosal immune response  
Mucosal surfaces are found in the nasal passage, lung, GI tract, intestine, urinary 
tract, reproductive tract, eye and mouth. They serve many vital functions, such as respiration, 
nutrient absorption, excretion and reproduction. Because the mucosal surfaces are in constant 
contact with the external environment, they must also function as barrier to protect the host 
from chemical or biological insult. Mucus, glycocalyx and a single layer of epithelial cells 
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act as physical barrier, whereas peristalism, mucociliary clearance and antimicrobial agents 
(defensins) provide powerful mechanical and chemical cleansing mechanisms. In addition, 
these surfaces are protected by an immunological barrier, which involves highly specialized 
mucosal innate and adaptive immune responses elicited through the coordinated action of 
epithelial cells, mucosa-associated lympho-reticular system (MALT and immune cells) and 
secreted antibodies.  
The mucosal immune system is an integration of tissue, cells and molecules that 
function in both inductive sites and effector sites which is highly compartmentalized and 
functions independently from systemic immune system. Mucosal inductive sites exist where 
the naïve T and B cells are stimulated by antigen presenting cells, and are comprised of 
organized mucosal-associated lymphoid tissue (MALT) and the local/regional draining 
lymph nodes (LN). MALT can be found in various sites of the body such as the 
gastrointestinal tract, nasopharynx, lung, breast, salivary glands and eye (Figure 1.6). NALT 
and GALT are similar in their microstructure, but are different in orgranogensis. The 
mucosal immune response is manifested in mucosal effector sites that have less organized 
lymphoid tissue with diffusive lymphocytes in lamina propria (lamina propria lymphocytes 
LPL), the stroma of exocrine glands, and surface epithelia (intraepithelial lymphocytes IEL). 
Mucosal effector sites can be characterized by production of secretory IgA, as well as the 
presence of CD4
+
 and CD8
+
 T cells. 
1.2.2.1.NALT species difference 
Most rodents being obligate nose breathers have evolved prominent NALT close to 
the nasal cavity opening with symmetric lymphoid tissues located bilaterally in the 
ventrolateral mucosa of the nasopharyngeal meatus. Rodent NALT has been well 
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characterized in many laboratory animal models. Humans being simultaneous nose and 
mouth breathers, developed lymphoid tissues covering several distinct areas in the 
oropharyngeal region (aerodigestive tract), instead of one specific region of lymphoid tissue 
like in most of the rodent animals, as the first line of defense against both inhaled as well as 
possible ingested antigens. In humans, the collection of lymphoid tissue from superior to 
inferior, including nasopharyngeal tonsil (adenoids), palatine tonsil, lingual tonsil and tubular 
tonsil constitute major parts of Waldeyer‟s ring, which is considered the lymphoid equivalent 
of murine NALT. Most recently Casteleyn et al. reported histological study with rabbit nasal 
cavity, which revealed the organization of rabbit NALT and oropharyngeal palatine tonsils is 
very similar to human nasopharyngeal tonsils. Both primary and secondary lymphoid 
follicles are found in the region 1 to 3.3 cm from the tip of the nose. In addition, 
intraepithelial and lamina propria lymphocytes as well as isolated lymphoid follicles were 
observed in this region. The structure and location resemblance of the rabbit and human nasal 
cavity, further support the use of rabbit as a valuable animal model for human nasal vaccine 
development and possible toxicological testing.  
1.2.2.2.Mucosal inductive site 
Studies regarding the structure and function of human NALT have been limited. A 
few studies performed using adenoid tissue collected after patient adenectomy showed great 
similarity of human NALT to GALT
61
, as is also the case in rodents. In particular, microfold 
M cells found in adenoid tissue are ultrastructurally and functionally similar to those in 
Peyer‟s patches and colonic lymphoid follicles. M cells are found in the single layer of 
follicle-associated-epithelium (FAE), and are specialized epithelial cells that provide immune 
surveillance at mucosal surfaces. The structural and functional properties of M cells promote 
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antigen uptake. Structural features of M cells include less glycocalyx, less organized 
microvilli, which facilitate constant sampling of antigen across the mucosal surface. Fewer 
lysosomes and rich of tubulovesicular system, modified basal lateral membrane facilitate 
antigen transport to the lymphoid cells enfolded in the M cell pocket. In the intraepithelial 
pocket, particulate or soluble antigens are presented in the intact form to professional antigen 
presenting cells (APC) i.e. macrophages, B cells and dendritic cells (DC). In addition, in 
vitro studies with human adenoid tissue suggested that follicle associated epithelial cells can 
also pick up soluble antigen to a less extent
62
, probably through macropinocytosis. And the 
role of dendritic cell, epithelial cells in the antigen presentation in either inductive site or 
effector site of human nasal mucosa has not been full characterized in human NALT. But 
studies with murine NALT and GALT suggested possible involvement of both dendritic cells 
and epithelial cells in the antigen presentation in the inductive and effector sites. Dendritic 
cells underneath FAE can take up luminal antigen transported by M cells and present them to 
T cells. On the other hand dendritic cells found in the lamina propria of effector sites can 
form interjection of dendrites to sample antigen from mucosal surface directly without 
crossing the epithelium
63
. Intestinal epithelial cells (IEC) can also process and present 
antigen through MHC-II and nonclassical MHC I type of molecules, however their precise 
role in T-cell activation and immune-priming is unknown.  
1.2.2.3.Mucosal effector site 
Naive B and T cells enter MALT (and lymph nodes) via HEVs (high endothelial 
venules). After being primed with antigen, B cells and T cells migrate from MALT and 
lymph nodes to peripheral blood for subsequent extravasation to become memory / effector B 
and T cells at mucosal effector sites, mainly the mucosa of origin. Immune responses can 
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also be elicited at selective distal mucosal sites other than the site of vaccination. This 
homing process is largely directed by site-specific integrins, the different local profile of 
vascular adhesion molecules and chemokines
64
. These homing mechanisms have led to 
significant compartmentalization among different mucosal surfaces. Depending on the site of 
induction, type of antigen and adjuvant, the effector sites of mucosal immune response can 
vary. As mentioned in previous section NALT immunization in humans can induce 
significant responses in upper airway mucosa with no response in gut mucosa. However, oral 
immunization through GALT have shown to induce substantial antibody response in the GI 
tract, and some in the mammary and salivary glands but little, if any response in the lung
65-67
. 
These findings demonstrate that route of immunization can play a very important role in 
inducing effective immune responses at the desired sites.  
1.2.2.4.Mucosal effector mechanism 
A number of immune cells near mucosal surfaces, including phagocytic neutrophils 
and macrophages, DCs, NK cells and mast cells contribute to the innate immune response as 
initial host defense mechanism against pathogens. The primary adaptive immune response is 
characterized by production of secretory IgA (S-IgA) antibodies. Upon activation, B cells 
migrate to peripheral blood through local and regional lymph node to desired mucosal 
effectors sites, where they differentiate into antibody producing plasma cells. Local 
cytokines, growth factors and lamina propria DC releasing B cells activating factor (TNF 
family) have been reported to promote B-cell class switching to IgA producing cells in the 
intestine
68, 69
. S-IgA antibodies produced by B cells are in dimeric or polymeric forms linked 
by the joining chain (J chain protein) and can bind to polymeric Ig receptor (pIgR) expressed 
at the basolateral surface of epithelial cells with high-affinity. S-IgA is then actively 
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transported to the lumen of mucosal surfaces, where mucosal antigens are neutralized and 
excluded. IgA neutralization can also occur in the lamina propria or intracellularly during 
transepithelial transport through fusion with intracellular vesicles containing either IgA or 
target antigen.   
Although SIgA is the most prevalent antibody that can provide humoral defense 
mechanism, locally produced IgM and IgG also play important roles in mucosal immunity. 
IgM produced is also coupled by J-chain and actively transported to the mucosal surface as 
SIgM after coupling to polymeric immunoglobulin receptor, where as IgG is transported in 
its monomeric form through paracellular leakage and by active transport upon binding to 
neonatal Fc receptor
70
.  
In addition to antibody mediated protection, T cell derived immune responses present 
other important effector mechanisms of the adaptive immune response in the defense of 
mucosal surfaces. Mucosal CD8
+ 
cytotoxic T lymphocytes (CTLs)
71
 and antigen specific 
IFN-γ producing CD4+ T cells 53 have been described after mucosal vaccinations. These T 
cell mediated responses at mucosal surfaces are important for the initial containment and 
subsequent clearance of pathogens from the mucosal infection sites, in particular they have 
been shown to be crucial for the defense against intracellular pathogens including viruses, 
parasites in several infection animal models
72-74
. However, their protective role against 
extracellular bacteria has yet to be defined. Notably, recent studies revealed a novel class of 
CD4
+
 effector cells, Th17 cells, which is a third subset of T helper cells (besides Th1 and 
Th2) responsible for protection against extracellular bacteria and fungi
75, 76
. Th17 cells are 
characterized by production of cytokine IL-17 which interacts with IL-17R expressed on 
fibroblasts and epithelial cells to induce release of a variety of chemokines. These 
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chemokines either recruit neutrophils and induce granulopoiesis or activate macrophages to 
recruit additional immune cells, all of which can lead to clearance of extracellular pathogen. 
In addition, Th17 cells are known to produce effector cytokine IL-22 which can induce the 
secretion of antimicrobial peptides by epithelial cells to maintain the barrier function and 
organize tissue repair. These aforementioned mucosal T cell derived adaptive immune 
responses can be induced either by the live pathogen or by mucosal immunization with 
subunit vaccines in combination with CT or other robust mucosal adjuvants e.g. cytokines as 
adjuvant including IL-1α, IL-12, GM-CSF53.   
1.3. Mucosal Vaccine Adjuvant 
1.3.1. Current development of mucosal vaccine adjuvant 
Nasal mucosal vaccination is a promising approach for the management of infectious 
disease. Yet, nasal immunization without adjuvants suffers from limited efficacy due to the 
induction of a weaker or undetectable immune response than that induced by traditional IM 
vaccination
40
. In some cases, nasal vaccines have elicited strong immune responses in mice, 
while such responses have been disappointing in primates and humans. A safe and effective 
adjuvant becomes very important to a successful vaccine strategy. Adjuvants have immune 
potentiating effects brought about by activating the innate immune system that lead to dose-
sparing of antigen and may be used to enhance the immune response profile by inducing 
rapid and long-lasting response. In addition, adjuvants can modulate the immunity by driving 
the differentiation of T cells towards the Th1 or Th2 responses, or enhance the cross-
protective response against pathogen evolution. Finally, adjuvant is also potentially important 
for host immune deficient patient. Mechanisms of stimulation of immune response by 
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adjuvant are complicated depending on individual adjuvant and can involve multiple modes 
of action.  
Aluminum-salts (aluminum hydroxide, aluminum phosphate, potassium aluminum 
sulfate) are widely used in human vaccines, and the only current FDA-approved adjuvants in 
the United-States. The mechanism of immune stimulation by Aluminum adjuvants is poorly 
understood. However, it is believed that aluminum salts can act as a depot to prolong antigen 
uptake. Other mechanisms to enhance the immune response have also been suggested, e.g. 
direct or indirect stimulation of dendritic cells, activation of complement and inducing the 
release of chemokines. However, the relative importance of these mechanisms remains to be 
determined. The adjuvant effects of aluminum compounds are weak with certain antigens, 
and no adjuvant effect has been observed when delivered via the oral or nasal route
77
. In 
addition, when an aluminum salt is used with recombinant protein antigen, loss of protective 
effect has been reported due to cold or lyophilization induced aggregation of the adjuvant 
particles
78, 79
.  
Cholera toxin (CT) and E. coli heat-labile enterotoxin (LT) enhance the immune 
response by increasing the mucosal epithelial membrane permeability of antigen and through 
the release of pro-flammatory cytokines. CT  and LT are best-studied and widely used as 
experimental mucosal adjuvant and have been proven to be potent mucosal adjuvants
80, 81
. 
But safety is a concern when it comes to human use. CNS toxicity has been attributed to CT 
or LT given nasally
82
.   
Studies with CpG oligonucleotide as adjuvants for nasal vaccines have also shown 
positive results in small animal models 
40, 83
. CpGs are bacterial or synthetic 
oligodeoxynucleotides containing unmethylated Cytidine-phosphate-Guanosine repeats (CpG 
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ODN). CpG activate toll-like receptors (TLR9) present on innate immune cells such as DC, 
macrophages and B cells, and enhance the immune response through release of a variety pro-
inflammatory cytokines triggering mainly a Th1-type of response. Nevertheless, the adjuvant 
effects of CpG are only similar to aluminum hydroxide when applied to nasal vaccines in 
rabbits
40
, and concerns exist that multiple boosting may elicit an  immune response to CpG 
oligonucleotide itself.  
Cytokines or chemokines can be downstream mediators of previous described 
adjuvants. Different cytokines and chemokines can be used to selectively or in combination 
to promote desired Th1 vs Th2 type of respones
84
. However, cytokines, being proteins, are 
often subject to degradation, difficult to produce and might require special storage 
conditions.   
Most recently other molecules such as alpha-galactosylceramide (α-GalCer), have 
also joined the list of novel mucosal adjuvants. This is a glycosphingolipid originally derived 
from a marine sponge. Once α-GalCer is presented by CD1d molecules on APCs to invariant 
Vα14+ NKT cells, large amounts of cytokines (IFN-γ, and IL-4) can be produced, leading to 
enhanced innate and adaptive immunity
85
.  
Despite the variety and number of available adjuvant molecules, safe and effective 
mucosal agents for human use have yet to be developed.  
1.3.2. Mast cell activator as adjuvant for nasal vaccination 
Mast cells are traditionally known for their role in allergy and anaphylaxis, while 
their role in the regulation of innate and adaptive immune responses has only recently been 
appreciated
86-88
. Mast cells (MCs) are highly specialized cells that are present throughout 
vascularized tissues (Fig.6), in particular they are found in large concentrations near surfaces 
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where pathogens are frequently encountered, for example mucosa of nose, lungs and 
digestive tract. MCs are placed in a wide range of tissues to guard against invading 
pathogens. Upon activation by bacteria, viruses or allergens, MCs can release a myriad of 
proinflammatory mediators either preformed or de-novo synthesized. Mast cell degranulation 
occurs within seconds of activation, a variety of preformed mediators stored in the granules 
will be released including toxic mediators such as histamine and heparin and/or chondroitin 
sulphates, enzymes such as tryptase, chymase, cathepsin and carboxypeptidases, and TNF-α. 
These preformed mediators cause increase in local blood flow and vessel permeability and 
increase the expression of adhesion molecules which promotes the influx of inflammatory 
leukocytes and lymphocytes into tissues.  Furthermore, mast cells synthesize and release 
chemokines, lipid derived mediators such as prostaglandins, leukotrienes and platelet-
activating factor (PAF), growth factors and additional cytokines such as IL-4 and IL-13 
which enable Th2 response. While among these mediators are potent activators of innate 
immune system,  mast cell activation also influences dendritic cells activation, maturation 
and migration, T cell and cell activation, differentiation and migration, and consequently 
plays an important coordinating role in the development of adaptive immune response.  
Most recently, supported by recognition of mast cell‟s immunomodulatory role in 
adaptive immune response, mast cell activators have been studied as a new class of vaccine 
adjuvants and appear to be highly effective for nasal administered vaccine
89
. Compound 
48/80 is a cationic condensation product of N-methyl-p-methoxyphenethylamine and 
formaldehyde, is a specific activator of mast cells
90-92
 and has been used in humans
93, 94
. 
C48/80 is known to induce the release of preformed and newly synthesized TNF-α and IL-8 
from mast cells
95
. The adjuvant properties of c48/80 were tested after nasal administration of 
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anthrax antigen PA in a mice model in Dr. Staats Lab
89
. Large numbers of MCs were found 
in the nasal mucosa and were highly sensitive to c48/80. Notably, the combination of PA 
with adjuvant c48/80 induced comparable or higher titers of IgG compared with PA plus 
cholera toxin. This adjuvant also induced comparable levels of antigen-specific IgA. Serum 
antibodies were functional in neutralizing PA to prevent toxicity to macrophages in an in-
vitro toxin neutralization assay. The adjuvant properties of c48/80 were further demonstrated 
in a vaccinia virus challenge model, in which nasally administered PA and c48/80 resulted 
significant protection. Most encouragingly, no notable toxic side effects or anaphylaxis were 
observed for the different dosage levels of c48/80 tested. Other data suggest that c48/80 did 
not enter the upper airways or the lung. The protective humoral immunity and minimum 
toxicity of c48/80 observed using the mouse model renders this novel class of nasal adjuvants 
appealing, and warrants further investigation in larger animal models. The newly identified 
role of MC activators in the induction of the humoral immune response have inspired the 
development of a new generation of vaccine adjuvants, and the nasal administration of MC 
activators might provide safe and effective mucosal adjuvant for future vaccine development. 
1.4. Powder Vaccine Formulation and Preparation 
Liquid vaccine formulations are known for their instability during storage and 
distribution. They are temperature sensitive. Elevation or lowering of temperature can cause 
aggregation of the protein component, and loss of activity due to increased hydrolytic activity 
at elevated temperatures. The most commonly used method to stabilize biological active 
component is to prepare them into a dry powder form, which is potentially more stable due to 
reduced mobility of the macromolecules and elimination of degradation pathways such as 
hydrolysis. In addition dry powder formulation is superior in sterility and eliminates cold 
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chain required by liquid formulation, is more economical and can facilitate mass vaccination. 
Dry powder formulations have found their application not only in nasal vaccine delivery, but 
also in pulmonary, epidermal
96-98
 and oral
99
 vaccine delivery system.  
Conventional dosage forms for nasal drug delivery include solution, suspension, 
emulsion and ointments, while novel dosage forms such as microspheres, liposomes, and 
hydrogels have been developed to enhance nasal permeability
100, 101
. Dry powder 
formulations have been exploited for direct nasal delivery instead of being delivered as 
suspensions as in the case for microparticulate delivery systems. Nasal delivery of dry 
powders was first exploited as an alternative formulation to enhance the systemic availability 
of therapeutic agents such as insulin in the 1990s
102
. The interest in local mucosal immunity 
and the stability of the powder vaccine have resulted in investigation of dry powder vaccine 
delivery to the respiratory tract. Dry powder vaccines were first investigated for pulmonary 
delivery to prevent measles
103
, followed by a dry powder vaccine preparation for nasal 
delivery to cattle in early 2000
104
. Nasal delivery of liquid formulations has long been 
established but progress of nasal dry powder drug/vaccine delivery has been limited. The 
difficulty of producing powders under controlled conditions with reproducible particle 
characteristics, disease state complications, and lack of efficient and fully characterized 
delivery devices have been perceived as barriers to the development. 
1.4.1. Dry Powder Preparation 
Dry powder preparations are suitable for protein subunit vaccines, whole virus 
vaccine and DNA vaccines, with the last two being more involved in pulmonary and 
epidermal delivered vaccines. Potentially there are several methods available to prepare a 
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powder formulation, their suitability for biopharmaceutical preparation and nasal delivery 
will be discussed.  
1.4.1.1.Spray-drying and freeze-drying 
Historically several methods have been used to prepare dry powder vaccine 
formulations, spray-drying, freeze-drying (lyophilization) and spray-freeze-drying. Spray 
drying involves atomization of the liquid feed into small droplets and then drying by feeding 
it through hot gas. One advantage of spray-drying is the process parameters can be controlled 
to engineer particles with different physical properties. The particle size prepared by this 
method is often in the range of 1-10µm which is more suitable for pulmonary delivery 
105-107
. 
This process is more suitable for conventional small molecule pharmaceutics, since the high 
temperature required during the drying process can induce heat stress, which can not only 
cause excipient to crystallize, but also lead to denaturization/aggregation of the bioactive 
macromolecules thereby loss of antigenic activity. However, freeze drying (lyophilization) is 
considered the most convenient and popular drying method for biopharmaceuticals
108
. 
Aqueous solution containing biomaterial is first frozen followed by removal of water by 
sublimation under reduced pressure. Several process parameters including freezing rate and 
drying steps need to be controlled to ensure product integrity
108, 109
. Different sugars/polyols 
(see Table 1.3) are often added in bulk as stabilizers to prevent potential damaging effects 
during freezing, drying and subsequent storage. Disaccharides such as trehalose have been 
used with whole inactivated influenza virus during freeze-drying preparation of nasal 
delivered dry powder influenza vaccine
110
 as well as Anthrax vaccine
111
. The mechanism of 
stabilization can be twofold. Upon lyophilization bioactive macromolecules is incorporated 
inside a glass state of the sugar matrix, this reduces the mobility of each molecule and 
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provides a physical barrier between molecules, thereby, preventing aggregation and 
degradation during the process. Furthermore, the hydroxyl groups on the sugar molecules can 
replace H-bonding interaction provided by water molecules which help maintain the tertiary 
structure/structural conformation of the macromolecules as water is removed during drying. 
However there are other concerns caused by the freezing stress during this process. The large 
ice/liquid interface created during the process might cause protein adsorption which may lead 
to conformational changes and loss of activities. Moreover, as the solute concentration 
increases during freezing, there is acceleration of reaction kinetics which may increase 
hydrolytic degradation and changes in ionic strength may further destabilized the vaccine.  
Buffer selection for the lyophilization process is also very important. Freezing 
induced pH changes can be dependent on buffer type and concentration, freezing rate, and 
presence of sugar and other excipients
112-117
. The pH normally will drop to a more acidic 
value during lyophilization, and the shift can be as large as 3 pH units. This means selection 
of buffer types for lyophilization becomes very crucial to maintain the integrity of pH-
sensitive bioactive macromolecules. Amorij et al reported conformational change of 
haemagglutinin (HA) during freezing due to pH change in PBS to acid-pH which makes HA 
more prone to hydrolytic degradation by trypsin, whereas the pH shift in HBS is smaller and 
the freeze-dried powder appears to be more stable in HBS than in PBS
117
. 
Freeze-drying does not have the flexibility required for particle engineering. After 
lyophilization further milling and mixing is necessary to break up the lyophilized „cake‟ and 
reduce the particle size, thereby enhance the dispersion properties of the powder to achieve 
direct nasal application
118
. This process introduces mechanical forces which might be another 
potential cause for loss of activities.  
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1.4.1.2.Spray-freeze-drying 
Spray-freeze-drying (SFD) is a relatively new process for the production of dry 
powder biopharmaceuticals, which combines conventional spray drying and freezing drying. 
In this process the aqueous solution containing the active ingredients are passed through a 
spray nozzle, atomizing nitrogen gas, with a fixed back pressure used to supply the energy to 
drive the liquid into small droplets, which are collected in a container of liquid nitrogen. The 
large surface area of the liquid droplets and their direct contact with the freezing medium 
leads to rapid vitrification, which prevents possible phase separation. Once the liquid 
nitrogen has evaporated, the frozen droplets are dried under vacuum. The large surface area 
of the frozen particles allows rapid drying which is more energy efficient. SFD frequently 
produces porous spherical particles that are larger than those produced by spray-drying
105
. 
SFD particles rarely require further particle size reduction, and can either be used directly or 
after blending with other vaccine component. When SFD is carried out under optimized 
conditions, by adjusting and selecting process parameters including nitrogen flow rate, liquid 
feed rate and atomization pressure, particles with desired sizes and in narrow ranges are 
produced and may be used directly for nasal application. For example, SFD powders were 
prepared for nasal influenza vaccination with target size of approximately 25m for rabbit 
nasal cavity
119
.  
1.4.1.3. Vacuum drying and supercritical drying 
Other techniques vacuum drying and supercritical drying provides alternative 
methods that are to some extent complimentary to the above mentioned methods for dry 
powder preparation. According to the water phase diagram, the boiling point of water is 
lowered at low pressure. Vacuum drying takes advantage of this physical phenomenon and 
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dries biopharmaceutical at room temperature, which eliminate freeze-stress and atomization 
stress associated with FD and SFD. However, this process may be lengthy and increase the 
risk of sugar glass transition to rubbery state. Supercritical drying is a relative new method 
for drying for which the mechanisms have been reviewed elsewhere
120, 121
.  This process can 
be operated at moderate temperature (20-50°C) and shorten the duration of drying as 
compared to FD and SFD
121
.Dry powder vaccine development encompasses a series of 
processes in which the biological active component is incorporated into pharmaceutical 
ingredients to become the actual product. The structural and functional activity of the antigen 
is a prerequisite for a successful dosage form. It is important to monitor the structural and 
functional integrity of the antigen during manufacture and storage. In this chapter we will 
focus on proteinaceous antigens. However, the methods might apply to other macromolecular 
entities.  
1.4.2.1 Structural integrity  
It is known that the structural properties of proteins are closely correlated to their 
biological activity and stability. Freezing, drying, pH shifts and interaction with excipients 
can all cause structural changes
114, 122-124
, which might lead to aggregation and degradation. 
While more advanced biophysical methods are now available to study the protein structure in 
detail or its interactions with surroundings
125, 126
, basic spectroscopic techniques such as 
circular dichroism (CD) and Fourier Transform infrared (FTIR) play a major role in this area 
due to their ease and simplicity of performance. They provide a global view on overall 
protein secondary structure and may be sufficient to discriminate structural changes caused 
by manufacturing process and storage. CD spectroscopy is a form of light absorption 
spectroscopy that measures the difference in the absorbance of right- and left-circularly 
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polarized light due to asymmetry components in protein structure, such as the peptide bond 
and the amino acid side chains. Protein secondary structure in terms of backbone 
conformation is most sensitive in the far-UV region (190-250nm), where the peptide bonds 
have dominant contributions. The CD spectrum is obtained for samples of protein in solution, 
with concentrations in the range 0.2-0.5mg/ml while maintaining the total UV absorbance of 
the cell, buffer, and protein at less than 1. Amorij et al. employed CD to investigate the 
conformational changes of HA during freezing and freeze-drying. CD spectra of HA had a 
negative absorption at far-UV region, the intensity of the absorption was lower for HA 
exposed to freezing, whereas freeze-drying induced a more substantial loss of negative 
absorption which can be attribute to conformational change of an α-helix to a more β-sheet 
structure
117, 127
. In the same report, Amorij et al. demonstrated using CD that the structure of 
HA can be stabilized by addition of sugar such as trehalose and inulin to the freeze-drying 
mixture. CD can also be used to monitor the physical stability of protein antigen at different 
pH and temperature, and aid in the screening of stabilizers and excipients
111
. CD does not 
give absolute structural information, but different secondary structure content can be 
estimated with selection of reference protein using computation analysis
128-130
.  
FTIR can measure samples presented in both the liquid and solid state. Like CD 
spectra, similar information can be derived from FTIR spectroscopy. FTIR is based on the 
sample absorption of electromagnetic energy at infrared region where molecules vibrate and 
rotate at discrete energy levels. The basic structure repeat of protein is peptide bond, also 
called amide bond. Different vibration modes of amide bond give rise to characteristic 
absorption bands in different regions of infrared. The most intensive absorption is the amide I 
band (1600cm
-1
-1700cm
-1
), which originates mainly from the carbonyl stretching of the 
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amide group (Figure 1.8). The carbonyl group is prone to hydrogen bonding and, thus, 
directly related to protein backbone conformation. Different secondary structure content can 
be obtained through analysis of amide I region. Schüle et al. studied the secondary structure 
of IgG before and after spray-drying with transmission FTIR, no major change in the 
secondary structure was observed for the reconstituted powder of IgG which was consistent 
with CD results
131
. The authors also measured the IR absorbance of the spray-dried sample of 
IgG in the solid state using attenuated total reflectance (ATR) FTIR, and found increase in β-
sheet elements which has been recognized as a favored conformation in a dehydrated state
132
. 
And the structural change appeared to be reversible upon rehydration. ATR-FTIR (Figure 
1.8) employs novel sample preparation technique, which allows liquid or solid sample to be 
loaded directly onto the surface of an optical dense crystal, where the IR beam can be 
directed through the crystal at a certain angle to create reflectance on the surface, which 
generates an evanescent wave on the surface. The evanescent wave penetrates into the 
sample in close contact to the surface and as a result be attenuated and altered due to sample 
absorption in the IR region. This technique requires a small sample (a few microliters) and 
fast analysis without KBr processing. Multiple reflections of the IR beam dramatic increase 
the optical path and sensitivity on a small quantity of sample. Facilitated by the development 
in data processing, FTIR and CD have become robust methods for protein structure 
determination with increasing number of publications on a range of proteins. CD and FTIR 
spectroscopy are complementary to each other, and can be used together to ensure accuracy 
in the analysis.  
1.4.2.2 Aggregation detection 
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Aggregation may occur at various stages throughout vaccine formulation preparation, 
storage and transportation. It has been a major concern and challenge in liquid vaccine 
formulation, and should also be closely monitored for dry powder vaccines. CD and FTIR are 
the most sensitive to protein secondary structural change, which are clues for protein 
denaturization. However, sometimes CD and FTIR may not be sensitive to different 
aggregation states of a protein
131, 133
. This may be explained by the aggregates being present 
in small quantities or by the unfolding that occurs in some areas that may not affect the 
secondary structure but might change the tertiary structure
134, 135
. Depending on the nature of 
the aggregates, different analytical methods and techniques are available to detect, 
characterize and quantify the aggregates
136
. The simplest method is based on the concept of 
Rayleigh scattering, which is requires UV absorption measurements of the turbidity or 
opalescence of a protein solution at optical densities of around 340-360nm range and at 
550nm
135
. By measuring optical density (O.D.) at 360nm Jiang et al. compared the 
aggregation levels of rPA at different trehalose concentrations, and identified different 
stabilizing excipients. Sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis 
chromatography (SDS-PAGE) is another quick and easy method which separates protein 
based on its size and can resolve protein content on a microgram scale. This technique is 
most useful for detection of covalently linked aggregates, or SDS non-dissociable aggregates. 
Jiang et al. demonstrated the retention of rPA integrity during the SFD process under 
reducing and non-reducing conditions. SDS requires heating of the protein sample at high 
temperature which might introduce artifacts due dissolution of existing aggregates or 
formation of new aggregates as in the case of membrane proteins
137
. Alternatively, Native-
PAGE involves preparing samples under mild conditions without heating or addition of 
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denaturizing agent SDS. Proteins may be separated using their inherent charge or by addition 
of negatively charged protein-binding dye Coomassie Brilliant Blue G-250
138
. The migration 
of a protein will not only depend on its size but also on its shape and hydrodynamic radius, 
so the band location with respect to the molecular weight marker might not reflect its true 
size except for globular proteins. Size exclusion chromatography (SEC) or gel filtration is 
essential for protein purification. This method can be coupled with high performance liquid 
chromatography (HP-SEC) with increased selectivity and efficiency in separation. Buffer, 
pH, ionic strength of the mobile phase needs to be carefully selected to limit introduction of 
artifacts. The detection method can be UV, light scattering, fluorescence, and mass spectrum 
with increased sensitivity and accuracy. Hawe et al. quantified the aggregate formation using 
HP-SEC. Their results demonstrated that the heat stress induced more aggregation compared 
to freeze-thawing
133
. By using a combination of techniques further analysis showed the 
differing nature of the aggregates. Freeze-thawing tended to produce a greater proportion of 
aggregates in the µm size range. Whereas heating produced more structurally perturbed 
aggregates which is evidenced by CD and ATR-FTIR. Furthermore, the shape and 
morphology of the aggregates can be closely examined by microscopic methods such as 
TEM and AFM
139
, and provides understanding to the causes and pathways of aggregation 
with the aim to better control protein aggregation and ensure successful products.  
1.4.2.3 Functional stability 
Instrumental analyses of the antigen after powder formulation can provide quick and 
general information on the structural stability. However, it is important to confirm that the 
antigen or adjuvant maintains its functional activity. The functional stability of the bioactive 
component of the antigen and adjuvant can be tested with different biological assays in-vitro 
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using reconstituted powder, e.g. macrophage toxicity assay for anthrax PA activity
27, 49, 140
, 
and haemagglutinin titer for HA
141-143
. It is very important to monitor the effects of the 
bulking agent (sugar), mucoadhesives and excipients on the in-vitro activity of the antigen. A 
well designed in-vitro biological assay gives definitive information on the stability of the 
antigen. However, it is more time consuming and highly variable. A practical approach 
would be to establish a quantitative correlation between the structural activity 
characterization and in-vitro biological performance and eventually substitute the bioassay 
routinely.  
1.4.3 Dry Powder Formulation Characterization 
While ensuring biological activity of the antigen in the dry powder formulation is a 
prerequisite, it is very important to characterize and control pharmaceutical properties of the 
powder formulation to achieve successful and reproducible delivery as well as stability of 
nasal vaccines. Factors such as particle size, bulk density, device associated parameters such 
as spray pattern and plume geometry, are the most important variables that affect powder 
deposition and will be discussed in this section. Factors important for powder stability will 
also be mentioned.  
1.4.3.1 Particle size  
Particle size distribution is one of the most important parameters that dictates the 
performance of dry powder inhalation products
144
 and nasal products. However, the 
requirements for nasal sprays are less stringent and less well established
145
. In general, 
particles should be large enough to impact in the nasal cavity with minimum deposition in 
the pulmonary airway. It is believed that particles greater than 10 μm are deposited within the 
upper respiratory tract of the nasal cavity, while particles less than 5μm are inhaled, and 
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those less than 0.5 μm are exhaled146. There are few reports for nasal vaccine delivery in 
animal models, of the particle size properties of the dry powder. A D50 (volume median 
diameter) of 37μm was reported for influenza vaccination in rats110, a freeze-dried mixture of 
Amioca 
®
starch/Carbopol
®
 947P with D50 about 60μm was used for influenza vaccination in 
rabbits, and a D50 of ~50μm and ~70μm was reported for FD and SFD Anthrax powder 
vaccines delivered to rabbits
40
. Mostly notably Garmise et al. prepared dry powder particles 
under optimized conditions of SFD which produced particles with a target volume median 
diameter of 26.9μm for influenza vaccination in rats119. The deposition in human nasal cavity 
has been characterized with nasal spray devices using nasal airway replica
147
, silicone human 
nose model
148
 or a computational fluid dynamics (CFD) model of the human nasal 
passages
149. General findings in these studies are that large particle sizes (50μm to 60μm) 
tend to deposit mainly in the anterior region of the nose with a small proportion reaching the 
turbinate or nasopharynx, while a smaller size, such as 20μm, has a better penetration beyond 
the nasal valve.  
It needs to be emphasized that the anatomy of the nose and the site of action should 
be considered before selecting an optimal size range for nasally delivered products. The nasal 
cavity can anatomically be segregated into five different regions: nasal vestibule, atrium, 
respiratory area, olfactory region and the nasopharynx as shown in Figure 1.9
101
. The 
respiratory region, including inferior turbinate, middle turbinate and superior turbinate, is the 
most permeable region due to large surface area and rich vasculature, which has been the 
targeted absorption site for nasal drug delivery for local or systemic effect. The site of action 
for nasal delivered vaccine is believed to be towards the back of the nasal cavity, where the 
nasopharynx is located. Nasal associated lymphoid tissue (NALT) lies directly under the 
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epithelium of nasopharyngeal region and is known as the inductive site for mucosal immune 
response. Two types of deposition were described for insulin uptake after nasal powder 
administration and may also be the pathways for antigen delivery to NALT
148
. Direct initial 
deposition in the nasopharynx region can be limited given that the powder has to pass the 
narrow nasal valve and highly humid and structured turbinate region. However, it is more 
likely that the antigen is brought to the nasopharynx through secondary deposition due to 
translocation by the mucociliary clearance. The site and pattern of powder deposition in the 
nasal cavity can lead to different biologic/pharmacologic outcomes as evidenced by study 
with nasal delivery of insulin dry powders where the bioavailability of insulin increased with 
anterior deposition of the formulation. Similarly it is reasonable to predict particle deposition 
might have significant influence on the overall immune response elicited. However this 
hypothesis has yet to be tested. It is important to understand the diversity in the anatomy and 
physiology of different animal species
146
 when designing the study and interpreting the 
results. Extrapolation to human situations can become complicated.   
1.4.3.2 Bulk density 
 Bulk density is another variable of the powder that may affect the dispersion and, 
therefore, deposition of the powder. Pringles et al. reported the plume pattern from a powder 
device is influenced by bulk density. However no effect on the bioavailability of insulin was 
observed. Garmise et al. reported bulk density of SFD trehalose powder to be 0.26 mg/mm
3
, 
a similar bulk density (0.12-0.18 mg/mm
3
 depending on the solid fraction) was reported by 
Pringles et al. for a freeze-dried mixture of Amioca 
®
starch/Carbopol
®
 947P. Bulk density 
with other powder properties such as tap density, static angle of repose and specific surface 
area are indicative that surface properties of the powder can impinge on the flow 
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properties
119
, the dispersion behavior of the powder, which should be closely monitored to 
ensure the performance of the final product. 
1.4.3.3 Particle Sizing Techniques 
Laser diffraction is a widely used particle sizing technique in aerosol formulation 
development and is rapidly becoming a standard method in pharmaceutical industry for 
inhalation and nasal formulations
150
. LD can measure a wide size range, 0.5-1000µm, 
providing information on volume equivalent diameter. However, deviation might occur with 
the presence of non-spherical particles in the dry powder products, since the assumption of 
spherical particles in the algorithm is invalid. In addition, the diameter measured by LD is 
not directly related to the particle volume or surface. Thus, the particles measured may not 
represent primary particle size but rather the size of aggregates. Complementary techniques 
such as scanning electron microscopy (SEM) are often used in conjunction with LD, which is 
useful to determine the primary particle size, shape and morphology.  
While particle size of nasal dry powders reported in the literature is often determined 
by LD, the most appropriate measure of aerosol particle size is the aerodynamic diameter 
(Dae) which combines particle density and shape factor into a measure of the particle 
dynamic behavior and can lead to important information on particle deposition. Since dry 
powders produced by SFD and FD are often porous particles with a low density, they often 
have a smaller Dae compare to particle in the same volume. It is known that even for particles 
with Dae up to 20µm, that as much as 10% of the particle mass is able to escape impaction in 
the nasal cavity and deposit in the lungs, which is an undesirable outcome for nasal 
products
151
. It is important to characterize the aerodynamic size of the dry powder 
formulation to ensure that the minimum quantity of respirable particles appear in the 
37 
 
products. Conventional Andersen cascade impaction (CI) is an ideal technique for sizing 
pulmonary aerosols. However, this method does not cover the entire size range that has the 
potential to enter the lungs. A modified CI with reduced flow rate were developed by 
Garmise et al. which extended the upper limit of the size range to 16.5µm, and is more 
suitable for the characterization of nasal products
152
. 
1.4.4 Device and device related parameters 
Nasal dry powder can be delivered via passive and active systems. Passive systems 
require patients‟ sniffing (inhaling through the nose) to deliver the powder. In contrast, for an 
active system, dry powder delivery is driven by pressured air flow, which passes through the 
container and carries the powder into the nasal cavity. Most devices used in animal study are 
active devices. In a nasal vaccination study for Anthrax, Valois Monopowder device (Valois 
Pharmaceutical Division, Le Vaudreuil, France) was employed to delivery 10mg of powder 
to the rabbit nasal cavity
118
. A syringe containing 1 ml compressed air was used to assist 
powder delivery through polyethylene tubes (Medisize, Hillegom, The Netherlands), where 
10mg of influenza vaccine powder was delivered to each nostril of rabbits
153
. The 
Monopowder device has also been used in a clinical study of diphtheria vaccine
154
. A similar 
device have been developed by BD technology which instead of polyethylene tube, it 
includes a housing unit for powder-filled capsule at the end of  the syringe, upon depressing 
the syringe plunger the compressed air will rupture the capsule film and deliver the powder 
through the diffuser
110
. The diffuser can be modified to fit narrow nasal passages of different 
animal models such as rabbit
110
 and rat
40
.  
As mentioned above the deposition of the dry powder is very important in nasal 
vaccine delivery, which is not only affected by the inherent properties of the powder such as 
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size and density, but can vary greatly depending on different device used. Device associated 
parameters such as spray pattern and plume geometry including plume width, plume length, 
spray cone angle, and spray velocity are often characterized for nasal spray products as is 
required by FDA. Spray pattern looks at the shape and the cross section of the plume at 
specified distance from the spray nozzle. Experimental data on nasal sprays with nasal casts 
showed that larger spray angle 60°-70° resulted in an increase deposition in the anterior 
region, whereas reduced spray angle to 30° or 35° lead to more posterior deposition
147, 148, 155
. 
Similar findings were implicated in a powder study by Pringles et al. where the spray pattern 
of powder formulations delivered through the polyethylene tube was examined. It was 
demonstrated that the powder formulation composed of drum dried waxy maize starch 
DDDMC/C974P (90/10) had a smaller cross-section area which speculated by the author 
might contribute to a posterior deposition in the nasal cavity. In a separate study using a 
computational fluid dynamic model of the human nasal cavity, the author simulated 48 
different spray conditions with 8 different spray variables based on the characterization of 18 
different commercially available nasal spray devices
149
. The author was able to predict the 
best nasal valve penetration condition which had a particle size of 20µm and spray velocity 
of 1m/sec, with spray nozzle 1cm from the nose and a gentle inspiratory airflow, but at a 
larger spray angel of 79° which seemed a little contradictory to the experimental findings. 
Nasal dry powder formulation development is still a relatively new area, little has been done 
in terms of characterization of deposition from nasal dry powder devices and this should be 
emphasized in future studies. A few experimental studies looked at patient variables such as 
inhaler orientation
156
, head position
157
 and inspiratory flow
158
, which appeared to have no 
significant effect on spray distribution or patterns.  
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1.4.5 Storage stability of dry powder formulation 
Dry powder formulation of protein/peptide vaccines provides greater stability than 
liquid formulation. However, chemical and physical degradation can still occur in the solid 
state leading to inactivation of the antigen or powder delivery failure. Chemical degradation 
pathways observed for protein/peptide in the solid state are very similar to possible 
degradation pathways for liquid formulations, which involves covalent modifications such as 
deamidation, oxidation, disulfide exchange and hydrolysis. In addition proteins/peptides are 
often susceptible to physical degradation due to non-covalent interactions such as 
hydrophobic interactions which leads to protein denaturization and aggregation. Chemical 
and physical degradation may both occur during dry powder manufacture as well as during 
storage. Various factors such as buffer properties, the presence of other excipients, freezing 
and drying rate affect the stability of dry powder formulation during manufacture process 
have been mentioned in the earlier sections. It is also of great importance to examine factors 
that could influence the storage stability of the dry powder formulation.  
The matrix glass transition temperature (Tg) is a critical parameter for solid state 
protein/peptide stability, which refers to the transition temperature between the glassy (solid-
like) states and the rubbery (liquid-like) states. In general for excipients of the same kind, 
higher matrix Tg often affords greater stability. Increasing Tg for excipients 
sucrose<trehalose<raffinose<stachyose have been correlated with increasing stability of 
lyophilized recombinant human interleukin-2 (rH-IL-2)
159
. As is true for any solid state 
pharmaceuticals, the protein formulation needs to be stored at temperatures well below Tg in 
order to ensure long-term storage stability, more specifically a Tg of at least 20°C higher than 
ambient storage temperature has been recommended for solid protein pharmaceuticals
160
. 
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The preferential use of trehalose rather than other sugars and polyols in dry powder protein 
formulations
111, 161
, is in part due to the amorphous trehalose having a high Tg of around 
120°C
162
. An extensive list has been generated by Wang regarding glass transition and 
collapse temperature of commonly used buffers, excipients and proteins reported in the 
literature
108
. Many factors, such as the concentration of the excipient (sugar/polyols or 
polymers), moisture content and the presence of buffer salts and other excipients can greatly 
influence the overall matrix Tg. During formulation development, Tg is one of the most 
important physicochemical properties of the product, which can be determined by differential 
scanning calirometry (DSC), and is often evaluated as part of the screening  process for 
different excipient combinations
161, 163
.  
The effect of moisture on the stability of solid state protein or peptide has been 
known and studied extensively since the late 1980s
164
. Moisture induced aggregation has 
been a well known phenomena for lyophilized pharmaceutical protein, as exemplified by the 
cases of lyophilized recombinant human albumin (rHA)
165
 and lyophilized insulin
166
. Three 
possible roles have been proposed for water during the aggregation process, water might act 
as reactant, reaction media, or plasticizer
167
. Sugars/polyols are known as cryoprotectants 
which have wonderful stabilizing effect during freezing and drying, they have also been 
widely used for the stabilizing effect to lyophilized proteins for long-term storage. It has been 
proposed that sugars/polyols stabilize proteins by forming an amorphous glassy matrix and 
providing hydrogen bonding to the protein thereby limiting molecular mobility
132, 168
, 
physical separation and dilution of protein preventing protein intermolecular interactions and 
aggregation
84
, and the substitution of water protein interaction with water excipient 
interaction
165
. However, the hygroscopic nature of the sugars/polyols, combining the large 
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surface area of the dry powder particle prepared by SFD or FD render the dry powder 
formulation very susceptible to moisture uptake during storage. Increased moisture content 
can significantly decrease the Tg of the matrix and increase the free volume of the protein, 
thereby accelerating the degradation rate and causing possible product collapse
169-171
. Solid 
state water content is known to cause increased covalent aggregation for lyophilized BSA
172
, 
rhIL-1ra
122
, and rHA
165
. Residual moisture after powder manufacture and moisture content 
during storage should be closely monitored; the most common methods used are mass loss on 
drying or Karl Fischer titration. 
 Furthermore, many amorphous sugar/polyols excipients have a tendency to 
crystallize during storage, especially under elevated temperature and moisture content. 
Spray-dried amorphous sucrose, trehalose and lactose can crystallize under RH ≥ 52% at 
25°C
162
. Crystallization of excipient can cause phase separation and destabilize the protein 
during storage. For example, the storage stability of anti-IgE monoclonal antibody was 
drastically decreased at 5°C or 30°C and the apparent reason was attributed to mannitol 
crystallization
173
. The crystallization tendency of amorphous excipient can be affected by 
multiple factors, such as the amount used in a protein formulation, interaction with second 
excipient or the spray-drying process. For detailed review, the author refers to the paper by 
Wang 2000
108
. In addition, the crystallization can been inhibited by many polymer 
excipients, such as maltodextrins, PVP, dextran, and carboxymethyl cellulose
108
.  
Many factors contribute to the storage stability of the powder formulation. 
Aggregation state of protein/peptide is often indicative of antigen stability, which can be 
easily measured by SEC-HPLC, providing a robust method to access the storage stability, 
quantitatively.  Loss of powder stability can also be reflected in the change of particle size 
42 
 
distribution and powder flow properties which could also cause deterioration of powder 
performance by changing the deposition and powder delivery efficiency.  
1.4.6 Nasal residence time and mucoadhesives  
Mucociliary clearance of the nasal cavity is an important defense mechanism against 
inhaled pathogens. Cilia, which line nasal epithelium, are covered by a thin layer of mucus, 
and beat rapidly in a coordinated fashion propelling particles trapped in the mucus layer to 
the posterior nasopharynx. In humans, the average clearance rate is about 8mm/min, and a 
normal clearance half life about 15-20min
174
. Mucociliary clearance presents one of the 
major challenges in nasal drug/vaccine delivery. The nasal residence time has been increased 
by addition of mucoadhesives and this is considered a key strategy to improve performance 
of nasal products by the pharmaceutical delivery.  
When a dry powder formulation is delivered to the nasal cavity, local dehydration of 
the mucus may occur thereby reducing the ciliary beat frequency leading to an increase in the 
local residence time compared to liquid formulations. In order to prolong the nasal residence 
time, mucoadhesive compounds such as natural and synthetic polymers may be included in 
the formulation. Recently, Smart reviewed mucoadhesive compounds and their possible 
mechanisms of action and the background theory for mucoadhesion
175
 (see Table 1.4). First 
generation mucoadhesives have been studied extensively since the 1970s. However, they 
may be associated with significant formulation challenges, e.g. high viscosity, pH sensitive 
and low concentration in aqueous solutions
176
.  Second generation mucoadhesive materials 
were developed to address the issues of associated with poor physico-chemical properties. 
These molecules interact with mucus in a number of ways.  
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Chitosan has been widely used in liquid formulations, or prepared as microparticulate 
delivery systems to enhance nasal bioavailability. Its salt form is positively charged in 
solution, which has strong electrostatic interaction with negatively charged sialic acid in 
mucin. Powder formulation of trehalose and chitosan have also been prepared by Huang et al 
for influenza vaccine, which elicited a comparable serum anti-HA titer to IM injection and a 
significant higher HA inhibition titer than group contains just trehalose
110
. Starch and 
Carbopol mixtures have been demonstrated to enhance the bioavailability of nasal 
administered insulin in rabbits. Based on same concept of increasing the nasal residence 
time, these mixtures were incorporated into an influenza vaccine formulation. A faster anti-
HA IgG response was demonstrated with higher proportion of Carbopol in the mixture
153
. 
However, in other cases the administration of antigen with mucoadhesive compounds did not 
have a significant effect on the overall immune response compare to IM administration
44, 177, 
178
. The inclusion of chitosan in the  powder formulation for nasal administered anthrax 
vaccine did not give rise to a significant difference in the serum antibody titer after third 
immunization, nor did it have any effect on survival of the rabbits after challenge
40
. These 
findings suggest that there is more than one factor that could affect the immune response 
elicited through nasal delivery of vaccine besides the increase in nasal residence time with 
mucoadhesives. It is believed that the residence time of certain pharmaceutical compound is 
determined by the coordinated interaction between the mucoadhesive compound, the nasal 
mucosa, and the pharmaceutical compound. It may be speculated that the antigen release 
profile from the delivery system will play a role in the immune response elicited. Yet again 
no correlation occurred between antigen in vitro release profile and in vivo immune response, 
similar immune response was detected with both delivery systems that have rapid and 
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extended in vitro antigen release
179, 180
. It is important to realize the fundamental difference 
between small molecule drug absorption and antigen presentation in the nasal cavity. The 
relationship between the antigen release rate and antigen absorption/ presentation window is 
complicated and poorly understood. More research is required in order to elucidate the 
correlation between residence time, release profile and nasal immune response elicited.  
1.4.7 Powder safety study 
Dry powder delivery to the nasal cavity raises more concerns regarding safety 
compared to simple liquid formulations, which may explain the small number of studies 
performed and the apparently limited success of nasal dry powder products. Mucosal 
irritancy or damage can be influenced by the stabilizer/sugar, mucoadhesive compound and 
excipients used in the formulation, or the application dose, frequency and individual 
tolerance. Local irritation, burning and stinging have been reported with nasal application of 
surfactant such as Laureth-9, bile salts and sodium taurodihydrofusidate
181
; slight nasal itch 
occurred when β-cyclodextrin was used; others reported nasal burning and sinusitis when 
glycocholate and methylcellulose was used to enhance nasal absorption of insulin
182
. Other 
clinical signs of discomfort can be evident in human as well as in animal studies including 
struggling, sneezing, salivating, head shaking and nose rubbing, for which different methods 
are available to assess mucosal toxicity.  
The standard method to assess local effects is histological evaluation of nasal 
membranes upon exposure to formulations, where metaplasia, granulocyte formation, and 
submucosal infiltration of inflammatory cells can be indicative for mucosal toxicity
183-185
. 
Several in-vitro cell studies have been described previously for toxicological investigation of 
different nasal absorption enhancers, hemolytic activity of red blood cell was compared 
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among different surfactant
186
, and classical mucoadhesives such as a chitosan derivative (N-
trimethyl chitosan (TMC) polymers) and carboxymethylcellulose (CMC) were examined by 
using ciliated chicken embryo trachea tissue or human nasal cell culture system to monitor 
cytotoxicity and ciliotoxicity indicated by ciliary beat frequency (CBF)
183, 187
. Results 
showed that TMC had marginal effects on CBF on ciliated chicken embryo trachea tissue, 
whereas CMC had mild-to-moderate cilio-inhibition in human nasal epithelial cells 
suspensions. Since the aforementioned methods can be invasive and time-consuming, Callens 
et al. developed a non-invasive method measuring protein markers from nasal lavage of 
rabbit nasal cavity
185
, instead of using conventional nasal perfusion methods described by 
Hirai
188
 and Marttin
189
. The amount of total protein and release protein lactate dehydrogenase 
(LDH) and membrane bound alkaline phosphatase (ALP) was monitored as an indication of 
mucosal toxicity by DDWM/Carbopol
® 
974 P (90:10)
185
. The mucosal toxicity of the 
formulation was also evaluated with an alternative animal model, which has been developed 
by Adriaens and Remon
190
 which uses slug Arion lusitanicus for mucosal toxicity evaluation. 
The results showed a significant release of LDH after administration of positive control 
DDWM/Benzalkonium chloride (BAC) and DDWM/Carbopol
® 
974 P (90:10), however 
released LDH in the Carbopol group remained constant after repeated treatment. The LDH 
released from slug body wall was not significant for DDWM/Carbopol
® 
974 P (90:10) group. 
However, this treatment induced more mucus secretions. These findings were extended by 
histological study, which lead to the conclusion that the formulation DDWM/Carbopol
® 
974 
P (90:10) had negligible toxicity on nasal mucosa. In a separate study slug mucosal irritation 
test was used to evaluate the mucosal toxicity of a dry powder influenza vaccine which 
contains a spray-fried mixture of Amioca
® 
/Carbopol
® 
974P (SD), results indicated that the 
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mixture containing 50-100% of Carbopol
® 
974P with influenza virus can be classified as 
mildly damaging. 
Developments in the toxicological assessment for nasal mucosa have been promising. 
However, no standardized method has been proposed by regulatory agencies. Nevertheless, 
extensive mucosal and mucociliary toxicity studies are necessary to ensure success in the 
development of dry powder nasal products. 
1.5 In-Situ Formed Hydrogel Delivery Systems 
1.5.1 Traditional polymer hydrogels   
Hydrogels are a class of very important biomaterials built from continuous structure 
with macroscopic dimensions that is permanent on the time scale of the experiment which 
give rise to solid-like rheological response
191
. Hydrogelation maybe explained by formation 
of chemical or physical cross-linking which result in water trapping
191, 192
. Hydrogel 
networks can retain as much as 90-99% w/w water in its interstitial space without collapsing. 
Due to their higher water content and biocompatibility, hydrogels have been exploited for a 
wide range of biological applications e.g. drug delivery carriers, tissue engineering templates, 
and medical devices 
193, 194, 195
. Their biodegradable scaffolds have often been used as 
implant in tissue engineering for delivery of cells or growth factors, or can be used for 
sustained and localized drug delivery e.g. inserts for ophthalmic drug delivery. Hydrogels 
have been utilized for delivery of proteins such as insulin through injection
196
 as well as oral 
route
197
. Other studies have indicated hydrogel as potential matrices for controlled nonviral 
and viral gene delivery
198, 199
.  
Traditional hydrogels are based on synthetic or natural polymers that can form cross-
lined network via covalent bonding, physical entanglement and/or physical interaction from 
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secondary forces including ionic, H-bonding or hydrophobic forces. Synthetic hydrogels are 
often made of polymers with an abundance of hydrophilic groups, such as polyvinyl alcohol 
and poly acrylates. In 1960, Wichterle and Lim reported the pioneer work in synthetic 
hydrogels based on copolymerization of acrylates HEMA (hydroxyethyl methacrylate) with 
the crosslinker EGDMA (ethylene glycol dimethacrylate)
200
. Today the most common 
application for acrylate polymer hydrogel is gel electrophoresis. Natural polymers based on 
carbohydrates such as methylcellulose, hyaluronan, alginates, agarose and chitosan, or 
proteins based polymers such as collagen, fibrin and cartilage have also been investigated for 
a variety of biological applications. Hydrogels may have many different physical forms, 
including solid molded forms (e.g., contact lenses and electrophoresis gels), colloidal 
assemblies, microencapsulations, coatings, pressed powder matrices, microparticles etc
193, 195
.  
1.5.2 Hydrogel formation via self-assembly 
Recently, enlightened by the very important ubiquitous self-assembly processes of 
nature, such as the formation of collagen in the extracellular matrix
201
 and fibrin in blood 
clotting
202
, lipid formation, scientists have begun to exploit self-assembly for fabricating 
novel synthetic biomaterials
203
. Novel building blocks based on peptides or small 
amphiphilic organic molecules have emerged as a new class of hydrogelators, forming 
supramolecular or molecular hydrogels via self-assembly through non-covalent 
interactions
204, 205
, notably hydrogen bonding, electrostatic interaction, hydrophobic 
interactions, van der Waals interactions, and water mediated hydrogen bonds. The whole 
self-assemble process can be spontaneous driven largely by entropic gain along with 
moderate enthalpy change due to the formation of non-covalent bonds. Just like protein 
folding process, these inter-molecular interactions lead to formation of certain secondary 
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structure aggregates, which can be micelles, vesicles, fibers, ribbons or sheets
205
. And further 
aggregation occurs between individual secondary aggregates and leads to formation of higher 
order aggregates such as fibers or fibrils. Eventually, hydrogelation starts when nano or 
micro scale fibers in solutions become entangled into three dimensional tertiary structure and 
trapping water inside via surface tension. The interactions between individual secondary 
aggregates and surrounding environment (pH, buffer type, ionic strength) ultimately 
determine whether gel is formed or aggregates precipitate from solution rather than trapping 
it
206
.  
1.5.3 Enzymatic hydrogel formation via self-assembly 
Peptide based biomaterials have unique advantages such as programmability, 
biodegradability and bioresorbability
207
. Stimuli-sensitive peptide based biomaterials have 
been designed to self-assemble and undergo phase-transition in response to environmental 
cues such as enzyme
208
, pH
209, 210
, temperature
211
, ionic strength
212
 and light
213
. More 
importantly, it can be tuned to undergo solution to gel phase transition under physiological 
conditions for in situ gelation, thus eliminates the need of invasive surgery or syringe and 
needle for administration.  
Inspired by the critical enzyme-regulated molecular self-assembly processes in 
nature, such as formation of microtubules and the polymerization of actins, a lot of efforts 
have been focused on developing building blocks that can form hydrogel upon enzymatic 
conversion. The advantages include enzyme catalyzed reactions can be achieved with great 
selectivity under mild physiology conditions and can be designed to target specific cell 
pathways or disease states. Hydrogel formation based on enzymatic reactions has been 
reported in several studies. Transglutaminase (TGase) is known to catalyze transamination 
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reaction responsible for fibrin cross-linking in blood coagulation. Hu et al conjugated PEG to 
different peptides that are TGase substrates, rapid hydrogel formation was observed due to 
formation of cross-linking polymers. Toledano et al. utilized the biological function of 
thermolysin to couple Fmoc amino acids and (Phe)2 dipeptide to form Fmoc-tripeptides that 
can form hydrogel via self-assemble driven by π-π stacking interactions between fluorenyl 
groups
214
. One other interesting and versatile pair of enzymes is phosphatase and kinase 
which catalyze enzymatic (de-)phosphorylation reactions. Besides their regulatory role in cell 
signaling pathways, phosphorylation reactions have also been used to modify structural 
features of proteins through the bulky charged phosphate group. Pattanaik et al. were able to 
use phosphorylation reactions to control the transition temperature of elastin-like protein 
between un-folded and folded viscoelastic phase
215
. Similarly, Winkler employed (de-) 
phosphorylation to control the β-sheet formation of recombinant silk proteins. Most 
interestingly, Yang et al have reported a powerful hydrogel precursor that can self-assemble 
into hydrogel upon dephosphorylation
216
. Yang and colleagues further expanded the 
precursor designs to be substrate for a variety of enzymes, e.g. esterase, β-lactamase 216 
(Figure 1.10). The hydrogel precursors designed by Yang et al. are small molecule 
amphiphilic peptidomimetics which carry a functional group that allows the precursor to stay 
as their monomeric form due to steric hindrance or charge repulsion. The hydrogel precursor 
can be substrate for simple phosphatase or esterase, or it can be designed to be substrate of 
specific enzymes to meet certain research interest. Upon enzymatic cleavage of the 
functional group, the hydrogelator can spontaneously self-assemble into a secondary 
structure such as nanofibers, which ultimately forms supramolecular hydrogels (Figure 
1.11). Yang and colleagues presented powerful hydrogelators that are peptide-based small 
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molecule amiphiphiles containing Phe-Phe motif and a naphthalene end group to confer 
strong π-π stacking interaction. The diphenylalanine motif has been identified as a key 
peptide sequence in amyloid fibril-forming peptides in Alzheimer's disease, and is prone to 
self-assembly in aqueous environment as demonstrated by Reches et.al
217
. After cleavage off 
of the charged and bulky phosphate group, the remaining small molecule amphiphile can 
self-assemble spontaneously and rapidly to form superamolecular hydrogel. These small 
molecules are very powerful hydrogelators that can self-assemble to form gel in aqueous 
solutions at very low concentrations. Depending on the enzyme used, the minimum gelation 
concentration can be as low as 0.05 wt % of Nap-FFY-P(O)(OH)2 1 in PBS buffer
216
. In-vitro 
hydrogelation of Nap-βPhg-βPhg-Y-P(O)(OH)2 2 in biological conditions such as rabbit 
blood and broken Hela cells have also been demonstrated
218
. Yang et al were also able to 
demonstrate the hydrogelation in vivo using a mice model when solution containing the 
hydrogelator 1 and 2 (0.5mL, 0.8 wt % in PBS) together with the alkaline phosphatase were 
co-injected subcutaneously under the mouse skin. They also assessed the toxicity by 
monitoring the weight change. The dosage resulted in a little acute toxicity to the mice, since 
the weight loss was averaged 4% on the first day, mice recovered and start to gain weight 
after the second day
218
. 
1.5.4 Phosphatase activity in nasal cavity 
Phosphatases are a group of enzymes that catalyze the hydrolysis reactions in removal 
of phosphate group from their substrates (also called dephosphorylation). Based on substrate 
specificity, phosphatases can be subdivided into different classes such as tyrosine 
phosphatase, serine/threonine phosphatase, histidine phosphatase et al. Alkaline phosphatases 
(ALP) are mainly ectoenzymes which are most effective at alkaline pH, whereas the 
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optimum pH for acid phosphatases (AP) activity (mainly lysosomal) is below 7. Phosphatase 
activity is found throughout the body and phosphatases are involved in a wide range of very 
important biological functions, e.g. cell signaling pathways (ALP), liver function (ALP), 
bone regeneration (ALP, AP), lyososomal function (AP) et al. It is well known that 
endogenous alkaline phosphatase activity is prominent in human mucosal surfaces. In 
particular, alkaline phosphatase participates in digestion, detoxifies lipopolysaccharide (LPS) 
and prevents bacterial invasion in intestine
219
, while in mouth and nasal olfactory mucosa it 
is found to be responsible for taste and smell
220
. The presence of brush broader alkaline 
phosphatase has also allowed scientist to design phosphate ester prodrugs to improve the 
bioavailability of poorly soluble drugs after oral or parenteral administration
221
. Most 
interestingly, recent studies have also identified alkaline phosphatase as one of the two 
ectoenzymes (besides ecto 5‟-nucleodase) that are involved in extracellular conversion of 
AMP to adenosine at the surface of human nasal and bronchial epithelial cells
222
. Two ALP 
isoforms, tissue nonspecific ALP and placental ALP have been localized in human airways. 
ALPs are known to catalyze nonspecific hydrolysis of a variety of substrates, including 
nucleotides, pyrophosphate,  proteins and small molecule substrates such as p-nitrophenyl 
phosphate
222, 223
. It has been reported that mucosal ALP are not only GPI-anchored (glycosyl 
phosphatidyl inositol) membrane proteins 
224-226
, but can also be secreted outside of the cell 
and into the intestine lumen
227, 228
 or can be secreted as nasal glandular secretion upon 
stimulation
229
. These findings support the use of phosphate functionalized hydrogel 
precursors for their nasal application in humans as well as in rabbits. Since alkaline 
phosphatase activity have also been indicated in rabbit nasal cavity and have been used as a 
toxic marker for nasal irritation in rabbits
185, 230
.  
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1.5.5 In-situ formed hydrogel formulation for nasal delivery 
As stated in earlier sections, a major challenge in nasal delivery of either small or 
macro molecules have been to overcome the limited residence in the nasal cavity due to 
mucociliary clearance. Powder formulations offer the advantage of stability in storage and 
shipping and allow prolonged nasal residence time with or without addition of mucoadhesive 
compounds compare to simple liquid formulations. However they require sophisticated 
delivery devices for efficient delivery and accurate dosing. Simple liquid formulations are 
currently the only approved nasal formulations on the market, which can be administered 
through a simple spray device. However, these formulations can often drip from the nose or 
drain rapidly in to be back of the nose and be swallowed, which can ultimately lead to 
variability or failure in therapeutic response. Second generation mucoadhesive polymers used 
in powder formulations have also been included in liquid formulations to improve the nasal 
residence time and have lead to promising results in nasal delivery efficiency. One drawback 
for these gel-like solutions containing mucoadhesive polymers is they are often highly 
viscous and difficult to be applied intranasally. A solution to this problem has been to 
develop mucoadhesive materials which are solution-like and exhibit low viscosity under 
ambient conditions, but can form a gel in situ upon nasal administration. Aikawa et al. 
reported encouraging results with pH-sensitive polyvinyl diethylaminoacetate (AEA) 
hydrogel for nasal drug delivery in rats
231
. Hydrogel formation was observed in rat nasal 
cavity thirty minutes after administration of AEA (7%) in acid solution (pH 4) due to pH 
increased to around neutral or physiology pH in rat nasal cavity. Drug disappearance rate 
constant was decreased with increase in AEA concentration. Wu et al. reported a 
thermosensitive hydrogel for nasal delivery of insulin in rats
232
. Solution state mixture 
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containing modified quanterized chitosan and poly (ethylene glycol) (PEG) with a small 
amount of α-β-glycerophosphate (α-β-GP) was found to undergo thermal transition from 
solution below or at room temperature to hydrogel around 37°C in several minutes. Delivery 
of insulin with this formulation decreased the blood glucose level for between 4-5 h after 
administration. Most encouragingly, an intranasal fentanyl formulation (NasalFent

) based 
on  in-situ formed hydrogel system PecSys technology, has successfully completed phase II 
clinical studies and has filed for regulatory approval in both US and EU for the treatment of 
breakthrough cancer pain
233
. PecSys containing low methoxyl pectin (a plant-derived 
polysaccharide) is a low viscosity solution, which can be delivered reproducibly with a nasal 
spray pump. Nasal spray droplets deposited in the nasal cavity will form a thin layer of 
hydrogel upon contact with the mucosal surfaces due to metal coordination interaction with 
calcium ion present in the mucosal fluid. This system allows fentanyl to retain in the nasal 
mucosal for enhanced absorption while avoiding problems such as dripping and swallowing 
of the drug solution seen with simple solution systems. The expected half-life for the gel 
droplets is ~30  40 min which is moderate increase in residence time comparing to ~ 15  
20 min mucus clearance time
234
. It is not known whether this moderate increase in residence 
time is adequate for optimum antigen absorption in terms of nasal vaccine delivery and it 
remains to be tested. In-situ hydrogel system based on existing polymers and novel 
biomaterials continues to be an encouraging and yet challenging field for nasal delivery of 
biopharmaceuticals.   
1.6 Statement of problem 
A safe and effective anthrax vaccine is needed for mass vaccination for protection 
against potential weaponized inhalation anthrax. Currently licensed vaccines (AVA, AVP) 
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contain varying amount of PA and unknown amount of EF and LF that cause not only 
significant variations in the immune response elicited but can also resulted in unwanted side 
effects after repeated vaccination via IM injection. In addition these vaccines follow a 
complex vaccination schedule that requires multiple primary vaccination and annual booster 
vaccination for long lasting protection. Recombinant protein technology permits the 
development of second generation anthrax vaccines that incorporate well-defined and 
controlled components in vaccine formulation. Recombinant PA-based vaccine is in clinical 
trial for safety and efficacy evaluation, however it appears that annual booster vaccination 
might still be required for rPA-based vaccines to ensure durable protection.  
An integrated approach has been proposed in this thesis to address the problems with 
current anthrax vaccine products, which would take into consideration of antigen and 
adjuvant selection, formulation preparation and storage, route of delivery and device factors:  
 i. Nasal mucosal vaccine delivery would be suitable for mass vaccination, by 
eliminating the needle usage and biohazardous disposal as well as trained personnel, which 
are required by the conventional invasive IM injection.  
ii. The use of a novel mast activator as adjuvant would have the potential to induce a 
quick, effective and long-lasting immune response for rPA-based vaccine.  
iii. Dry powder formulation of the vaccine components would offer the potential to 
increase shelf-life and eliminate cold chain requirement for storage and shipping to maintain 
potency.   
iv. In-situ formed enzyme responsive hydrogel formulation would allow vaccine 
powders to be delivered as reconstituted liquid using a simple liquid pump while maintaining 
sufficient nasal residence time for antigen uptake. This formulation would likely to offer 
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more dosing flexibility, in terms of the device required and patients‟ compliance issue 
associated with nasal vaccine delivery.  
1.7 Hypothesis and Specific aims 
It is proposed that the mast cell activator Compound 48/80 (see section 1.3.2) may be 
used as adjuvant for nasal vaccination in rabbits. It is hypothesized that dry powder 
formulation of Compound 48/80 and rPA can be prepared with trehalose suitable for nasal 
delivery in rabbits, in which formulation both the adjuvant and antigen are compatible and 
stable for extended room temperature storage.  
It is further proposed that an in-situ formed hydrogel formulation will be examined as 
a compliment formulation to avoid high device cost and patient compliance issue associated 
with dry powder formulation. It is hypothesized that in-situ formed hydrogel formulation can 
not only be delivered as a liquid spray using simple liquid pump, but also can form a thin 
layer of gel and become mucoadhesive upon contacting the nasal cavity entrapping the 
antigen and adjuvant in the network, which ultimately will lead to increased local residence 
time of antigen and adjuvant and enhanced immune response in terms of systemic and 
mucosal antibody production. The following specific aims are proposed to address the 
hypotheses: 
1.7.1 Specific aims 
I. To prepare and evaluate the compatibility of adjuvant and rPA in a dry powder 
formulation with trehalose and demonstrate its effectiveness in eliciting immune 
response in rabbits after nasal vaccination.  
a) Dry powder formulation of rPA and adjuvant were prepared with trehalose. Physical 
properties of powders including size distribution, particle morphology, moisture content, 
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thermal properties and bulk/tap density were characterized. Powder dispersion efficiency was 
examined using Unitdose powder device (Pfeiffer GmbH, Germany).  
b) Physicochemical stability of rPA and adjuvant in the powder formulation were monitored 
with spectroscopic methods such as CD, ATR-FTIR. Structural integrity of rPA was 
examined with SDS and Native-PAGE.  
c)  Functional stability of rPA and adjuvant were confirmed in vitro with macrophage 
toxicity assay and mast cell degranulation assay. 
d) Sugar based powder formulations appears to be moisture sensitive. In order to obtain 
optimal storage conditions, powder formulations were stored at different temperature and 
humidity levels, storage stability testing were performed by monitoring rPA functional 
stability using in-vitro macrophage toxicity assay.  
e) Dry powder vaccine with rPA and C48/80 was delivered to the nasal cavity of rabbits 
with Unitdose powder device to determine the in-vivo efficacy, by comparing immune 
response elicited in different control groups. Blood samples were taken and production of 
systemic anti-PA IgG was measured after each of three immunizations. Rabbit serum was 
further analyzed for functional antibody response (toxin-neutralization titer) by testing its 
ability to neutralize LF toxin and confer protection to macrophage cells.  
II. To further improve the dry powder vaccine formulation, a peptide-based in-situ 
hydrogel will be evaluated for its compatibility as a nasal vaccine delivery system. 
a) Phosphatase sensitive hydrogel precursor Nap-FFY-P(O)(OH)2
218
 were synthesized by 
solid phase peptide synthesis, purified by Prep-HPLC and structural confirmation was 
obtained with LC-MS.  
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b) Alkaline phosphatase activity in rabbit nasal cavity was examined using p-nitro 
phenolphosphate (p-NPP) as substrate.  
c) Different buffer systems were examined, compared and selected for optimum in-vitro 
hydrogelation using two different exogenous enzymes: calf intestine phosphatase (CIP) and 
bacterial alkaline phosphatase (BAP).  
d) In-vitro hydrogel formation in presence of vaccine components was confirmed by 
inverted tube test and SEM and AFM.  
e) Viscoelastic properties of hydrogel with selected buffer system at different concentrations 
were further evaluated by dynamic mechanical analysis. Viscoelastic properties of the 
mixture of the hydrogel and mucin were examined to demonstrate the potential 
mucoadhesive property of the hydrogel.   
f) Protein release studies were performed with fluorescent labeled rPA and BSA to obtain 
in-vitro release profile of rPA from selected buffer system at different gel precursor 
concentrations. 
g) Compatibility of vaccine components with in-situ formed hydrogel system was 
determined, by monitoring structural stability of the released proteins from the gel network 
by CD, and testing the functional stability of the release protein in-vitro with cell based 
assays.  
III. To evaluate the in-vivo effectiveness of in-situ formed hydrogel as a vaccine delivery 
system in eliciting systemic immune responses after nasal vaccination of rPA and 
C48/80 in rabbits.  
a) Vaccine formulations based on in-situ formed hydrogel system were prepared by adding 
rPA and C48/80 directly or by adding reconstituted powder vaccine to hydrogel precursor 
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solution, which were delivered to rabbit nasal cavity by instillation with a pipette. Blood 
sample were collected and examined for systemic anti-rPA IgG response, as well as 
functional antibody titer. Results were compared among different formulation groups 
including nasal liquid formulation controls and IM controls.   
1.8 Significance 
Mast cell activator Compound 48/80 has recently been demonstrated as an effective mucosal 
adjuvant in mice nasal vaccine delivery, it is important to confirm its adjuvant activity in 
larger animal model such as rabbit. Positive results from this study would support the use of 
mast cell activator as a new class of mucosal adjuvant, which indicate a variety of potential 
applications with other mucosal delivered antigens. Dry powder formulation of C48/80 and 
rPA in trehalose confers excellent stability for both the antigen and adjuvant during spray-
freeze drying process and after storage, which provides a stable and affordable formulation 
alternative to current anthrax vaccine products. In addition, a new concept is proposed and 
tested in this project, to resolve issues associated powder vaccine systems such as a special 
device requirement and patient compliance issues. An aqueous system containing peptide 
based hydrogel precursor will be employed as a novel delivery system for nasal delivery of 
anthrax vaccine, which would not only allow the use of reconstituted powder formulation but 
can be dispersed easily using a simple liquid pump while maintaining mucoadhesive 
properties to elicit effective immune response. The results of this thesis project will not only 
provide solution to limitations of current vaccine methods, but also open the window to new 
formulation strategies for other mucosal transmitted diseases such as HIV, TB. 
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Figure 1.1 Schematic illustration of anthrax infection in human. 
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Figure 1.2 Early History of Anthrax.  
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Figure 1.3 Recent anthrax history in United States (1951-2005*). 
(Modified from CDC website http://www.cdc.gov/vaccines/vpdvac/anthrax/downloads/ed-
vpd2006-anthrax.ppt)  
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Figure 1.4 Different protective layers of endospore. 
(Image modified from Endospore Structure page. Kerr, T. J., and B. B. McHale. 2001. 
Applications in General Microbiology: A Laboratory Manual. 6
th
 ed. Hunter Textbooks Inc., 
Winston-Salem, NC.) 
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Figure 1.5 Mechanism of intoxication of the anthrax toxins. 
(Modified from Prince, A., J.Clin. Invest. 2003, 112, 5, 656-658)  
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Figure 1.6 Distribution of mucosal-associated lymphoid tissue. 
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Figure 1.7 Mechanisms of mucosal induction and effector response. 
(Modified from Brandtzaeg et al Mucosal Immunology 2008, 1, 31-37) 
 
Possible mechanisms of  antigen presentation from mucosal surfaces: antigen can be 
taken up (1) directly by specialized epithelial cells (M cells); (2) by absorptive epithelial cells 
and then be shuttled to B lymphocyte or Macrophages and FDCs; (3) directly by professional 
APC like DC, or (4) after being processed and presented by epithelial cells, antigen can 
presented toi ntraepithelial T cells. 
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Figure 1.8 Vibrations in amide bond that can lead to characteristic infrared absorption (top). 
Simplified working mechanism of ATR-FTIR (bottom). 
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Figure 1.9 Schematic illustration of human nasal cavity. 
Nasal vestibule (A), atrium (B), respiratory area: inferior turbinate (C1), middle turbinate 
(C2) and the superior turbinate (C3), the olfactory region (D) and nasopharynx or pharyngeal 
tonsil (E).  
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Figure 1.10 Examples of hydrogel precursors, the enzymes and minimal gelation 
concentration (mgc). 
(Modified from Yang, Z. et al. 2008, 41, 315-326)  
 
 
  
69 
 
Figure 1.11 Schematic illustration of hydrogel formation upon enzymatic conversion. 
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Table 1.1 Sequence of events involved in the establishment of inhalation anthrax.  
(Summarized from Passalacqua, KD et al.; Future Microbiology, 2006, 1, 397-415)  
Form/Action Time Location 
Dormant endospore 0 Lungs alveolar space 
Germination 1-5min Inside phagocyte (lung) 
Growth 30min-2h 
Inside phagocyte-outside phagocyte? 
Lung to lymph node 
Vegetative growth ≥2.5h 
Extracellular, lymph node, circulating lymph and 
blood 
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Table 1.2 Nasal Vaccine Applications for different diseases. 
Bacterial Respiratory 
Infection 
Viral Respiratory 
Infection 
Sexual Transmitted or 
Blood-borne 
Other 
B. anthracis Influenza
44
 HIV Malaria 
Streptococcus 
pneumoniae 
SARS Herpes Tetanus
45
 
Haemophilus influenzae  Human papillomavirus Plague
46
 
Moraxella catarrhalis  Hepatitis B virus Alzheimer 
Neisseria meningitides    
Borella pertussis    
Pseudomonas aeroginosa    
Mycobacterium 
tuberculosis 
   
Diphtheria
47
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Table 1.3 Excipients and the stabilizing effect for solid state biopharmaceuticals preparation 
and storage. 
Common Excipients/Bulking 
agents  
Possible Advantages  Possible Disadvantages  
Polyols  
Mannitol  
Water replace property 
during drying  
low Tg, high concentration of 
mannitol display increased 
crystallization tendency, same 
is true at elevated temperature 
and moisture level  
Sorbitol   Low Tg  
Nonreducing 
Sugars  
Trehalose  
High Tg, around 120°C, 
disaccharide with good 
water replacement 
property, non-reducing 
sugar  
Formation of fused and sticky 
agglomerates  
Sucrose  
Good water replacement 
property for drying  
fairly hygroscopic  
Inulin  
High Tg,low 
crystallization rate,low 
number of reducing 
groups (Hinrichs et al. 
2001)  
bulkiness, steric hindrance, not 
good water replacement 
property  
Dextran   
Reducing 
Sugars  
Fructose   
Reducing sugars, potential for 
Maillard reaction and cause 
protein glycantion; moisture 
induced crystallization  
glucose 
(dextrose)  
 
lactose  
Safety FDA approved 
excipients for inhalation  
maltodextrin   
maltose   
Polymers  
poly(D,:-
lactide-co-
glycolide) 
(PLG)  
High matrix Tg  
Requires the use of organic 
solvents  
PLGA  
Amino Acid  
Glycine  Hydrophobic properties, 
benefit to powder flow 
property  
 
Isoleucine  
Surfactant  
Tween80  Prevent protein 
aggregation  
 
Brij 30  
Salts  
PBS  Provide buffering effect 
during freezing or 
drying  
 
HBS  
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Table 1.4 Mucoadhesives and Mucoadhesion Mechanisms. 
(Adapted from Smart 2005).  
First Generation of Mucoadhesives 
Possible Mucoadhesion 
Mechanisms 
Natural polymers 
Chitosan 
Positive charge interact with 
negative charge on sialic acid in 
mucin 
Sodium alginate Hydrogen bonding 
Cellulose and its derivatives Hydrogen bonding 
Synthetic polymers 
polyacrylic acid and its 
derivatives 
Hydrogen bonding, physical 
entanglement, dehydration 
Second Generation of Mucoadhesives  
Modification to first 
generation materials 
Addition of thiol functional 
group 
Disulfide bond formation within the 
polymer or between the polymer and 
mucin 
Copolymer with ethyl hexyl 
acrylate 
Increase hydrophobicity, reduce 
polymer hydration to allow polymer 
mucus interaction 
Grafting PEG Promote interpenetration 
Novel materials 
Poloxomer: Pluronics Thermal induced phase transition 
Amino acid: 
Dihydroxyphenylalanine 
Found in mussel adhesive protein 
Glyceryl monooleate 
Forms liquid crystalline phase with 
water 
Glycoproteins: Lectins 
Weak (secondary) interaction with 
specific sugar residue 
 
  
 
 
2 DRY POWDER ANTHRAX VACCINE FORMULATION 
PREPARATION AND CHARACTERIZATION 
 
2.1 Introduction 
2.1.1 Powder formulation selection and preparation 
As described in section 1.4 dry powder formulation have many advantages over 
liquid formulation in regards to biopharmaceutical preparation including therapeutic proteins, 
vaccines and gene delivery systems. It is well known that carbohydrates can stabilize proteins 
during the manufacture process and subsequent storage based on several mechanisms 
(section 1.4.1.1). Among the variety of sugars reported in the literature, trehalose seems to 
provide a better stabilizing effect for solid state protein preparation (Table 1.3). It is a non-
reducing sugar formed from two glucose units joined by α-1-glucoside bond with no residual 
hemiacetal or hemiketal bond which prevents the unwanted reaction (glycation) with lysine 
or arginine residues from proteins. The bonding also makes trehalose very resistant to acid 
hydrolysis, and, therefore, is stable in solution at high temperatures, even under acidic 
conditions. In addition, trehalose has a relative high Tg (~ 114°C), which affords stability 
during room temperature storage or under conditions of temperature fluctuation commonly 
experienced during transportation. Trehalose has been successfully used for the stabilization 
of biopharmaceuticals, including rPA-based anthrax vaccine
111
, inactivated influenza virus 
(WIIV)
119
 and IgG
235
. Recently, intranasal delivery of SFD anthrax powder formulation with 
rPA and CpG in trehalose prepared by Jiang et al. to rabbit nasal cavity provided complete 
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protection upon anthrax spore challenge. In another study the authors demonstrated 90% of 
rPA in trehalose formulation retained its monomeric form (size-exclusion HPLC) after 15 
days of storage at 25°C, whereas monomer of rPA in liquid formulation was reduced to only 
15% at day 15. The stabilizing effect of trehalose on rPA formulation was also observed 
when the SFD powder formulation was stored at 40°C with 90% stability of over 29 days, 
whereas rPA completely lost its monomeric content in 1 day. These results suggest potential 
long term storage stability of the powder vaccine formulation with the possibility of 
elimination of the cold chain requirement for storage and transportation. Therefore, it is 
reasonable to select trehalose as the bulking agent for the anthrax vaccine formulation of rPA 
with adjuvant C48/80.  
SFD is a relative new drying process and has yet to be commercialized. This process 
is a combination of conventional spray-drying and freeze-drying that involves the 
atomization of liquid feed into small droplets, which are rapidly vitrified in liquid nitrogen, 
followed by lyophilization of the frozen droplets. SFD has been recognized as a better 
process for protein biopharmaceutical preparation due to several advantages it may offer. It 
avoids high inlet-outlet temperature often involved in spray-drying process; rapid 
vitrification prevents potential phase separation during lyophilization; and large surface area 
of the small droplets allows energy saving rapid drying.  Optimization of the SFD process 
parameters will allow preparation of particles with different size distributions suitable for 
direct nasal application eliminating the need for further size reduction, which could be a 
potential cause of loss of protein activity. For optimum nasal delivery of anthrax vaccines to 
a rabbit model, the target particle size obtained after SFD is 25µm median diameter, which 
will have minimum deposition to the lung and is believed to have better penetration beyond 
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the nasal valve to reach the rabbit NALT. The effect of different SFD process parameters 
(e.g. solute concentration, solution feed rate, atomization pressure and nitrogen flow) on 
particle size, span and morphology has been examined previously using a Büchi 7mm two-
fluid spray nozzle
161, 236
. Results showed that solution feed rate and nitrogen flow had a 
significant effect on D50, whereas the solution feed rate, nitrogen flow and solute 
concentration, had a significant effect on span. The best condition to produce particles of 
25µm in size with minimum span is perform the SFD process with 10% solute concentration, 
10 ml/min feed rate, 500 L/hr nitrogen flow with a fixed 3 bar backpressure
161
.   
2.1.2 Compound 48/80 
Since the early 1950s, compound 48/80 has been known to be a potent mast cell 
activator that promotes release of histamine
237, 238
. It is a condensation product of N-methyl-
p-methoxyphenethylamine with formaldehyde
239
 (Figure 2.1). A mixture of oligomers is 
thought to be formed, from tetramer to octamer, with hexamer being the most potent 
compared as a mast cell activator
240, 241
. Commercially available C48/80 contains various 
amounts of these oligomers, which is a potential cause of variability of adjuvant activity 
between different batches. UV spectrum of commercial available C48/80 (Sigma-Aldrich) 
showed strong UV absorptions peaks at 230nm and 280nm.   
2.1.3 Particle sizing and morphology 
Laser diffraction (LD) and Scanning electron microscopy (SEM) are often used in the 
early stage of formulation development for nasal delivery of pharmaceutical products. 
Parameters generated by these techniques are not only required to characterize powder 
formulation particle size, morphology and its distribution, but also can provide important 
information which reflects powder product quality such as dose uniformity, which are 
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important factors that could influence the deposition, delivery efficiency and reproducibility 
of the powder vaccine formulation.   
Laser Diffraction (LD)  
LD is a widely used particle sizing technique in aerosol for characterization and is 
rapidly becoming a standard method in pharmaceutical industry for inhalation and nasal 
formulation assessment
150, 242, 243
. Its popularity maybe explained by the short duration of 
analysis, robustness, high precision, reproducibility, wide measurement range (0.5-1000µm) 
and flexibility of operation using liquid, spray and dry dispersion attachments. Most LD 
instruments employ a standard He-Ne laser light source (632.8nm wavelength) and after 
being processed, the expanded beam passes through the sample which can be a suspension 
either in an organic solution (for hydrophobic molecules) or in air.  Different size particles 
scatter the light at different angles, and by passing through a Fourier lens, the scattered light 
was focused onto a detector array, using an inversion algorithm, a particle size distribution is 
inferred from the collected diffracted light data. Since the instrument measures very large 
numbers of particles at the same time rather than individual ones, it is known as an ensemble 
technique, which gives some statistical significance to the measured results. For measuring 
non-spherical particles, which have a different refractory index than spherical particles, the 
results might deviate from its true size due to the fact that the algorithm is based on the 
assumption of spherical particles. Conversely, LD is very suited to the measurement of 
aqueous droplets from nasal spray pumps or spherical particles produced by SFD where the 
assumption in the algorithm is valid. Another error may originate from high concentrations of 
particles analyzed, which result in multiple light scattering and bias associated with over-
broadening of the true size distribution. Lastly, since the equivalent diameter measured by 
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LD is not directly related to the particle volume or surface, it is important to confirm that the 
particles measured represent primary particle size rather the size of aggregates.  
The median diameter D50 is used to represent the 50
th
 percentile of the particle size 
distribution The median of a size distribution can be based on the count (number), mass, or 
volume and are termed count median diameter (CMD), mass median diameter (MMD) and 
volume median diameter (VMD). Geometric standard deviation is used to represent the 
breadth of the particle size distribution. The geometric standard deviation (GSD) for a normal 
distribution can be calculated from the following equation
244
: 
%16
%84
%16
%50
%50
%84
D
D
D
D
D
D
GSD   
Where D84% and D16% represent the diameters at the cumulative percentiles of 84% and 16%, 
respectively, and the median diameter of the distribution is represented by D50%. Particle 
distributions with higher GSD are more polydispersed and represent a greater range of 
deposition properties.  
%50
%10%90
D
DD
Span

  
Alternatively, span can be used to assess the breadth and uniformity of a size 
distribution obtained by laser diffraction technique, which is commonly used to describe 
nasal formulations
243, 245
. D90% and D10% represent the diameter at the cumulative percentiles 
of 90% and 10% respectively. Both GSD and span are dimensionless parameters. For span 
values around 2, the dispersion is considered to be uniform and near monodisperse. 
Scanning Electron Microscope (SEM) 
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Electron Microscopes (EMs) function exactly as their optical counterparts except that 
they use a focused beam of electrons instead of light to obtain high resolution image of the 
sample and gain information as to its surface structure and morphology. SEM measures the 
projected surface area diameter or length and is suitable for analyzing particles in the range 
of 0.01-150 µm. SEM image provide information on primary particle size with morphology 
and aggregation state which is often used in conjunction with LD as a complementary 
technique to measure the particle size. 
2.1.4 Powder moisture content (mechanism of Karl Fischer Titration).        
Residual moisture content in a dry powder formulation not only affect its thermal 
stability and shelf life (section 1.4.6) but could potentially affect powder flowability and 
performance. Karl Fischer (KF) titration is a convenient and fast technique that is widely 
used to quantify water content in a variety of pharmaceutical products. Coulometric KF 
titration based on redox reactions in a non-aqueous medium can measure water in the range 
of 10µg-10mg in a single titration. This reaction involves the redox reaction between sulfite 
and iodine, where 1 mole of alkylsulfite is oxidized to alkylsulfate by iodine which is 
subsequently reduced to hydroiodic acid. This reaction consumes 1 equivalent mole of water 
and the amount can be back calculated by the voltage change caused by the consumption of 
I2. The reaction can be described as follows,  
Step 1. SO2 + ROH + B  MeSO3

+ HB
+
 
Step 2. MeSO3

 + H2O + I2 + 2B MeSO4

 + 2 HB
+
 + 2 I

 
B=Base (imidazole or diethanolamine) 
2.1.5 Powder bulk/tapped density   
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Powder bulk and tapped density are important indicators of powder flow property 
which could influence the powder spray pattern and other dispersion properties of the powder 
(see section 1.4.4.2). The SFD process has been previously optimized only based on 
production of different particle sizes. It is important to examine powder bulk and tapped 
density properties after SFD process, especially when adjuvants and macromolecules could 
influence the interface phenomenon during freezing or drying and lead to significant 
deviation of particle density from particles prepared with trehalose alone.  
Bulk density is defined as the mass of powder particles divided by the total volume 
they occupy after “free settling”, whereas tap density refer to the mass divided by volume 
after tapping (or other specific compaction process) till no volume change occurs. The Carr‟s 
compressibility index (CCI) derived from these two parameters can be used to assess powder 
flow property
246
. A free-flowing powder should have a CCI less than ~20-21%, however care 
must be taken in the data interpretation since variation in the method (diameter of cylinder 
used, number of times powder is tapped, the mass of the material used and the rotation of 
sample during tapping) could affect the final determination of CCI.  
     
                           
              
       
2.1.6 Powder thermal stability (DSC) 
Thermal analytical technique DSC was first introduced in the 1960s by E.S. Watson 
and M.J. O'Neill, which has since become a very popular technique in studying phase 
transitions of different materials. DSC measures the difference of the amount of heat required 
to increase the temperature of a sample and reference as a function of temperature or time. 
DSC can be used as a general tool for chemical purity analysis (impurity causes broadening 
of melting peak), or can be used to determine the degradation temperature, crystallinity, 
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curing process in polymer industry and many other applications. In pharmaceutical industry, 
DSC is widely used to examine the polymorphism of drugs and their amorphous content, 
glass transition temperature (Tg) of excipients, which could not only affect solubility, 
dissolution and, consequently, affect bioavailability, but also storage condition requirements. 
In the current study we are particularly interested in evaluating the effect that protein antigen 
and adjuvant might have on the Tg of bulking agent trehalose and thermal stability of the 
powder formulations which could provide useful information on the selection of storage 
conditions. Glass transition is universal to all amorphous material, which refers to the 
transition between solid glassy states and the rubbery liquid-like states. Glass transition is not 
a formal phase change, but involves heat capacity change. For aged amorphous material and 
materials with significant water content, other kinetic transition process such as evolution of 
water and enthalpic relaxation could occur before or during glass transition temperature. The 
total heat flow obtained from conventional DSC scan would show no clear glass transition 
regions due to these overlapping events. It would be difficult to characterize Tg using 
conventional DSC; second scan is often required in order to isolate the normal glass 
transition signal by removing the effect of water and relaxation history from the sample. 
Otherwise, an enhanced technique, modulated DSC can be very useful in this case which can 
separate the total heat flow into reversing (heat capacity: glass transition) and non-reversing 
(kinetic, evolution of water and enthalpic relaxation) components. 
2.1.7 Examination of protein secondary structure using CD and FTIR 
It is important to examine the structural properties of proteins since they are closely 
correlated to protein biological activity and stability. Although X-ray crystallography offers 
most detailed structural information, however it is not often possible to perform the analysis 
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due to the difficulty in protein crystal formation. In addition, the dynamic properties of 
protein in solution can be different and hard to extrapolate from the crystallographic data. 
Nuclear magnetic resonance spectroscopy is another useful technique that could provide 
detailed structural information of a protein in solution, but it requires substantial amount of 
protein for the analysis and the data interpretation process can be cumbersome. As a result, 
the two vibrational spectroscopies FTIR and circular dichroism (CD) remains the most 
commonly used techniques for protein structure analysis, which were used in a 
complimentary manner to monitor the possible protein secondary structure change due to 
formulation with hydrophobic C48/80, the manufacturing process and storage.  
CD is the most sensitive physical technique for monitoring secondary structural 
changes of biomolecules.  A CD signal arises when a chromophore is chiral, which could 
originate from a chiral center in the molecule, or involve the formation of asymmetric 3-
dimensional structure in the case of biomolecules (proteins or nucleic acids). These 
asymmetric molecules often absorb right and left-circularly polarized light of a plane 
polarized light to a different extent (also called dichroism), which in turn was converted into 
elliptically polarized light. Although the difference (A = AL-AR) is small (in the range of 
millidegree) but it is readily detectable using modern techniques, and is generally reported in 
terms of the ellipticity () in degress with the relationship with A to be  = 32.98 A. The 
CD spectrum is obtained when the dichroism is measured as a function of wavelength. The 
most prominent chromophore in peptides and proteins is the amide group which has UV 
absorption below 240nm. There are four  electrons associated with three  orbitals and two 
lone pairs (n and n orbitals) from the carbonyl oxygen that can participate in four possible 
electronic transitions, namely 0  *, +  *, n  *, n  * (Figure 2.3). Only two of 
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the transitions have been identified, that is 0* (near 190nm) and n* (near 220nm)
247
.  
Formation of secondary structure could bring a number of amide groups in close vicinity, 
which can behave as a single absorbing unit and ultimately give rise to characteristic spectral 
features in a CD spectrum.  According to their secondary structure, proteins can be grouped 
into five different classes
248
, namely all-α proteins (mostly α helices), all-β proteins (mostly 
β-sheets), α+β proteins (α helices and β sheets in separate domain), α/β proteins (intermixed 
segments that often alternate along the polypeptide chain) and finally the fifth class refers to 
proteins with very little ordered structure
248
. The energy of 0* and n* transitions can 
be different depending on protein backbone conformation (secondary structure). All-α 
proteins have characteristic CD signal showing a strong double minimum at 222 and 208-
210nm and a stronger maximum at 191-193nm, while all-β proteins usually have a single, 
negative and a single, positive CD band with intensities lower than those of α helix. For α+β 
and α/β proteins, as most proteins are, the CD signal is a mixture of α helix and β sheet with 
displaying signals one predominate the other. A typical spectrum can have two negative CD 
bands at 222 and 209-210nm and one positive band near 190-195nm. In some cases, for α+β 
proteins, the 208-210nm band can have larger intensity than the 222nm band, and the reverse 
is true for the α/β proteins249. In other cases a single broad minimum may appear due to 
overlapping of the two component bands. Finally, the unordered polypeptides can display a 
strong negative band near 200nm and some weak bands between 220 and 230nm, which can 
be either positive or negative signals. This basic information on protein secondary structure 
was mostly obtained by referencing CD spectrum of proteins whose structures have been 
resolved by X-ray crystallography or NMR. CD measurement in far-UV region provide 
important information on overall structure features of proteins and conformation, and is a 
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robust method to monitor conformation changes in proteins. However, quantitative 
estimation of secondary structure composition (% helix, sheet, turns etc) can be problematic 
and remain an empirical task even with the aid of mathematical algorithm for data analysis.  
FTIR spectroscopy measures the wavelength (correlates to vibrational energy levels) 
and intensity of the absorption of infrared light by a sample. The protein/polypeptide 
structural repeat units can give up to nine characteristic IR absorption bands (amide A, B and 
I-VII)
250
. Among them, Amide I and II bands are two most prominent bands due to protein 
backbone vibration
250-252
 (Figure 1.8). Amide I band (1700-1600 cm
-1
) is mainly associated 
(80%) with the stretching vibrations of the C=O bond contained by the amide bond (peptide 
linkages). The stretch frequency of the amide I band components are directly related to 
protein secondary structure, due to the hydrogen bonding propensity of C=O groups.  Amide 
II being mostly derived from in-plane NH bending (40-60% of the potential energy) and from 
the CN stretching vibration (18%-40%)
250
, is much less sensitive to protein backbone 
conformation and amide I band. Other vibrational bands can be very complex due to side 
chain interaction and hydrogen bonding which are of little practical use in the protein 
conformational studies. Attenuated total reflectance (ATR) offers a more advanced sampling 
technique comparing to traditional FTIR sampling, which allows small sample size 
(microliter volume) analysis without further sample preparation. It also eliminates the 
mechanical stress associated with KBr pelleting, which can be a potential cause of protein 
denaturization. Consequently, it has become quite popular in protein sample analysis (section 
1.4.3.1).  In ATR-FTIR, the intensity of the absorption spectrum does not correlate to the 
concentration of the sample, but can be dependent on the sample reflective index and the 
penetration distance of the evanescent wave into the sample.  
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Amide I band has been most useful in study protein secondary structure composition 
and conformational changes
131, 253-255. Different type of secondary structure (i.e., α-helix, β-
sheet, turn, and unordered structure) having unique geometry is formed due to different 
intermolecular interactions mainly the hydrogen bonding patterns, which directly correlates 
to the difference in C=O stretching frequency in the amide I region of the IR spectrum. 
However one major drawback has been that the amide I absorbance is often featureless and 
appear to be a single band contour, due to the overlapping of the broad underlying 
component bands which is beyond instrument resolution. Several mathematical data analysis 
methods have been employed to better resolve the individual band components including two 
most popular methods, Fourier self-deconvolution (FSD) and second derivative method
254
.  
Second derivative manipulation offers several advantages over FSD method, in which it 
eliminates the need for subjective input of arbitrary parameters and allows the identification 
of various structures present in the sample protein
251
. The resultant protein spectra are often 
subjected to curve smoothing to remove possible broad baseline fluctuation and background 
noise
254
. IR-solution software offers the Savitzky-Golay smoothing method
256
, which has the 
advantages of preserving features of the distribution by keeping the maxima, minima and the 
band width.  
2.1.8 Examination of antigen functional stability by in-vitro cell-based assays   
It is known that C48/80 is a mast cell activator that causes mast degranulation
257
. 
Acid glycosidase, β-hexosaminidases (EC 3.2.1.52) have been identified as important 
enzymatic markers for mast cell granules
258
. They are lysosomal enzymes that remove 
terminal β-glycosidically bound N-acetylglucosamine and N-acetylgalactosamine residues 
from a number of glycoconjugates. The release of β-hexosaminidases has been widely used 
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as a measure of degranulation of mast cells with p-nitrophenyl-N-acetyl-β-D-glucosaminide 
(NAGpnp) as substrate (Figure 2.2). The UV-absorbance of p-nitrophenol released after the 
enzymatic hydrolysis can be an indirect measure of β-hexosaminidase activity.  
Macrophages are particularly sensitive to anthrax lethal toxin, the combination of PA 
and LF (LeTx). It has been demonstrated that individual proteins alone exhibit no toxicity
259
, 
because the killing mechanism of LF can only occur with the assistance of PA for its cell 
entry and endosome escape. When LF is added to the reconstituted SFD formulations, the 
functional stability of rPA can be estimated by measuring the macrophage toxicity caused by 
LeTx.  
2.2 Methods 
2.2.1 Powder vaccine manufacture 
Spray-Freeze-Drying  
Aqueous solutions containing one or more components of antigen, adjuvant and 
trehalose were prepared with an overall solute concentration of 10% w/v, which were passed 
through a two-fluid pneumatic spray nozzle (7 mm diameter, Buchi Spray-Dryer B-191, 
Flawil, Switzerland) with a liquid feed rate of 10 ml/min. Nitrogen gas with a flow rate of 
500 L/hr and a fixed back pressure of 3 bar was used to force the liquid into small droplets, 
which were collected in a stainless steel vessel containing liquid nitrogen. Upon evaporation 
of liquid nitrogen in -80°C refrigerator, the frozen droplets was transferred to a pre-chilled jar 
and lyophilized for 72 hours with a manifold temperature of -55°C and a vacuum pressure of 
20 mtorr (Kinetics Flexi-Dry, Kinetics Thermal Systems, Stone Ridge, NY).  
2.2.2 Physicochemical characterization of powder particles 
Particle Morphology and Size Determination 
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The morphology and shape of the SFD powders were examined by Hitachi S-4700 
Cold Cathode Field Emission Scanning Electron Microscope. Samples were loaded on SEM 
stubs with double-sided adhesive carbon conductive tab by dipping into dry powder stock, 
and sputter coated with Pd/Au with a thickness of 3 nm.  
A small amount of powder from each formulation was suspended in a 1% Span 80 in 
light mineral oil and sonicated for 10 seconds, which were added to a stirred sample cell 
(~15ml) until idea sample concentration was reached (obscuration level of 20-30%). Particle 
size analysis by laser diffraction was performed using particle-in-liquid (pil) mode on 
Malvern 2600c (Malvern Instruments, Worcestershire, UK) with 100mm focal lens. Powder 
spray from Unitdose device (Pfeiffer) was suspended in a 10cm  10cm custom build 
chamber equipped with glass windows facing the laser path, and PIA (particle-in-air) mode 
was selected for the analysis. Volume median diameter and span were measured. 
Bulk and Tapped Densities 
Approximately 10ml of SFD powders were measured using a 10ml graduated 
cylinder. The mass and volume of the unsettled/poured powder was recorded and the ratio 
between the two was calculated as bulk density. The tapped density was obtained following 
about 200 taps until no further decrease of powder volume occurred.   
Moisture Analysis 
Coulometric Karl-Fischer titration powders (Model 270, Denver Instrument, Denver, 
CO.) was used to determine the moisture contents of the SFD. Approximately 20-25 mg of 
powder was added to the reaction cell directly. 
2.2.3 Powder thermal stability examination  
Differential scanning calorimetry (DSC) 
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DSC (Perkin Elmer DSC 6, Wellesley, MA) was performed on powder samples. 
Known quantities of the powders (1-3mg) were loaded in an aluminum pan and differences 
in heat flow were measured against an empty reference pan. Analysis was performed with a 
temperature ramp rate of 10°C/min.  
2.2.4 Physicochemical stability of antigen 
ATR-FTIR 
FT-IR measurements were conducted with Shimadzu FTIR-8400s (Shimadzu 
Corporation) in combination with attenuated total reflectance by MIRacle™ ATR accessory 
equipped with ZnSe crystal (PIKE technologies). SFD powder formulation was filtered 
through with Centricon
®
 centrifugal filter device with Ultracel
®
 YM-30 membrane 
(Millipore, MA), protein component was recovered in 10mM sodium phosphate buffer and 
loaded onto the crystal surface for direct measurements (scan range 1000cm
-1
-2000cm
-1
, 
120scans, resolution 4cm
-1
). Buffer spectrum was subtracted from the sample spectrum using 
IRsolution software. Each spectrum was minimum-maximum normalized and then taken 2
nd
 
derivative followed by curve smoothing using Savitzky-Golay method. 
Circular Dichroism  
Far-UV CD spectra (190nm-260nm) were recorded at 25°C with an Applied 
Photophysics Pi-Star 180 circular dichroism spectrapolarimeter. Spectra were recorded in 
0.5nm steps and averaged over 1.25s. All measurements were carried out in a 1-mm quartz 
cuvette. The powder vaccine formulation was reconstituted with deionized water, and was 
concentrated by centrifugation filter using a Milllipore Centricon centrifugal filter device 
with an Ultracel® YM regenerated cellulose membrane with a molecular weight cut-off of 
30KDa (15°C, 5000  g, 30min), while removing interference from the adjuvant C48/80 at 
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the same time. Protein retentate was then recovered in 10mM phosphate buffer by reverse 
spinning at 1000  g for 3 mins. Final protein concentration for CD analysis is about 0.2 
mg/ml. A blank spectrum with buffer only was subtracted. Molar ellipticity     in the units of 
deg.cm
2
.dmol
-1
 is calculated based on the equation:               , where  is the 
millidegree obtained from instrument, C is the molar concentration of the protein and   = 
0.1cm is the path length of the cuvette.  
SDS-PAGE & Native PAGE 
SDS-PAGE was performed with a precast NuPAGE 4-12% Bis-Tris gel (Invitrogen, 
Carlsbad, CA). Powder samples (reconstituted in deionized water) and standards ~10µg per 
band were mixed with NuPage LDS sample buffer (Novex) with addition of 5% (v/v) 2-
Mercaptoethanol. Samples were incubated at 70°C for 10mins. Electrophoresis was 
performed with NuPAGE MOPS SDS running buffer (Invitrogen) at constant voltage of 
200V for 50min. The resulted gel was stained with GelCode Blue Stain Reagent (Pierce 
Biotechnology, Rockford IL) and destained with distilled water. 
Native-PAGE: A precast Native-PAGE
TM
 Novex
®
 3-12% Bis-Tris Gel (Invitrogen) 
was used to perform native electrophoresis. Powder samples (reconstituted in deionzed 
water) ~10µg per band were mixed with NativePage
TM
 sample buffer and kept on ice prior to 
loading. NativeMark
TM 
Unstained protein standard was used as molecular weight reference. 
Eletrophoresis was performed with NativePAGE
TM 
anode and cathode buffer with cathode 
additive (light blue) at constant voltage of 150V for 90min. Gel was stained with Colloidal 
Blue Staining Kit (Invitrogen) after separation and destained with distilled water.  
2.2.5 Functional stability of antigen and adjuvant in-vitro 
Macrophage Toxicity Assay 
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Recombinant LF was added to reconstituted powder formulation in a 1:1 ratio, the 
activity/stability of rPA was evaluated by measuring the PA dependent toxicity of rLF using 
mouse macrophage J774A.1 cells (ATCC, Manassas, VA).  J774A.1 cells (6 104 cells/well) 
in 100µl Dulbecco‟s Modified Eagles Medium (DMEM) phenol-red free with 10% fetal 
bovine serum, 4.5 g/L Glucose and 2mM L-glutamine were seeded in a flat-bottom 96-well 
microtiter plates and incubated for 24h at 37°C for cells to adhere at the bottom. rLF was 
added to the reconstituted powder formulation and control rPA in a 1:1 ratio with a final 
starting concentration of 1.5 µg/ml, followed by 2 fold serial dilution across the plate. After 
incubation at 37°C for one hour, 100µl of the rPA/rLF mixture was transferred to the plate 
containing macrophage cells with media removed. The rPA/rLF mixture were incubated with 
cells for 4 hours, 20µl of CellTiter 96 Aqueous One solution (Promega, Madison, WI) was 
added and incubated for another 2 hrs before measuring the absorbance at 490 nm for cell 
viability. 
β-Hexosaminidase Release for Mast Cell Degranulation  
Mast cell degranulation activity of the adjuvant was examined by measuring the 
release of a granule marker, β-hexosaminidase (montemurro et al., 2002). MC/9 cells 
(ATCC, Manassas, VA) were washed and plated in Tyrode‟s buffer (135 mM NaCl, 5mM 
KCl, 1.8mM CaCl2, 1mM MgCl2, 5.6 mM glucose, 1mg/mL bovine serum albumin, and 
20mM Hepes, pH 7.4) at concentration of 2 105 cells/well. Cells were spun down, and 
media was removed. Powder formulations reconstituted in Tyrode‟s buffer with desired 
concentration of the stimulus were added to the plate, and incubated at 37°C for 1.5 hour. β-
Hexoaminidase substrate, p-nitrophenyl-N-acetyl-β-D-glucosaiminide (NAGpnp, Sigma-
Aldrich) 3.4 mg/mL was prepared in 0.1M citrate buffer (pH 4.5). After the incubation, 30µl 
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of the supernatant were taken from the mixture and added to 10µl NAG in a separate plate 
which was further incubated for 1 hour. The reaction was then stopped with 100µl sodium 
carbonate buffer (0.1M, pH 10), and absorbance at 405nm was recorded. 0.1% Triton 
prepared in Tyrode‟s buffer was used as positive control. Percent degranulation was 
calculated using the following formula ((TestMedia only) / (TritonMedia only))  100.  
2.2.6 Storage stability of anthrax vaccine formulations 
The anthrax vaccine formulations were aliquotted into 2mL micro-centrifuge tubes 
(Fisherbrand). Each tube contained about 40-50 mg of SFD powder formulation, which was 
stored at 25°C, 40°C with different humidity levels (55% RH maintained with saturated 
sodium bromide solution or 75% RH with saturated sodium chloride solution). After storage 
powder samples were reconstituted in about 300-400µL of water for macrophage toxicity 
assay. Liquid formulation containing rPA (125 µg/mL), C48/80 (100 µg/mL) and Trehalose 
(123 mg/mL) in sterile water were also prepared, 320µl of which were aliquotted into 2mL 
micro-centrifuge tubes and stored at 4°C, 25°C and 40°C for in-vitro stability analysis.  
2.2.7 Animal study 
Female New Zealand White rabbits ~2.5-3kg (Robinson Services, Mocksville, NC) 
were cared and used under conditions approved by Duke University‟s Institutional Animal 
Care and Use Committee. Rabbits (4 rabbits/group) were anesthetized with 
acepromazine/butorphanol (1mg/kg each) prior to intranasal immunization. Rabbits were 
immunized three times on days 0, 21, and 42. Liquid formulations of rPA (30µg) with or 
without C48/80 (120µg) in 200µl PBS (100µl each nostril) were delivered intranasally to 
rabbits using a laboratory pipette or via IM injection. Powder vaccines of the same antigen 
and adjuvant dose (30µg rPA, 120µg C48/80 in 15mgs of powder) were delivered using a 
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Unitdose powder human device fitted with a tip (modified from P10000 pipette tip, with tip 
diameter of 2.33mm) (Figure 2.16) for smaller openings of rabbit nasal cavity (6-9mg per 
nostril). Rabbits receiving liquid formulations were held on their back for 30s after nasal 
immunization before returning to their cage, whereas rabbits were immediate turned over 
after receiving nasal powder vaccination with Unitdose device. Blood were taken via 
marginal ear veins on days 7, 35, and 56 for ELISA and toxin neutralization analysis.  
2.2.8 ELISA 
A fluorescent ELISA was used to measure anti-PA immunoglobulin G (IgG) endpoint 
titers in the serum of rabbit after each immunization. PA was coated onto black 384-well 
plates (Nuncbrand) with a final concentration of 2µg/ml in sodium carbonate-bicarbonate 
buffer (CBC). After incubation overnight at 4°C, Nonfat dry milk (3% w/v) in CBC buffer 
with Kathon (0.1% v/v) was added and incubated for at least 2 h. to block the non-specific 
binding sites. Plates were washed four times with ELISA wash buffer (0.1% kathon and 
0.05% Tween20 in PBS) and diluted serum samples (1:32) were plated in complete sample 
diluents (1% w/v bovine serum albumin, 1% w/v non-fat dry milk, 5% normal goat serum, 
0.05% Tween20, 0.1% Kathon in PBS) for overnight incubation at 4°C. Plates were washed 
with ELISA wash buffer and 2
0
 antibody (goat anti-rabbit IgG, alkaline phosphatase 
conjugated, Southern Biotech) was added with 1:5000 dilution in secondary antibody diluent 
(0.5% w/v bovine serum albumin, 5% v/v normal goat serum, 0.05% v/v Tween20 and 0.1% 
v/v Kathon) and incubated for at least 2 h at room temperature. Plates were washed with 
ELISA wash buffer and 15 µl AttoPhos substrate (Promega) was added to each well and 
incubated for 15 min before reading at 440nm(excitation)/560nm (emission). The log2 
endpoint titers were used for statistical analysis. Samples with no detectable anti-PA IgG 
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titers were assigned a value of 1 for statistical analysis. Anti-log2 titers were calculated and 
plotted with geometric mean titer (GMT).  
2.2.9 Toxin neutralization assay 
The ability of serum anti-PA antibody to neutralize LeTx was determined in a similar 
manner as macrophage toxicity assay using J774A.1 cell. A typical method has been 
described previously
27
. In general, rabbit serum is serially diluted
 
and incubated with PA 
protein (0.375µg/ml) in 96 well plates for 1 h to allow neutralization
 
to occur. Then LF is 
added to the serum-PA mixture from previous incubation step to achieve a final 
concentration of 0.1875 µg/ml of
 
LeTx.  A standard curve was also prepared with starting 
PA/LF concentration at 1.5µg/ml followed by serial 2-fold dilution.  J774.1 cells that was 
plated one day before and incubated at 37°C overnight in sterile, 96-well, clear-bottom. After 
medium was removed, sample and standard curve mixture (100µl) were added to the cells 
and incubated for 4 h at 37°C in 5% CO2.  Cell viability was determined using CellTiter 
96Aqueous (Promega, Madison, WI). Percent neutralization was calculated using the 
following formula: (sample OD value − LeTx standard OD value)/(cells-only OD value − 
LeTx standard OD value) × 100. The optical density (OD) of a medium-only well (i.e., no 
cells) was subtracted from all values before percent neutralization was calculated. The 
percent neutralization was plotted versus antibody concentration, and the linear range was 
used to calculate the concentration of antibody needed to neutralize 50% of LeTx (NC50). 
Fifty percent neutralization titers (NT50) were similarly calculated for the serum collected 
from rabbit. The neutralization concentrations or titers reported represent the final 
concentration or dilution of antibody when combined with LeTx and the J774A.1 cells. 
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Samples that had no detectable LeTx neutralization activity were assigned a value of 1 for 
statistical analysis. 
2.3 Results and Discussion 
2.3.1 Physicochemical properties of SFD powders  
Different powder formulations were prepared by SFD. The amount and ratio of rPA 
and compound 48/80 were adopted from liquid formulations optimized in Dr. Staats lab 
(Table 2.1).  
Scanning electron micrographs (Figure 2.4) show that the particles prepared by SFD 
were in general spherical and very porous, which is consistent with their relatively low 
tapped density (Table 2.3). Low and high magnification of trehalose formulation (Figure 
2.3-A, B) demonstrated primary particles with sizes consistent with LD measurements. SEM 
image of C48/80 (Figure 2.3-C) showed spherical particle appears to have smaller pores and 
more materials inside. In addition, smaller particle size and higher tapped density were 
measured for these particles in comparison with SFD trehalose particles, which could be a 
result of introducing hydrophobic content to trehalose formulation. The addition of protein to 
the formulation has yielded particles with hollow porous structure as shown in image D and 
E. The particle backbone structure seems very fragile and was easily broken off due to 
frequent handling.  
The volume median diameter of the SFD particles from each formulation was very 
close to the target size D50=25µm (Table 2.2) when prepared under optimized SFD process. 
Formulation with adjuvant C48/80 and antigen rPA did not change the particle size 
distribution very much in comparison to pure trehalose formulation (Figure 2.4).  
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Powder flow properties are important factors that could affect delivery efficiency of 
the powder spray products. In the current project, a simple CCI index based on powder bulk 
and tapped densities was used to evaluate powder flow property. The bulk (0.05-0.16 g/ml) 
and tapped (0.08-0.24 g/ml) densities of the SFD powders were significantly lower than bulk 
trehalose (~0.5 and 0.6 g/ml). The bulk and tap densities of the SFD formulation-2 were 
similar to SFD trehalose (Table 2.3). The bulk and tap densities (0.16 and 0.24 g/m, 
respectively) of SFD c48/80 seems to be larger than other SFD formulations listed in the 
table. The CCI indices for all SFD powders were high (between 32-38%), suggesting the 
powders are easily compressible, and indicating large cohesive forces acting on the SFD 
powders. This can be attributed to the large porous structure of the SFD particle, the 
brittleness of the structure. Surrounding moisture levels during the experiment is another 
factor that could influence the cohesive forces between the particles due the moisture 
sensitive nature of SFD trehalose. As mentioned in the introduction section, a free-flowing 
powder has a CCI less than ~20% to 21%. None of the SFD powders would be considered 
free flowing based on their CCI index.   
However, the flow property of the SFD powders as determined by CCI index did not 
seem to dictate the performance of the final product. A Unitdose powder device was able to 
deliver almost complete amount of SFD powders packed (loading amount 6-9mg). When the 
Unitdose device was fitted with an extra tip for nasal delivery to rabbits, the emitted dose for 
SFD powders decreased slightly with overall efficiency to be over 98% (Table 2.4). Powder 
spray from Unitdose device showed very similar particle size distribution with powders 
measured in oil suspension (Figure 2.5). The overall volume diameters of powder sprays 
appear to be very close to SFD powders measured by PIL. Although the volume median 
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diameter seems larger for powder sprays in PIA measurements, it could be an artifact 
introduced by the difference in sample treatment and sampling technique. Nevertheless, these 
results indicate that SFD powders tested showed good dispersion properties and delivery 
efficiency (complete dispersion) with Unitdose powder device. 
2.3.2 Thermal properties and moisture content 
The moisture content of the SFD powders was around 2-5% (Table 2.3) following 
lyophilization and storage at room temperature with desiccant. To determine whether the 
formulation components and the water content will affect the Tg of amorphous trehalose, 
which might subsequently influence the storage temperature, DSC scans of SFD powders 
were performed at 10°C/min (Figure 2.6). Non-typical glass transition peak of SFD 
trehalose, SFD rPA-1 and SFD rPA-2 formulations were detected due to interference from 
other thermal transitions that occur at the same temperature range, namely the previous broad 
dehydration process, and the onset of an accompanying relaxation endotherm at Tg (also 
called enthalpic recovery)
260
. Since these formulations have been manipulated under ambient 
conditions during the one year storage before DSC measurements, it is likely that water 
content in these powders could have acted as a plasticizer and introduced increased 
molecular mobility of the amorphous trehalose matrix which has lead to structural relaxation. 
As a result a detectable magnitude of enthalpic recovery was observed overlapping glass 
transition, which has prevented identifying Tg in the first scan. Nevertheless, after removing 
water, by subjecting the sample to a heat cool cycle, the second DSC scan showed fully 
resolved glass transition, with Tg of 106°C (see Figure 2.6 insert), which is consistent with 
what has been reported in the literature (106-120°C)
119, 162, 261
. Commercially available 
C48/80 displays a broad endothermic peak between 30-90°C, which might be due to the fact 
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that C48/80 is a mixture of different molecular weight oligomeric polymers. SFD powders 
containing C48/80 showed a broad endothermic peak as well. In some cases like SFD rPA-1 
and SFD rPA-2 formulation, the broad peak extends through dehydration temperature to near 
110°C, which is likely due to a mixed contribution from C48/80 and loss of unbound water. 
Interestingly, a small spike around 60°C was observed among the broad C48/80 peaks for 
two formulations containing rPA antigen, which is most likely the result of protein melting 
since it is very close to the Tm of rPA determined by CD measurements
111
.  
2.3.3 Structural stability and integrity of rPA 
CD is a widely used method for protein secondary structure determination (section 
1.4.3.1). However, it requires the protein concentration to be in the milligram per milliliter 
range for analysis. Since CD measures the protein secondary structure in the far-UV region, 
buffer or any other component in the sample solution that has high UV absorption could 
mask the CD signal. For a powder vaccine formulation prepared for rabbit model contains 
20µg of rPA and 80µg of C48/80 per 10mgs of SFD powder, there would be excess amount 
of C48/80 and trehalose in the reconstituted solution in order to meet the concentration 
requirement of protein for CD analysis. In order to eliminate the UV absorbing C48/80 and to 
concentrate protein, reconstituted SFD samples were subjected to ultrafiltration using 
Millipore‟s Ultracel® YM regenerated cellulose membranes with a molecular weight cut-off 
of 30KDa. Centrifugal forces, time and temperature were selected according to manufacture 
guidelines for maximum recovery. Figure 2.9 shows the molar ellipticity of rPA at the Far-
UV region. The CD spectrum of rPA in the SFD formulation appears to be very close to the 
unprocessed rPA protein. Both CD spectra display a broad negative absorption with a single 
dominating minima at around 208nm, suggesting a mixture of α-helical and β-sheet 
98 
 
component, which is comparable to CD spectraof PA reported in the literature
111
. The 
positive α-helical signal near 195 nm (0*) is not observed, which may be due to the 
possible interaction from certain aromatic amino acid side chain in PA
262
. 
ATR-FTIR experiment was carried out to confirm the CD result. ATR FTIR 
absorption spectra (2000cm
-1  1000cm-1) of rPA in unprocessed control sample (Figure 2.7-
A) and rPA concentrated from reconstituted SFD formulation (1 year of storage) (Figure 2.7-
B) showed great overall similarity in 10mM phosphate buffer. The difference in absorption 
intensity was due to the difference in refractive index and penetration of the evanescent 
wave. Second derivative manipulation allows direct comparison of the two spectra. Figure 
2.8 shows the second derivative spectra of the two samples in the Amide I region (1600-
1700cm
-1
), which depicted overall resemblance regarding the peak shape, position and 
intensity. Different components of the secondary structure can be assigned according to the 
literature
131
. One major band at 1652 cm
-1
 has been assigned to α–helical component of the 
structure. Several other band components at 1680cm
-1
, 1634cm
-1
 and 1618cm
-1
 are 
attributable to formation of β-sheet in the protein structure. Finally, the small band 
component at 1670 cm
-1
 is indicative of turn structure. These secondary structure 
components correspond to the structure element of PA as reported in protein data bank 
(PDB:1ACC). 
Both CD and FTIR spectroscopy confirmed the structural stability of PA in the SFD 
formulation. The integrity of the protein was further examined by gel electrophoresis (Figure 
2.10). SDS-PAGE (left image) under reducing conditions shows that powders stored for 1.5 
years (lane 2) and freshly prepared powders (lane 3), have similar migration patterns to 
unprocessed rPA control, which means the rPA is maintaining its molecular size and 
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integrity. This result is also true for samples prepared and analyzed under non-reducing and 
native conditions, as shown in the right image. This result indicates the absence of antigen 
aggregation due to oxidation.  
2.3.4 Functional stability of rPA and compound 48/80 
The biological functions of the adjuvant and antigen allow us to examine their 
functional stability in-vitro with cell-based assays. The functional stability of C48/80 was 
confirmed by mast cell degranulation assay. SFD formulations (prepared 1.5years ago, 
followed by r.t. storage with desiccant) showed comparable mast cell degranulation activity 
with respect to control C48/80 at different concentration dilutions. Variability of 
degranulation activity among groups might be due to the batch to batch variability of 
commercial available C48/80. This result demonstrates functional stability of C48/80 after 
SFD process and upon 1.5 years of storage.  
In addition, the functional stability of rPA was assessed in macrophage toxicity assay. 
A 1:1 ratio of LF was added to reconstituted SFD formulations, where the cellular toxicity of 
LeTx to macrophage cells was an indirect measurement for PA functionality since the killing 
mechanism of LF can only occur with the assistance of PA for its cell entry and endosomal 
escape. Figure 2.12 shows the cell viability across the PA/LF concentration dilutions. Low 
optical density corresponds with few viable cells which, in turn means PA is still active. The 
toxicity profile across PA/LF dilutions of LF+SFD rPA formulation-2 prepared two years 
previously with room temperature storage with desiccant and freshly prepared SFD rPA 
formulation-2+LF are very close to control rPA+LF. Whereas, when LF was added alone, no 
toxicity is observed, and trehalose did not affect the in-vitro function of rPA+LF very much.  
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This macrophage toxicity assay has been a useful tool to monitor the functional stability of 
PA after formulation, manufacturing process and storage.  
2.3.5 Storage stability of powder formulations 
SFD trehalose powder formulation is highly moisture sensitive, rapid moisture 
absorption can reduce powder flowability, lead to powder collapse and dose delivery failure. 
To gain better understanding of the effect of moisture uptake on the stability of antigen, and 
to find a optimum storage condition for both the powder and liquid formulations, liquid and 
powder formulations contain rPA, C48/80 and trehalose were prepared and stored under 
different temperature and different humidity levels (4°C/liquid only, 25°C/ambient RH 
(average 30-40% RH), 25°C/55% RH, 40°C/75%RH) with either close or open top vials 
(Table 2.5). Instead of measuring physicochemical stability of rPA, the storage stability of 
each formulation was determined by rPA functional activity based on macrophage toxicity 
assay.  
Results (Figure 2.13-A) of SFD powder vaccine formulations stored at different 
conditions show that the rate of rPA degradation increases as humidity level increases for 
storing SFD powder formulations. SFD powder formulations stored with desiccant were the 
most able in terms of PA functional activity preservation (Figure 2.13-A, C). For SFD 
powders stored at 25°C at ambient humidity levels (average 30-40% RH), initial fast 
degradation was observed during the first week, then a steady PA activity level was reached 
(refer to next page for explanations). SFD Powders stored in a regular screw top plastic vial 
was not able to prevent moisture uptake and appeared to have a similar degradation profile as 
powders stored in an open top vial. SFD powders stored at 55% RH seems more susceptible 
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to degradation, the rate is faster and similar to liquid formulations stored at room 25°C 
(Figure 2.13-C). 
The rate of degradation of liquid formulation increased as temperature is elevated 
(Figure 2.13-B). For liquid formulation stored at 40°C, PA activity was lost completely with 
in 1 day (Figure 2.13-B, D). However, SFD powder formulation stored at same temperature 
and 75% RH level was able to extend the PA activity for a longer period compare to liquid 
formulation. Furthermore, when SFD powder formulation was stored with desiccant at 40°C, 
80% of the PA activity remained after two weeks of storage (Figure 2.13-D).  
Thermal stability of SFD powder vaccines stored under different conditions was also 
examined by DSC (Figure 2.14). Crystallization occurred after one day for powders stored at 
25°C ambient humidity levels, as evidenced by the peak ~130°C  which is a result of 
evolution of bound water in trehalose dehydrate (Figure 2.14-A). The melting point of 
trehalose dehydrate was observed at day 3 and day 7 by DSC with the appearance of a sharp 
peak around 100°C indicating the removal of surface water. This initial recrystallization 
process might have prevented further moisture uptake to the crystal core which leads to a 
possible stabilizing effect as seen in Figure 2.13-A,D where rPA activity remains steady 
after first week. Conversely, as humidity levels were increased for storage SFD powders, 
recrystallization seems to be overwhelmed by the excess water content as no melting peak of 
trehalose dehydrate was observed. Nevertheless, formation of partial dehydrate as well as 
significant intermolecular hydrogen bonding in these samples
263
, might have resulted in the 
broad peak at ~130°C (Figure 2.14-B) or a higher temperature (Figure 2.14-C) due to 
removal of bound water or water involved in matrix hydrogen bonding.  
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Based on these results the SFD powder vaccine formulations was stable at room 
temperature upon 2 years of storage. However, the formulation is susceptible to degradation 
even at ambient humidity levels (average 30%-40% RH). Consequently, SFD powders 
should be either stored using special sealed device or stored with desiccant to limit moisture 
uptake. The upper limit of storage temperature can be increased to 40°C for up to two weeks 
as long as the SFD has limited exposure to moisture, which allows temperature fluctuation 
during storage and shipping. 
2.3.6 Powder efficacy study in rabbits 
2.3.6.1 Powder tested as reconstituted liquid 
An initial animal study was performed with liquid formulations of rPA alone or rPA 
+ C48/80 as adjuvant or reconstituted powder formulations (Table 2.1-A). All rabbits were 
immunized on days 0, 21 and 42. Serum samples were collected on days 7, 35 and 56 and 
tested by ELISA for the presence of anti-PA IgG. Day 35 and 56 serum samples were also 
tested for their ability to neutralize anthrax lethal toxin (LeTx) using a macrophage toxicity 
assay. ELISA results of serum samples collected on day 7 showed seropositive rabbits among 
each groups after 1
st
 immunization.  After 2
nd
 immunization, a strong booster effect was 
observed across all groups. The adjuvanted groups (rPA + C48/80 and reconstituted powder) 
showed significantly greater serum anti-PA IgG geometric mean titer (GMT) than that in 
rabbits immunized with liquid rPA alone (Figure 2.17-A), demonstrating the adjuvant 
activity of C48/80. No statistical difference was noted between rPA + C48/80 and 
reconstituted SFD powder vaccine groups in their anti-PA IgG titer. However reconstituted 
SFD powder formulation did demonstrate a 10-fold lower group mean anti-PA IgG ELISA 
titer than liquid formulation containing rPA plus C48/80 but without trehalose. After the 
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second boosting, similar level and trend with anti-PA IgG titer among all groups were 
observed (Day56 ELISA data not shown due to compromised naïve bleed). Importantly, the 
serum anti-PA antibody elicited in all groups was effective in providing neutralization of PA 
(Figure 2.17-B). Liquid groups containing rPA plus C48/80 and the reconstituted powder 
group induced a significantly higher toxin neutralization titer than rPA alone. Similar but 
lower TN titer was observed for reconstituted powder formulation than rPA + C48/80. 
However the antibody avidity (TN50 titer per anti-PA IgG titer) seems to be very close 
between these two groups.  
Animal studies with liquid formulations have demonstrated that C48/80 is an effective 
adjuvant for nasal mucosal vaccine in larger animal model such as rabbits. Comparable 
response in anti-PA IgG and TN50 titers of the reconstituted powder group to liquid rPA + 
C48/80 is a clear demonstration of in-vivo efficacy of rPA in SFD formulation. However the 
slightly lower responses observed for reconstituted powder group comparing to rPA plus 
C48/80 indicating possible negative effect caused by trehalose.  
2.3.6.2 Rabbit nasal SFD powder vaccination using Unitdose powder device 
In the previous study, a dry powder formulation of rPA and adjuvant C48/80, was 
prepared and shown to be stable upon one year storage at room temperature. Desired 
physicochemical properties of the SFD powder particles were achieved through parameter 
optimization. The reconstituted powder group was safe and effective in rabbit nasal 
vaccination study. However the SFD vaccine formulation prepared with trehalose appears to 
be moisture sensitive and required an appropriate device to prevent moisture uptake and 
ensure efficient and consistent delivery of the powder dose. A second animal study was 
carried out to further examine the in-vivo efficacy of the SFD powder vaccine formulations 
104 
 
using the Unitdose powder device (Pfeiffer) (Table 2.6). Two SFD powder formulations 
containing rPA + C48/80 were prepared with trehalose under the same optimized SFD 
process, and have been stored in a dessicator for either 2.5 years or 3 months before packing 
into the Unitpowder device (packing condition: RT, RH level under 40%). SFD powder 
loaded devices were stored in a zipplock bag for 2-4 months before final testing in animal 
study.    
After the initial immunization, no detectable serum anti-PA IgG was observed in 
rabbits vaccinated with liquid formulation. However, rabbits in the two IN powder groups 
and IM liquid control group showed 50% and 75% seropositive response respectively as 
determined by ELISA analysis of serum collected on day 7, while no statistical significant 
difference of the anti-PA IgG titers between the any of the three seropositive groups was 
noted (Figure 2.18-A). Even though the measurable titers were low (1:64- 1:128), this data 
demonstrates that a single dose of powder vaccine was similar to liquid IM immunization for 
eliciting an early vaccine-specific IgG titer, whereas vaccination with liquid formulations fail 
to respond after first immunization. The fact that powder vaccine formulation was able to 
induce a quicker immune response after only immunization suggests that powder nasal 
vaccines are superior to liquid nasal vaccines and comparable to IM immunization for rapid 
induction of vaccine-specific antibody response. This property of powder nasal vaccine can 
be especially valuable if used in the event of emergency (as with an expected biological 
attack).  
Following second immunization, a substantial increase in IgG titers (on day 35) was 
observed for all groups of rabbits (Figure 2.18-B) with the lowest being the group vaccinated 
with liquid rPA lone which had a geometric mean anti-PA IgG titer of 1:92,682. All 
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adjuvanted groups including nasal liquid, nasal powder as well as IM liquid group had serum 
anti-rPA GMT that were significantly greater than that in rabbits immunized with rPA alone, 
with titers in the range of 1:10
7
. In addition, no significant difference were demonstrated 
between the serum anti-rPA IgG GMT in any of the adjuvanted groups. Most notably, the 
powder vaccine formulation prepared in 2007 (stored for more than 2 years at room 
temperature) was as effective as any of the adjuvanted vaccines (liquid or powder) in 
eliciting systemic anti-PA IgG response. We should also note that rabbits were held on their 
back for 30s after vaccination with liquid formulations in order to maximize its nasal 
residence time, while rabbits receiving powder spray were immediately returned to their 
cages. The systemic IgG response could be much lower for nasal liquid groups if the rabbits 
were turn back immediately following immunization.  
Similar trends were seen in the day 56 ELISA results showing a continuous systemic 
immune response with moderate increase in overall anti-PA IgG titer among all groups (in 
the range of 1:10
6
-1:10
8
) (Figure 2.18-C). Additionally, the powder vaccine formulation 
prepared in 2007 (stored for more than 2 years at room temperature) was as potent as any of 
the adjuvanted vaccines and induced the highest serum anti-rPA IgG GMT of any of the 
nasal immunization groups with a titer of 1:1.1  108.  
Serum samples collected on day 35 and 56 were also tested for their ability to 
neutralize anthrax lethal toxin (LeTx) using an in vivo macrophage toxicity assay. LeTx 
neutralization titers are presented as the serum dilution required to neutralize 50% of the 
LeTx (NT50). At day 35, all adjuvanted vaccine formulations, delivered IN or IM, had serum 
LeTx NT50 titers that were significantly greater than the LeTx NT50 in rabbits immunized IN 
with rPA alone, which further demonstrates that C48/80 provided significant adjuvant 
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activity (Figure 2.19-A). There were no significant differences in the LeTx NT50 between 
any of the adjuvanted groups (nasal or IM delivery).   It is important to point out that only 
75% of the animals in the nasal liquid rPA + C48/80 group had measurable LeTx NT50 while 
the two powder groups and the IM group had measureable LeTx NT50 in all animals after 
only two immunizations. Similar to ELISA results, the LeTx NT50 results demonstrates that 
powder formulations induce serum antibody responses at a faster rate that the liquid IN 
formation and similar to the IM rPA vaccine. As mentioned in the introduction, the serum 
toxin neutralization ability in rabbits correlates very well to the protection against anthrax 
spore. We believe the long-term storage stability of the powder vaccine formulation (at least 
2 years room temp) and the ability of only 2 doses of powder vaccine to induce functional 
toxin-neutralizing antibody responses makes this an ideal vaccine formulation for biodefense 
anthrax vaccine that offers not only the advantage in stockpiling and shipping of the 
vaccines, but also would lead to better protection in case of emergency.   
Anthrax LeTx neutralizing antibody responses of day 56 samples had a similar trend 
to day 35 samples, which is another positive result that reinforces the statements favoring the 
dry powder vaccine. All adjuvanted vaccine formulations, delivered IN or IM, had serum 
LeTx NT50 titers that were significantly greater than the LeTx NT50 in rabbits immunized IN 
with rPA alone, once again demonstrating that C48/80 provided significant adjuvant activity 
(Figure 2.19-B). There were no significant differences in the LeTx NT50 between any of the 
adjuvanted groups (nasal or IM delivery). By day 56, all rabbits vaccinated with an 
adjuvanted vaccine formulation (IN or IM) had measurable anthrax toxin neutralizing 
antibody responses. The maximum serum LeTx NT50 was in the IM group (1:4,374) while 
the 2009 and 2007 powder nasal formulations had the next highest LeTx NT50 (1:1,122 and 
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1:1,085, respectively). The serum LeTx NT50 in the IN liquid rPA + C48/80 group was the 
lowest of the adjuvanted groups (1:607). 
These in-vivo results not only showed that the Unitdose powder device was able to 
efficiently deliver the powders after two months of device storage time, but also confirmed 
results from in-vitro stability study that rPA in a powder formulation was stable at room 
temperature upon 2.5 years of storage and C48/80 was an effective mucosal adjuvant in 
rabbit model. No evident toxicity was observed for all the vaccine groups. All rabbits 
maintained continuous weight gain throughout the study and all survived after the study.  
2.4 Summary 
SFD powders containing rPA were successfully prepared using previous optimized 
SFD condition, with particle physicochemical properties appropriate for delivery to rabbit 
nasal cavity.  Dry powder formulations containing rPA plus adjuvant C48/80 were prepared by 
SFD, a process that was previously optimized to produce particles for nasal delivery. Particles 
prepared by SFD are porous and spherical, and has volume median diameter very close to the 
target size D50 = 25µm for rabbit nasal delivery. Formulation with protein and adjuvant did not 
change the particle size distribution in comparison to SFD powders of pure trehalose.  
A potential secondary structural change of rPA during the manufacturing process and 
storage was examined by two spectroscopic methods. The second derivative spectrum from 
ATR-FTIR demonstrated that the secondary structure of rPA is very close to unprocessed rPA 
control, as is also indicated in CD spectrum of rPA in the Far-UV region. SDS-PAGE and 
Native PAGE were employed to demonstrate the retention of rPA integrity after the formulation 
process and storage.   
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The functional stability of antigen rPA and adjuvant was monitored using in-vitro cell 
based assays. A mast cell degranulation assay showed that C48/80 in SFD formulations has 
similar adjuvant activity to the control. When LF was added to the formulations, by the 
functional stability of rPA was assessed by measuring the toxicity of LF to macrophage cells. 
Results showed the toxicity of LF with SFD rPA formulation was similar to control LF and rPA 
across all concentration dilutions. No toxicity was observed when rPA formulations or trehalose 
alone were added without LF.  
Initial rabbit nasal vaccination was carried out using liquid formulations. Anti-PA IgG 
titer and TN neutralization titer demonstrated positive results for the reconstituted powder 
formulation. The effectiveness of the SFD powder formulation was further examined in a 
second animal study using Unitdose powder device for nasal delivery in rabbits. Both SFD 
powder groups were at least as effective if not more effective as liquid formulations and were 
able to elicit a comparable IgG response to IM group despite room temperature storage for 2.5 
years or 0.5 year.  
Storage stability studies have shown that the dry powder formulation confers 
excellent stability for both the antigen and adjuvant at room temperature. However, care must 
be taken to prevent moisture uptake in terms of storage and delivery which can be a major 
cause of loss of protein activity.  
Positive results from both in-vitro and in-vivo studies support the hypothesis based on 
the adjuvant and powder formulation of the vaccine. Further development of this approach 
may ultimately provide a stable and affordable alternative to improve currently available 
anthrax vaccines. 
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Figure 2.1 C48/80 chemical composition A) and UV spectrum B). 
A).  
 
B). UV absorbance of Compound C48/80 (0.8mg/ml) 
 
 
 
  
Compound 48/80 
condensation 
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Figure 2.2 Working mechanism for β-hexosaminidase assay with substrate NAGpnp. 
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Figure 2.3 Molecular orbitals and electronic transitions of the amide group. 
(Modified from Circular Dichroism and the Conformational Analysis of Biomolecules, 
edited by Gerald D. Fasman) 
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Figure 2.4 SEM images of SFD particles. 
A) SFD trehalose low magnification, B) SFD trehalose high magnification, C) SFD trehalose 
C48/80, D) SFD rPA formulation-1, E) SFD rPA formulation-2.  
 
 
  
A 
C 
113 
 
Figure 2.5 Particle size distributions of SFD powder formulations (PIL measurements) as 
determined by laser diffraction measurement.  
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Figure 2.6 Particle size distributions of SFD powder formulations measured as powder spray 
from Pfeiffer Unitdose device   (PIA measurements) as determined by laser diffraction 
measurement. 
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Figure 2.7 Differential scanning calorimetry of SFD powders and pure C48/80 (rPA alone 
not determined as sample size required is too large.  
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Figure 2.8 ATR-FTIR absorption spectra of rPA in 10mM sodium phosphate buffer, 
pH=7.4. 
A) rPA control (0.25 mg/ml), B) rPA concentrated from reconstituted SFD rPA formulation-
2 (0.24 mg/ml).  
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Figure 2.9 Second derivative FT-IR spectra of rPA showing Amide I region.  
Top:  rPA control (0.25mg/ml), Bottom:  rPA concentrated from reconstituted SFD rPA 
formulation-2 (0.24mg/ml).  
 
(Secondary structure element: Table 2 in Schüle et al Eur J Pharm Biopharm. 2007, 65(1):1-9)  
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Figure 2.10 Secondary structure of rPA. 
A) CD spectrum of rPA in Far-UV region (~0.24 mg/ml).  
B) Protective antigen structure from PyMol Image (PDB: 1ACC) with estimated 13% helical (17 
helices; 102 residues), 31% beta sheet (56 strands; 235 residues)
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Figure 2.11 SDS and Native PAGE of reconstituted rPA formulations. 
 
LEFT: SDS-PAGE under reducing conditions. Lane 1, MW marker; Lane 2, SFDrPA 
formulation-1 upon 1.5 year of storage;  Lane 3, SFD rPA formulation22 freshly prepared; 
Lane 4, rPA control; Lane 5, SFD C48/80 formulation freshly prepared. 
RIGHT: Native-PAGE under non-reducing conditions. Lane 1, MW marker; Lane 2, SFD 
rPA formulation-1 upon 1.5 year of storage;  Lane 3, SFD rPA formulation-2 freshly 
prepared; Lane 4, rPA control; Lane 5, SFD C48/80 formulation freshly prepared. 
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Figure 2.12 Mast cell degranulation activity of SFD powder formulations. 
 (MeanSD, n=3).  
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Figure 2.13 Antigen functional stability determined by macrophage toxicity assay. 
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Figure 2.14 Powder Storage Stability Study.  
A) rPA powder storage stability at different temperature at relative humidity (%RH), B) rPA 
liquid formulation stability at different temperature, C) powder liquid comparison at 25°C, 
D) powder liquid comparison at 40°C. 
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Figure 2.15 Thermal history SFD vaccine powders at different storage conditions.  
 (0-7 days). A) 25°C ambient RH, B) 25°C 55%RH, C) 40°C 75% RH 
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Figure 2.16 Pfeiffer Unitdose powder device (A), was fitted with a modified 10ml pipette tip 
(B) for small opening of rabbit nasal cavity, C) Unitdose powder assembly.  
(device Figures kindly provided by Pfeiffer GmbH)   
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Figure 2.17 Bacillus anthracis protective antigen (PA)–specific serum ELISA titers in 
rabbits.  
New Zealand White rabbits (4 rabbits/group) were immunized 3 times (on days 0, 21, and 42) with 30 
µg of recombinant B. anthracis PA either alone or C48/80 120 µg as adjuvant. The bars represent 
group geometric means with positive error. A) ELISA titers on day 35, after administration of 2 doses 
of vaccine, B) TN titers on day 56, after administration of 3 doses of vaccine.  
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Figure 2.18 Animal study serum ELISA results.  
A) day 7 seropositive results, B) day 35 serum anti-rPA IgG GMT titers, C) day  56 serum anti-rPA 
IgG GMT titers. A one-way ANOVA followed by Tukey‟s post test were performed on log2 
transformed ELISA titer. A statistical significance was revealed between the adjuvanted groups and 
rPA alone group. (n=4, *, P < 0.05). Data are presented as ELISA titers with geometric mean.  
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Figure 2.19 Animal study serum toxin neutralization results: A) day 35 serum LeTx NT50 
titer, B) day 56 serum LeTx NT50 titer. 
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Table 2.1 Different formulations prepared by SFD. 
Formulations 
a
 rPA
b
 (µg) Adjuvant 
b
(µg) 
SFD trehalose 0 0 
SFD C48/80/10mg trehalose 0 120 
SFD rPA formulation-1/3mg trehalose 2 30 
SFD rPA formulation-2/10mg trehalose 20 80 
SFD rPA formulation-3/10mg trehalose 20 240 
a
 Not studied on storage 
b 
Ratios are adopted from liquid formulations optimized from Dr. Staats Lab.  
 
  
A 
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Table 2.2 Particle sizes of SFD formulations (Mean (SD), n=3). 
Powders  D90 (µm)  D50 (µm)  D10 (µm)  Span  
SFD Trehalose  69.32 (1.77) 27.48 (1.41) 5.50 (1.17) 2.32 (0.11) 
SFD C48/80 Trehalose  37.09 (0.89) 20.15 (1.58) 4.45 (0.80) 1.62 (0.07) 
SFD rPA formulation-1  72.95 (2.48) 28.32 (2.52) 10.92 (1.32) 2.19 (0.10) 
SFD rPA formulation-2  50.13 (1.96) 24.37 (1.37) 8.28 (0.74) 1.72 (0.06) 
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Table 2.3 SFD powder physicochemical properties (Mean (SD), n=3). 
Powders  
Moisture 
Content  
(% w/w)  
Bulk Density 
(g/ml) 
Tapped 
Density (g/ml) 
Carr's 
Compress. 
Index (CCI)  
SFD Trehalose  2.4 (0.16) 0.05 (0.02) 0.08 (0.03) 38.1 (3) 
SFD C48/80 
Trehalose  
1.5 (0.14) 0.16  0.24 34.9 
SFD rPA 
formulation-1  
5.2 (0.15) 0.12 0.18 37.8 
SFD rPA 
formulation-2  
4.3 (0.17) 0.06 0.09 32.5 
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Table 2.4 Powder delivery efficiency with Unitdose device +/- tips (Mean (SD), n=3). 
SFD particles 
LD 
mode 
D50 (µm) Span 
Emit Dose 
% 
Emitted 
Dose (w tip) 
% 
SFD Trehalose   
PIL 27.48 (1.41) 2.32 (0.11) 
99 (1.7) 100  (0) Device 
PIA 
37.3 (2.73) 2.14 (0.29) 
SFD C48/80 
Trehalose  
PIL 20.15 (1.58) 1.62 (0.07) 
99 (1) 99.7 (3.5) Device 
PIA 
29.4 (1.95) 2.1 (0.28) 
 SFD rPA 
formulation-2  
PIL 24.37 (1.37) 1.72 (0.09) 
99 (1.3) 98.5 (3.2) Device 
PIA 
33.9 (1.60) 2.52 (0.32) 
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Table 2.5 Different storage conditions tested for liquid and powder vaccines. 
 
Liquid Powders 
Temperature -80°C 4°C 25°C 40°C 25°C 40°C 
Humidity 
Level 
not controlled desiccant 
30-40%RH 
(ambient) 
55% RH 
(sat. NaBr) 
75%RH 
(sat. NaCl) 
Vial closed closed closed/open closed/open closed/open 
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Table 2.6 Vaccine formulations prepared to test the potency of dry powder rPA vaccines. 
A) First animal study, B) second animal study.  
 
 
 
 
A. Groups rPA Dose (µg) Route Adjuvant 
1 liquid, rPA alone 30 Nasal NONE 
2 liquid, rPA and C48/80 30 Nasal C48/80, 120 µg 
3 Reconstituted powder (prepared 07/09) 30 Nasal C48/80, 120 µg 
B. Groups 
rPA Dose 
(µg) 
Route Adjuvant 
1 liquid, rPA alone 30 Nasal NONE 
2 liquid, rPA and C48/80 30 Nasal C48/80, 120 µg 
3 Powder (prepared 08/09) 30 Nasal C48/80, 120 µg 
4 Powder (prepared 07/09) 30 Nasal C48/80, 120 µg 
5 liquid, IM 30 IM C48/80, 120 µg 
  
 
 
 
3 EVALUATION OF A NOVEL IN-SITU FORMED HYDROGEL 
DELIVERY SYSTEM FOR NASAL DELIVERY OF ANTHRAX 
VACCINE 
 
3.1 Introduction 
3.1.1 A novel formulation strategy as improvement to dry powder vaccine 
Dry powder formulation of proteinaceous vaccines and other biopharmaceuticals may 
have several advantages over conventional liquid formulation including protection against 
hydrolytic degradation, increased shelf-life, the potential elimination of cold-chain 
requirement for shipping and storage, its sterility and suitability for mass vaccination. 
However, powder preparations often require a specialized device for successful delivery of 
the powder dose with low powder retention, and to prevent powder agglomeration during 
shelf storage. A powder dispensing device is often more expensive than a simple liquid 
pump, which can limit the use of powder vaccine products in the developing countries where 
infection diseases such as anthrax still prevail.  One possibility is to reconstitute the powder 
formulation prior to usage and to deliver the vaccine content using a simple liquid pump. 
However, this strategy may re-introduce another drawback associated with simple aqueous 
formulation, which is the short transit time in nasal cavity.  Due to non-adherent nature of the 
simple aqueous formulation, dripping and draining often occur with gravity flow and cause 
rapid clearance from the nasal cavity, which ultimately leads to dose insufficiency and 
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variability. An in-situ formed hydrogel formulation proposed in current thesis would offer an 
optimum formulation strategy, whereby vaccine would still be formulated in a dry powder 
form for storage and transportation, which would be reconstituted just prior to use with a low 
viscosity aqueous solution containing hydrogel precursor, which can be delivered into the 
nasal cavity with a simple liquid pump. The liquid formulation with hydrogel precursor will 
form viscoelastic hydrogel upon conversion by local enzymes such as phosphatase or 
esterase, thus, prolonging the nasal residence time (mucoadhesion) for the vaccine 
components (see section 1.5 for details on in-situ formation of enzyme responsive hydrogel). 
Mucoadhesion refers to the phenomenon whereby a certain delivery system may interact with 
the mucus layer covering the nasal epithelial cells leading to prolonged nasal residence time. 
3.1.2 Critical barriers in nasal vaccine delivery  
Mucus composition 
Nasal mucus is a viscoelastic blanket covering the respiratory region (the turbinates) 
of the nasal cavity, which consists of approximately 95% water, 2% mucins, 1% salts, 1% of 
other proteins such as albumin, immunoglobulin, lysozyme and lactoferrin, and <1% 
lipids
264
. The primary component of mucus is the cross-linked, bundled and entangled gel-
forming mucin fibers which is partly secreted by goblet cells, but mostly by submucosal 
glands located in the connective tissue below the respiratory epithelium
265, 266
. Individual 
mucin fibers are large molecular weight (0.3-0.5MDa) entities that are 3-10nm in 
diameter
267
. Each mucin molecule is made up of a protein backbone with densely 
glycosylated regions, where in most cases high sialic acid and sulfate substitutions present
268
, 
bringing in negative charges and leading to electronic charge repulsion that increase the 
rigidity of the polymer. Additionally, scattered along each monomer there are “naked” 
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globular protein regions with small exposed hydrophobic patches
269
 stabilized by disulfide 
bonds (Figure 3.1). Mucin monomers are cross-linked end-to-end via disulfide bonds 
between disulfide-rich domains near the amino- and caroboxy- termini 
268, 270, 271
. Additional 
interaction occurs via hydrogen bonding, other non-covalent interactions or physical 
entanglements
146, 272
. 
Mucociliary clearance 
The mucus blanket is thought to consist two layers (Figure 3.2): the upper gel layer 
(0.5-2.0µm) containing most of the glycoproteins overlies the low viscosity periciliary 
aqueous layer (7-10µm) also called the „sol‟ layer272. Many nasal epithelial cells possess 
actively beating cilia, the shaft of which is immersed in the dilute mucus “watery” layer, the 
periciliary layer, with the tip extends to the gel layer. This setting facilitates two components 
in ciliary beating: the effective stroke and the recovery stroke
273
. In the fast effective stroke, 
only the tips of the cilia engage into the gel layer and sweep against the viscoelastic mucus 
towards the nasopharynx. In the slow recovery stroke, the cilia move in a circular mode 
through the low viscosity periciliary fluid with little hindrance to the start position for the 
next stroke. The cilia beat frequency is about 10 Hz in the aqueous layer, while a much less 
effective shear rate (1-3 Hz) is applied to the mucus layer
274
. By this mechanism, the nasal 
mucus is transported from the anterior towards the posterior region of the nasal cavity, 
moving entrapped particles toward the nasopharynx for antigen sampling and presentation, 
followed by subsequent draining to the stomach for inactivation by the gastric acid, thereby 
limiting the residence time of potential toxic materials. The mucus clearance rate in human 
nasal cavity is reported to be 5mm/min, with half-life to be around 15min 
267, 275-277
. 
However, variation exists between each individual, influenced by environmental factors and 
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disease states, but largely independent of age and sex
146, 278
.  The reported half-life for liquid 
formulations in rabbits is 10min
146, 279
. While the outermost layer of the mucus blanket is 
removed by cilia mediated clearance, the periciliary layer adhering to the epithelium remains 
unstirred. The volume (height) of the unstirred layer and the viscoelasticity of the mucus is 
carefully regulated by soluble factors or by level of hydration, respectively, to ensure the cilia 
motion and the mucociliary clearance mechanism
280
. Additionally, in order to efficiently 
remove the irritants from the epithelium, the entire mucus blanket is continuously and rapidly 
replaced by freshly secreted new mucus. It is thought that the nasal mucus is renewed every 
20min
267, 275-277
. These natural defense mechanisms of mucosal surfaces have been 
recognized as critical barriers to nasal delivery of pharmaceuticals.  
Selective permeability of the mucus blanket 
Mucus is a viscid gel. Its unique structural features enable it to stick to almost every 
surface and trap all kinds of particulates. As mentioned above, mucin fibers consist of 
densely glycosylated regions that are negatively charged and hydrophilic, which are inter-
dispersed by hydrophobic regions from folded protein globules stabilized by disulfide bond. 
The presence of a flexible array of alternating hydrophilic and hydrophobic regions allows 
mucus fibers to form different kinds of adhesive interactions with different types of surfaces 
via ionic interaction or low-affinity bonds (hydrophobic interaction). Low-affinity bonds are 
easily broken by thermal energy, but when multiple affinity bonds are formed, mucus can 
trap a particle or stick to a surface with permanent high viscidity. Multiple low-affinity bonds 
are also utilized by mucin fibers to allow dynamic interaction, so that they can rearrange 
themselves on the surface of a particle, or re-anneal the gel after shear stress has caused a 
slippage plane to form
280
.  
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The bulk viscosity of healthy human mucus is 1000-10,000 times higher than 
water
267
. According to Stokes-Einstein equation, hardly any virus or hydrophilic 
macromolecules will penetrate the fluid layer with this viscosity assuming diffusion in 
homogeneous fluid. Conventionally, it is believed that it is unlikely for a macromolecule to 
diffusion over extended distances in mucus in a time scale of mucociliary clearance. 
However, a new theory has been established based on experimental data (fluorescence 
recovery after photobleaching FRAP) using fluorescent labeled probes
281, 282
, signifying that 
particulates are capable of diffusion through low viscosity pores. For particle sizes 
significantly smaller than mucus mesh pore size, the diffusion rates are expected to be similar 
to the rates in water if the fluid in the mucus pores has equivalent viscosity to water
267
. The 
mesh spacing of a mucus gel can range from ~100nm to ~1000nm depending on the 
technique used for observation
267
. In addition to steric hindrance from mucus mesh spacing, 
adhesion forces caused by formation of polyvalent ionic and low-affinity interactions can 
further reduce/limit particulate transport. It is thought that the complete immobilization of 
carboxy-modified polystyrene nano-particles (59 nm) in human cervical mucus
282, 283
 is 
mostly caused by the formation of strong polyvalent hydrophobic interactions with mucin 
fibers,  despite their possession of negative charge. While, viruses of a similar size range are 
readily transported and infect human mucosal surfaces, this may be due to their unique 
surface properties, namely the charge masking effect, by coating the surface with equal 
density of + and – charges and lack of hydrophobic patches for polyvalent interactions. The 
same is true with many soluble proteins that diffuse freely through mucus. Interestingly, 
BSA, being a carrier for fatty acid, contains a hydrophobic patch at the mouth of the tunnel, 
which slowed its transport in mucus by not complete immobilization. This is likely due to the 
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formation of “monovalent” instead of polyvalent interaction as in the case of polystyrene. 
The understanding of the presence of hydrophobic domains in the mucus mesh also helps to 
explain why many therapeutic molecules diffuse much slower through mucus than other 
molecules of comparable sizes. Nonetheless, it is believed small hydrophobic molecules 
being less likely to form polyvalent interactions with mucus, are able to diffuse through 
mucus. A detailed review regarding selective mucus penetration can be found in two recent 
papers
267, 280
.  
The understanding of physiology of nasal mucus layer, including its composition, 
thickness and clearance times, and the transport mechanism is important to the design and 
development of optimal delivery systems.  
Mucosal delivery systems: A balance between mucoadhesion and mucus trapping 
(immobilization) 
For mucosal delivery of vaccine formulations containing soluble antigens, the 
targeted area in the nasal cavity for antigen uptake would be the turbinate region and the 
posterior region where NALT is located. It is thought that particulate antigen (e.g. virus, 
bacteria) would be taken up either by dendritic cells sampling across the mucosal epithelium 
with extended dendrites, or the particulate antigens may be trapped by nasal mucus and 
transported to NALT for sampling by specialized follicle associated M cells. In addition to 
these pathways, soluble antigens have a high chance of penetration through the mucus layer 
and being taken up by epithelial cells in the turbinate region via macropinocytosis, and intact 
or possessed antigen would be transported to IEL, then to the APCs in the LP.  
When a vaccine formulation is delivered to the nasal mucosa, several scenarios might 
occur: (1) the vaccine formulation does not adhere to mucus and gravity flow leads to direct 
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transit through the nasal cavity, (2) the vaccine formulation adhere to mucin fibers in the 
upper layer. The trapped antigen would have limited penetration to the lower layer and 
would, therefore, be rapidly cleared (by mucociliary clearance) from the nasal cavity to the 
nasopharynx. The antigen would have another chance of uptake by M cells in NALT or 
completely immobilized antigen will be eliminated to the GI tract, (3) the soluble antigen is 
able to be transported across the mucus mesh to the unstirred layer avoiding the cilia 
mediated clearance mechanism. The prolonged residence time would increase the chance of 
antigen uptake by underlying epithelial cells. An optimal nasal vaccine delivery system 
would have moderate mucoadhesion to slow the transit time in the nasal cavity, but still 
allow rapid diffusion of the soluble antigen through the unstirred layer before mucus renewal.  
3.1.3 In-situ formed hydrogel formulation for nasal delivery of biopharmaceutics and 
its proposed mucoadhesion mechanism. 
Liquid formulations with addition of bioadhesive materials (cellulose derivative or 
synthetic polymers) have been proposed for nasal delivery of drugs and vaccines. The reason 
that these formulations have achieved limited success is twofold. First, these polymeric 
systems are associated with significant formulation challenges as mentioned earlier in 
section 1.4.2. Secondly, from a nasal mucoadhesion point of view, these aqueous dispersion 
system with macromolecular polymers may not be suitable for optimal mucoadhesion 
according to mechanism proposed in the current literature
175
. Mucoadhesion can be achieved 
by one or several possible mechanisms including physical entanglement between polymer 
and mucin fibers, formation of polyvalent ionic interaction (e.g. cationic chitosan), and 
formation of polyvalent low-affinity bonds (hydrophobic interaction). In order to achieve 
physical entanglement, or any molecular interaction with mucin fiber, an interpenetration 
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step is required after initial contact. The prerequisite is that the polymer dispersion system 
must be able to efficiently spread on the mucosal surface, which is largely dependent on the 
rheology and surface energy of the liquid dispersion systems. After initial contact, polymeric 
materials in a liquid formulation may not mix with mucus due to their high viscosity, which 
would lead to formation of a slippage plane, adhesive failure and result in the formulation 
(delivery system) being readily dislodged. Furthermore, polymeric materials can have limited 
mucus penetration in the time scale of mucociliary clearance due to their high molecular 
weight, or further interpenetration can be substantially inhibited as soon as rheological 
synergism is induced after initial penetration
175
. The interaction of the liquid and mucus 
required for spreading and mixing will be key factors influencing retention.  
Delivery systems that allow in-situ gelation on mucosal surfaces seem to clearly favor 
the mucosal retention as a liquid formulation. As a result many in-situ gelling systems have 
been developed for application in nasal or other mucosal surfaces (see section 1.5.5). Yang et 
al. developed a series of small hydrogel precursors that are peptide derivative and can form 
supramolecular hydrogel in-situ upon enzymatic conversions (see section 1.5.3). One of the 
peptide-based precursors Nap-Phe-Phe-Tyr(PO3H2)-OH (MW = 724) is a phosphatase 
substrate, which has been demonstrated to be a powerful hydrogelator with a low minimum 
gelation concentration (0.05% w/v in PBS). The authors also demonstrated its ability to form 
a hydrogel in-situ with biological fluids upon addition of acid or alkaline phosphatases
218
. In 
current thesis project, a novel nasal mucoadhesion delivery system is proposed to achieve in-
situ hydrogelation by adding this hydrogel precursor to the liquid vaccine formulation. The 
amphiphilic small molecule would be able to diffuse through the mucus gel readily. Upon 
conversion by epithelial membrane bound alkaline phosphatase, the hydrogel will form, 
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entangling with mucin fibers and trapping soluble antigen inside for increased nasal mucosal 
residence time.   
3.1.4 Characterization of Hydrogel 
3.1.4.1 Hydrogel formation 
Visual examination using the tube inversion method is a most common diagnostic test 
of gelation. During the test, a tube or a vial containing the sample is turned upside-down and 
before observing whether the sample flows under its own weight. The assumption is that 
samples (gels) with a characteristic yield stress will not flow whereas an inelastic sample 
(viscous solution) will demonstrate appreciable flow
284
. However, care must be taken in 
interpreting the observations, since different results might be obtained from the tube 
inversion experiment when different sample mass, vial size and observation time are 
employed
285
.  
3.1.4.2 Microscopic examination of hydrogel structure 
The formation of the hydrogel and its structure can be further examined by electron 
microscopy techniques such as scanning and transmission electron microscopy (SEM and 
TEM), which can resolve features in the micro to nano meter scale and can provide 
morphological information of the aggregates or nano-fibers that result in gelation. However, 
the SEM and TEM are often operated under high vacuum which requires complete drying of 
the sample and can lead to artifacts for gels that inherently exist in a solvated state.  
Atomic force microscopy (AFM) is a type of high-resolution scanning probe 
microscopy that can examine surface roughness and texture of a material at the nano-scale 
level. AFM have the potential to image the hydrogel without dehydration. However it 
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requires a high level of skill and experience to perform the experiment (tapping in solution). 
To facilitate imaging, the samples are often dried with possibility of introducing artifacts.  
Recently, cryogenic techniques such as cryoTEM, cryoSEM and freeze-fracture TEM have 
made the imaging of native gel state feasible and have been reviewed in several papers
205
. 
Most of the cryogenic techniques involve flash-freeze aqueous samples in liquid ethane at the 
temperature of liquid nitrogen, which helps create thin vitrified ice films that allow the 
visualization of gel aggregates in a state that is closest to an aqueous state.  
3.1.4.3 Viscoelastic property and oscillatory tests 
Hydrogels are viscoelastic materials that exhibit both solid-like properties (elastic) 
and liquid-like properties (viscous) when undergoing deformation. Besides visual 
examination of the hydrogel formation, the viscoelastic property of the hydrogel can studied 
in a more quantitative manner. By analogy to mechanical properties of a spring or a solid 
elastic material are often described using parameters such as K (spring constant) and E 
(Young‟s modulus) that are characteristic to different materials. Viscoelastic property of a 
material can be expressed using dynamic modulus G. This is a complex variable that can 
describe both the solid-like property and liquid-like property of a material, where i
2
 = − 1; G' 
is the storage modulus (elastic modulus) and G'' is the loss modulus (viscous modulus) (σ0 
and 0 are the amplitudes of stress and strain and δ is the phase lag between them).  
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Viscoelasticity is studied using dynamic mechanical analysis, where a small 
oscillatory strain (force) is applied to the material and the resulting stress (displacement) is 
measured (or vice versa). For pure solid (elastic) material under oscillating conditions, the 
phase diagram will look like the sine wave (Figure 3.3), where the deformation response is 
instant, showing stress and strain in phase. For pure liquid (viscous) the strain and stress 
responses show a 90 degree phase lag. Viscoelastic materials exhibit behavior somewhere 
between these two types of material, exhibiting some lag in strain: tan  < 1, G > G. The 
overall stiffness of the gel can be represented by    , which is the square root of the 
Gsquared plus G squared.  
      
  
  
 
           
 
 
3.1.5 Hydrogel release mechanisms 
Protein release from the hydrogel is dependent upon the physical structure of the 
hydrogel, its interaction with the mucin, its degradation (by nasal hydrolytic enzymes), and 
its interaction with the protein. Release mechanisms can be diffusion alone or through a 
combination of hydrogel degradation and protein diffusion. 
3.1.6 An in-vitro rheological approach to evaluate mucoadhesive behavior of hydrogel 
It is believed that the interactions (physical entanglement), conformational change or 
any bonding interactions between mucoadhesive materials and mucus are likely to produce 
changes in the bulk rheological behavior of the mixture. When the interactions exist at the 
molecular level, the mixture would be capable of exhibiting rheological synergy
286
, that is, to 
demonstrate increased gel-like properties when mixed, than separate examination of mucin 
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(or mucus) and polymer dispersions. The rheological synergism can often be represented by 
G and G, which compares the difference between the measured viscoelastic values of the 
mixture of polymer and mucin (Gmix or Gmix) and the sum of the viscoelastic components of 
polymer (Gpolymer or Gpolymer) and mucin (Gmucin and Gmucin): 
            
 
         
 
       
                              
The rheological properties of the polymer-mucin mixture including the rheological 
synergism can be examined via dynamic oscillatory test, the results of which have been used 
as in vitro parameters to evaluate the mucoadhesive properties of a material. This offers an 
acceptable representative model for the in vivo behavior of the mucoadhesive material
287, 288
. 
3.2 Methods 
3.2.1 Peptide Synthesis 
Materials and chemicals  
General reagents were obtained from Fisher and Aldrich. Peptide synthesis reagents 
including low loading Wang resin, 2-chlorotrityl chloride resin (100-200mesh), 2-(1H-9-
Azobenzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HATU), Fmoc-
Tyr(PO(Bzl)OH)-OH, Fmoc-Phe-OH, were obtained from NovaBiochem (EMD chemicals, 
Inc). Disposable polypropylene syringes purchased from Torviq USA were used as peptide 
synthesis vessel. Prep-HPLC was performed on a Waters 600 HPLC system equipped with 
GRACE Apollo C18 5μ PREP column, 25cm, ID 22mm). Mass spectra were obtained from 
Aglient 6110 quaduapole LC-MS (Agilent Technologies).  
Solid Phase Peptide Synthesis 
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Manual solid phase peptide synthesis of Nap-Phe-Phe-Tyr(PO3H2)-OH peptide was 
performed using two different resins.  
Loading of Wang resin: Low loading Wang resin (0.44mmol/g) 0.8mmol (1eq, 1.82g) was 
allowed to swell in the peptide synthesis vessel with 10ml of CH2Cl2 (DCM) for about 0.5 hr. 
In a separate dry round bottom flask, the first amino acid Fmoc-Tyr(PO(Bzl)OH)-OH (5eq, 
2.29g) was dissolved in 10ml DCM, and a few drops of THF was added  to aid the 
dissolution. The activation of the carboxylic group was achieved by addition of Melm 
(3.75eq, 0.25g) followed by MSNT (5eq, 1.19g) (reference: EMD catalog 2009-2010 Chapter 
2.32). Upon complete dissolution, the mixture was transferred to the vessel containing the 
resin and allowed to stand at room temperature for 2 hrs with gentle agitation. Upon 
completion the resin was washed with DCM 5 x 8ml, DMF 5 x 8ml, a colorimetric test using 
Alizarin-cyanuric chloride was performed to determine the complete loading of the first 
peptide as indicated by no red-colored beads.  
Loading of Trityl chloride resin: Fmoc-Tyr(PO(Bzl)OH)-OH (1.2 eq, 1.2mmol) and DIPEA 
(4eq) were dissolved in 10ml dry DCM. The mixture was added to 1mmol 2-chlorotrityl 
chloride resin (1.01mmol/g, 1eq) and stirred at room temperature for 2hr. At the end of this 
time, the resin was washed 3  with DCM/MeOH/DIPEA (17:2:1), then with alternating 3 
DCM, 3DMF, 3DCM and 3DMF.  
Coupling: After loading, deprotection of the Fmoc group was performed using 30% 
piperidine in DMF for 30min, followed by DMF wash 6 x 8ml. The following amino acid, 
Fmoc-Phe-OH (5 eq, 0.8mmol, 0.31g) was attached to the resin using HATU (4.9 eq, 0.30g), 
and DIPEA (10 eq, 0.21g) in 8 ml DMF for 1-2 hrs at room temperature, each coupling was 
performed twice to ensure complete coupling determined by observing the color change with 
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Ninhydrin test. The rest of the amino acids were coupled in the same manner. When finished 
the resin was washed thoroughly with DMF and CH2Cl2.  
Resin cleavage and deprotection: Deprotection of Benzyl protecting group and peptide 
cleavage from resin was achieved in one step, where the resin was treated with 5ml of 
TFA/TIS/water (95:2.5:2.5) twice for a total time of 2.5 h. The cleavage solution was 
collected and air dried followed by ether precipitation.  
The precipitated peptide was collected and purified by prep-HPLC with a gradient run. 
Solvent A: acetonitrile with 0.1% TFA. Solvent B: water with 0.1% TFA. Initial solvent mix 
is 97% A and 3% B for 50min, followed by 10% A, B:90% for 10min, with end gradient to 
be 3% A, 97%B from 60-77min. Nap-Phe-Phe-Tyr(PO3H2)-OH: C39H38N3O9P, mass 
calculated m/z 723.2, found 724.1 [M+H]
+
.  
3.2.2 In-vitro Buffer Dependent Hydrogel formation 
Calf intestinal alkaline phosphatase (CIP, 10 U/µl) was purchased from New England 
Biolabs (Ipswich, MA), and bacterial alkaline phosphatase (BAP, 150 U/µl) was obtained 
from Invitrogen (Carlsbad, CA). A stock solution of Nap hydrogel precursor (100 mg/ml) 
was prepared in DMSO. In-vitro hydrogel formation was studied using buffer solutions 
containing 0.2% w/v Nap hydrogel precursor in a 1 ml glass vial (8  40mm, Kimble Glass, 
Fisher Scientific, Pittsburg, PA). Briefly, two microliters of Nap hydrogel precursor stock 
solution was added to 98µl of buffer solutions of different type and concentration, followed 
by addition of 2µl of CIP (10U/µl) to initiate gelling process. Hydrogel formation was 
evaluated via visual examination in regards to precursor solubility, gel formation and 
stiffness (inverted tube technique) or whether gel precipitation occurred.  
3.2.3 Hydrogel Formation with SFD Formulations 
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Hydrogel formation with SFD formulations was studied in PBS or Tris. SFD (~ 5-10 mg) 
were dissolved in PBS, Nap precursor in DMSO (25µl) was added, followed by addition of 
10µl BAP (5U/µl). Alternatively, SFD formulations (~15mg) were reconstituted with 200µl 
of Tris 250mM containing 0.2% w/v Nap hydrogel precursor, four microliters of CIP 
(10U/µl) was added to the mixture to initiate the hydrogelation.  
3.2.4 Protein Release Experiment  
Recombinant PA was labeled using Alexa Fluor 488 protein labeling kit (Invitrogen), 
labeling process and subsequent purification was conducted following the protocols 
described in the kit. Labeled protein concentration was calculated based on the absorbance of 
the conjugate solution at 280nm and 494nm measured a NanoDrop ND-1000 
spectrophotometer. Alexa Fluor 488 labeled BSA and was obtained from Invitrogen.  
                           
                                  
    
 
Peptide hydrogel precursor in 250mM Tris buffer (pH=7.4) was mixed with labeled and 
unlabeled protein to reach a final concentration of 5µM and 0.5µM, respectively, in100µl 
final volume of 250 mM Tris Buffer. The mixture was transferred into the wells of a clear 
Corning Costar 96-well flat-bottom plate. Two microliters of CIP were added to each of the 
wells containing the mixture, which was then allowed to gel for 30min. Subsequently, 100µl 
of 250mM Tris was slowly added as release media. The 96-plate was covered with aluminum 
foil and placed on a rotating shaker for release experiment at room temperature. Forty 
microliters of the supernatant was transferred to a 384-well plate (SensoPlate
TM
, black with 
glass bottom, courtesy of Greiner Bio-One North America Inc., Monroe, NC) at frequent time 
points and was replaced with same volume of Tris. Fluorescence data of the supernatant were 
acquired using a Photon Technology QM-4 spectrofluorimeter at 30°C (ex = 494nm, em = 
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519 nm). Wells containing peptide hydrogel precursor only were also analyzed and its 
contribution to the fluorescent absorption was subtracted from the fluorescence data of the 
released supernatant. Released protein concentrations were calculated by correlating the final 
fluorescence data to a standard curve of labeled protein with known concentrations. 
Cumulative protein release was calculated and plotted versus time.   
3.2.5 Released Protein CD 
Sample solutions containing 1.2mg/ml unlabeled protein and 0.2% w/v Nap hydrogel 
precursor in 100µl of PBS were transferred to wells of a 96-well clear flat bottom plate for 
CD studies of released proteins. Five microliters of BAP (5U/µl) was added to the sample 
mixture to initiate the hydrogelation process. After 30mins of gelation, 100µl of PBS buffer 
was added slowly to the sample as release media. Release experiment was performed at room 
temperature on a rotational shaker. After 1h release, aliquots of supernatant were taken for 
protein concentration determination and CD experiments. Protein concentration was 
determined using BCA assay (570nm) with BCA
TM 
protein assay kit (Pierce, Thermo 
Scientific) following the microplate procedure. Individual blank-corrected standard curve 
was prepared and used for concentration calculation of each protein. Released protein 
samples were subjected to centrifugal filtration to remove the possible effect of hydrogel 
precursor, and recovered with 10mM potassium phosphate buffer. Far-UV CD spectra 
(190nm-260nm) were recorded at 25°C with an Applied Photophysics Pi-Star 180 circular 
dichroism spectrapolarimeter. Data were collected and analyzed as described previously in 
Chapter 2 section 2.2.4. CD spectra of proteins released from the hydrogel were compared 
with protein samples of similar concentration obtained from a control experiment in PBS 
(without addition of Nap precursor and BAP). 
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3.2.6 Released Protein Functional Assay: 
Release experiments for protein functional assays were conducted in both 1xPBS and Tris 
buffer (62.5mM), following the procedure described in the previous release protein CD 
experiment. Briefly, rPA solution was added to Nap precursor solution (0.2% w/v) to achieve 
final concentration of 1.2 mg/ml. Two microliters of BAP (20U) were added to 100µl of the 
protein hydrogel precursor mixture in a 96-well plate. Thirty minutes after gelation, 100µl of 
buffer was added as release media. Aliquots of the supernatant were taken after 1 hr of 
release for protein concentration determination and macrophage toxicity assay. Starting 
dilutions of the released protein sample for the macrophage toxicity assay were determined 
based on protein concentration from BCA assay. Controls include released sample collected 
from hydrogel only (without rPA), namely, PBS Gel control, Tris Gel control, and rPA in 
PBS without hydrogel formation (PA-PBS control, PA-Tris control).  
3.2.7 Scanning Electron Microscopy: 
Freeze-dried gel samples were used for SEM imaging. Briefly, a silicon wafer was dipped 
into the hydrogel and fast frozen in liquid nitrogen, then dried by lyophilization overnight. 
The silicon wafer was loaded on SEM pin stubs coated with double-sided adhesive carbon 
conductive tab (Ted Pella Inc., Redding, CA) and sputter coated with Pd/Au with a thickness 
of 3 nm. SEM images were recorded on a Hitachi S-4700 Cold Cathode Field Emission 
Scanning Electron Microscope with an accelerating voltage of 2.0 KV, 11.4mm working 
distance.  
3.2.8 Atomic Force Microscopy (AFM): 
Freeze-dried hydrogel samples were prepared on a rectangular glass slide. AFM images were 
recorded on Asylum Research MFP3D Atomic Force Microscope using tapping in air mode. 
153 
 
AFM tapping mode probes Tap 300 Al-6 were obtained from Budget Sensors with 300 kHz 
resonance frequency and 40N/m constant force. 2D and 3D images of sample height trace 
were presented.  
3.2.9 Rheological Analysis: 
The rheological analysis was carried out using AR-G2 rheometer (TA instruments) with a 
cone (40mm diameter, 1° angel stainless steel) and plate fixture with 26µm gap setting 
(Figure 3.12). Approximately 330µl of hydrogel precursor solution, mucin or mucin-gel 
mixture prepared in 250 mM Tris buffer was loaded onto the temperature controlled 
rheometer plate (25°C). After addition of 5µl (50 U) CIP to the precursor solution, the cone 
was lowered back to geometric gap, and a solvent trap was used to protect sample from 
solvent evaporation. Time sweep was performed for 2hrs at angular frequency of 2 rad/s and 
1% strain. Frequency sweep was delayed to 20mins after the CIP addition to allow time for 
gelation process. The oscillatory measurements were performed over a frequency range from 
0.1 rad/s to 100 rad/s with 10 points per decade at 1% strain. Storage modulus G, loss 
modulus G and loss tangent (tan) of sample triplicates were recorded at the intermediate 
frequency of 1 Hz after the frequency sweep and plotted according to different Nap precursor 
concentrations. Additionally, frequency sweep was performed at 37°C to examine the 
potential temperature effect on hydrogel viscoelasticity. Finally, a shear thinning experiment 
was performed with shear rate from 0.001/s to 1000/s.  
Mucin from bovine submaxillary glands was obtained from Sigma-Aldrich. The hydrogel 
precursor-mucin solution was prepared by mixing the stock solutions of hydrogel precursor 
(9% w/v) and mucin (12% w/v) to make the final concentration of 6% w/v hydrogel 
precursor and 4% w/v mucin mixture. To examine the rheological synergism, the frequency 
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sweep was performed on each stock solution, the mixture without addition of CIP and the 
mixture with the addition of CIP.   
3.2.10 Alkaline Phosphatase Activity in Rabbit Nasal Cavity 
Alkaline phosphatase activity was detected using a classic substrate p-nitrophenol phosphate 
(p-NPP) obtained from Anaspec, Inc (Fremont, CA). Different concentrations of p-NPP were 
prepared (0.01mM to 10mM) in PBS and 100 µl of the substrate solution was instilled into 
rabbit nasal cavity. After holding the rabbit for 1 min, 1 ml of PBS was used to wash the 
rabbit nasal cavity. Nasal wash was collected in a Petri dish for UV-vis analysis at 405nm.   
3.3 Results and Discussion 
3.3.1 Evaluation of alkaline phosphatase activity in rabbit nasal cavity 
Endogenous phosphatase is prominent in several mucosal surfaces in human, e.g. 
intestine and nasal mucosa (see section 1.5.4). It seems reasonable to use this phosphate 
functionalized hydrogel precursor Nap-FFY(P) (see section 3.1.3) for its application and in-
situ gelation in the nasal cavity. Since the rabbit was proposed as the animal model for this 
thesis project, it was important to confirm the presence of phosphatase activity in rabbit nasal 
mucosa. Although membrane bound ALP has been used as a toxicity marker for nasal 
mucosal irritation in rabbits, a simple qualitative experiment was performed using a classic 
substrate p-NPP. Upon cleavage of the phosphate group by ALP, the product p-NP has a 
strong absorption at 405nm and can be monitored by UV-Vis analysis.  
In this qualitative experiment, PBS solutions containing different concentrations of p-
NPP were instilled into rabbit nasal cavity, followed by nasal wash with PBS after holding 
the rabbit upside down for 1min. The ratio between the absorbance of nasal wash and the p-
NPP substrate solution was calculated (Table 3.1). A significant increase in the UV 
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absorption at 405nm was observed when 10mM of substrate was used for instillation, which 
is an indication of substrate conversion by ALP.  
3.3.2 Synthesis of Nap-Phe-Phe-Tyr(PO3H2)-OH (abbreviated Nap-FFY(P)) 
Initial preparation of Nap-FFY(P) using a solution phase method published Yang et 
al.
218
 (refer to supporting information) was not successful. Manual solid phase synthesis was 
carried out using Wang resin or trityl resin as solid support. The synthesis process was 
improved by selecting low loading Wang resin 0.44mmol/g vs. 2.3mmol/g with reduced 
times of coupling required for complete substitution (according to ninhydrin test) with a 5 
fold increase in the relative yield. The low loading Wang resin might have offered a higher 
proportion in the initial loading due to the bulkiness of the initial benzyl protected 
phosphotyrosine residue. The synthesis process was further optimized using 2-chlorotrityl 
chloride resin, to avoid the initial cumbersome loading step for Wang resin. Benzyl (bzl) 
protected Fmoc phosphotryrosine was used, to prevent side-reaction due to cross 
esterification of the phosphate group. A standard coupling procedure was followed, and 
deprotection of Bzl group and cleavage from the resin was achieved in one step. Crude 
product was successfully obtained by ether precipitation method. Crude product was purified 
by Prep-HPLC. The elution profile of the crude peptide was monitored at two different 
wavelengths. Final product should have absorption at both 254nm for phenol ring absorption 
(Figure 3.4-A), 220nm for peptide bond absorption (Figure 3.4-B). As shown in the 
chromatogram, the crude product appears to be very clean with only one intensive peak that 
has absorption at both wavelengths. Mass analysis of this fraction of collections shows the 
most intensive peak with a mass to charge ratio of 724.1 which corresponds to the calculated 
mass, thus confirms the peptide structure (Figure 3.4-C).  
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The stereochemistry of the final product is not characterized, since the self-assembly 
process based on - stacking interaction is likely to take place regardless of the 
stereochemistry of the final peptide, but might affect the final gel stiffness. Nonetheless, the 
use of trityl resin and coupling reagent HATU is believed to give little enantiomerization 
during solid phase synthesis.  
3.3.3 Buffer dependent hydrogel formation 
Due to the presence of hydrophobic functional groups (phenol rings), the hydrogel 
precursor is not soluble in water, as is true for many synthetic peptides. It is very important to 
find the right buffer system which can provide maximum solubility for the peptide while 
maintaining maximum gelation ability with limited use of organic solvent. It is important to 
find the right buffer system that can provide maximum solubility for the peptide peptide 
precursor while supporting gel formation (fibril structure formation trapping solvent inside) 
with limited aggregates precipitating from the solution (see section 1.5.2).  
An initial in-vitro experiment was performed to confirm the hydrogel formation of 
Nap-FFY(P) upon phosphate removal. Both BAP and CIP were able to facilitate the reaction 
with the hydrogel precursor in PBS (Figure 3.5), which suggests any non-specific ALP will 
be able to carry out the hydrolysis reaction to remove the phosphate group. In addition, Nap-
FFY(P)  is a powerful gelator, the minimum gelation concentration in PBS and Tris buffer 
can be as low as 0.1 % w/v.  
Further in-vitro hydrogelation was carried out in different buffer systems using CIP 
only. Results from visual examination are shown in Table 3.2. Hydrogel formation seems to 
be buffer type and concentration dependent. In general, at low buffer ionic strength, 
precursor tends to precipitate out. Increased solublization was observed with increased buffer 
157 
 
concentration. PBS and Tris are two good buffer systems that supported the hydrogel 
formation, while no gel formation was observed in HEPEs buffer. However, solubility of 
hydrogel precursor was limited in PBS, precipitation was observed at as low as 0.2% w/v in 
150mM PBS solution (pH=7.4), and precursor solubility did not increase in PBS with higher 
ionic strength. Interestingly, Tris buffer seems to be a better buffer that can successfully 
solublize hydrogel precursor up to 0.9% w/v in 250mM Tris, while supporting gel formation 
at the same time.   
3.3.4 Hydrogel formation with SFD powder 
Previous in-vitro experiments confirmed that the hydrogel precursor Nap-FF(Y) 
purified from solid phase synthesis self-assemble into supramolecular hydrogel upon 
enzymatic conversion. Since it is proposed that the hydrogel precursor is added to the 
reconstituted SFD formulation for in-situ gelation, it is important to examine whether that 
hydrogel formation will be affected with the presence of SFD vaccine formulations (~15mg). 
Hydrogel formation in PBS and Tris with the presence of reconstituted SFD formulations is 
confirmed using inverted vial method. Figure 3.6 shows photographs of upside down vials, 
demonstrating hydrogel formation at the bottom of the vial, while the vial held horizontally 
still has free flowing liquid inside indicating no gel is formed.  
The hydrogel sample formed in the presence of SFD rPA formulation was prepared 
for SEM image analysis. Figure 3.7-A) confirms the formation of fibril structure, while the 
image taken in another area of the same sample, appears to show trehalose precipitation 
occurred during drying. Precipitates are evenly distributed throughout the free space of the 
fibril structure of the gel. These results indicate that the presence of trehalose, C48/80 and 
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rPA did not affect the enzymatic conversion process, nor did they disrupt the self-assembly 
of the hydrogel precursor.  
Furthermore, the mesh spacing of the hydrogel was examined by AFM. AFM is a 
type of scanning probe microscopy that can examine the surface roughness and texture of a 
material at the nano scale. Figure 3.8-A shows the height trace of a 10  10 micrometers 
scan of the freeze-dried gel (in PBS buffer only) again demonstrating the formation of 
nanofibers. When the scan is focused to a 2  2 micrometers area in the middle of scanned 
region, more details are revealed regarding the pore structure and size. The instrument 
software that came with the instrument allows different presentation of the image.  The 3D 
presentation of the image gives a better illustration of the pores (Figure 3.8-B), which is in 
the range of 100-500nm. The hydrogel mesh size seems to be sufficiently large for proteins 
to fit in, without disrupting gel formation, and assuming the hydrodynamic radius of rPA 
(83KD) is between the size of rIgG = 5.6 nm and rBSA = 3.6 nm, protein diffusion through the 
pores should not be limited by steric hindrance from the mesh spacing. 
3.3.5 In-vitro protein release study 
In-vitro experiments have shown successful hydrogel formation of Nap-FFY(P) in the 
presence of reconstituted SFD vaccine formulation. It is also important to examine whether 
the peptide based hydrogel system is compatible with antigen rPA for its stability and 
release, or to be specific whether the self-assembly process will affect the structural, 
functional stability and the release properties of the protein. 
3.3.5.1 Released protein structural stability 
Protein aggregation and protein-peptide interaction resulting in protein denaturation 
could occur while the protein is resident in the hydrogel precursor solution, during the self-
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assembly and fibril formation, or during the release process. A protein release study was 
performed to determine whether the above mentioned process had occurred. BSA and rPA 
were collected from the released media after a total of 1.5 hour of interaction with the 
hydrogel system (enzymatic hydrogelation for 0.5hr followed by release from hydrogel for 
1hr), and subjected to centrifugal filtration to eliminate the possible interaction of phenyl-rich 
peptide hydrogel. The secondary structures of the released proteins were examined by far-
UV CD. CD spectra of BSA and rPA are very similar to those of the proteins collected in the 
PBS only control and closely resembled to those reported in the literature
111, 210
. A small 
deviation was observed in the BSA spectra below 200nm, where the total UV absorption is 
high. It is likely due to the interference from the residual peptide hydrogelator appeared in 
the filtrate solution. 
3.3.5.2 Released protein functional stability 
CD analyses demonstrate the structural stability of the released proteins during the 
1.5 hr residence with the peptide hydrogel system. It is also important to demonstrate their 
functionality after the release. The rPA release studies were carried out in the same manner 
as previously described for the CD studies, but employing both PBS and Tris buffer systems. 
Released protein concentration was determined by BCA assay and diluted accordingly in 
order to form a 1:1 mixture with LF. The functional stability of released rPAwas evaluated 
by measuring the macrophage toxicity caused by LeTx (Figure 3.10-A, B). Results show that 
when combined with LF, the rPA released from PBS gel had similar cytotoxicity to rPA 
collected from a solution containing PBS buffer only. In both cases, the activity observed 
was comparable to PA&LF standard. Importantly, no macrophage toxicity was observed 
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when the release media was collected from the hydrogel without addition of PA. The results 
are true when PA was collected from Tris-based hydrogel. 
The functional activity of BSA was not characterized due to the lack of an appropriate 
assay to provide conclusive data. However the minimum structural perturbation observed 
with CD study of released BSA suggests conservation of protein biochemical properties.  
3.3.5.3 Protein release profile 
Release studies were performed using a mixture of Alexa Fluor 488 labeled proteins 
and unlabeled proteins with varying peptide precursor concentrations. Results showed that 
release of rPA and BSA occured in a gel density dependent manner (Figure 3.11-A, B). 
Increasing precursor concentration might have resulted in a higher density network of 
nanofibers that would lead to slower release of the proteins. However, for the gel 
concentration tested (0.2% w/v, 0.4%w/v and 0.6% w/v), the influence of gel density on the 
protein release was less prominent at early time points. The cumulative release of rPA after 
24hrs was in the range of 60-90%, with highest release (~90%) observed with rPA in 0.2% 
w/v hydrogel. Low quantities of BSA were released, within the range of 50-70% after 24hrs 
(Figure 3.11-C). Although, none of the in-vitro hydrogel systems seemed to achieve 100% 
percent release in 24hr, faster and nearly complete release is expected in-vivo, since, besides 
protein diffusion, peptide precursor degradation by hydrolytic enzymes is likely to occur in 
the nasal cavity.  
Protein release profiles through the nanofibers with certain density are likely to be 
influenced by hydrodynamic radii, charge distribution on the protein surface and their 
interaction with nanofibers. Assuming the smaller mass BSA (66KDa) to a smaller 
hydrodynamic radius than rPA, which is about 83KDa, the release of BSA should be faster 
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than that of rPA. However, the reverse was observed in the current study, indicating possible 
BSA interaction of with nanofibers. At pH=7.4, the peptide hydrogel will be slightly negative 
charged, due to the presence of Phe, Try and only a carboxy terminus. Since the reported 
isoelectric point of BSA( pI =5.4)
210
 is very close to that of rPA (pI = 5.6)
289
, the degree of 
electronic repulsion interaction with the nanofibers would be similar for both proteins. 
However, as mentioned earlier, the presence of hydrophobic patches on the surface of BSA 
explain the difference in the release profile of the two proteins. These results also suggest 
that the properties of each delivery system should be examined individually, depending on 
the cargo they are carrying.  
3.3.6 Rheological properties of the Tris-based hydrogel  
3.3.6.1 Rheological examination of viscoelastic hydrogel formation upon enzymatic 
conversion. 
Dynamic mechanical analysis (controlled strain oscillatory test) was performed to 
confirm the formation of viscoelastic hydrogel. Figure 3.13-A, B show the dynamic 
frequency sweeps of 0.6% hydrogel precursor in Tris buffer with or without addition of CIP 
enzyme. The mechanical spectrum of the aqueous dispersion of hydrogel precursor 
demonstrates mostly liquid like behavior across the frequency range, with G dominating G 
at frequency > 1 rad/s (Figure 3.13-A). When CIP was added to the precursor solution, the 
storage modulus G was much larger than loss modulus G (sweep step obtained after 20min 
hold step), indicative of an elastic rather than viscous material (Figure 3.13-B). The plateau 
region of the viscoelastic gel was observed with no crossover point of G and G, exhibiting 
weak frequency dependency of dynamic modulii G and G from 0.1 to 100 rad s-1, which 
indicates a long relaxation time of the network
290
. Such rheological behavior matches the 
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characteristic signature of a solid like gel, suggesting the presence of secondary interactions 
rather than pure physical entanglement of the network
291
. The value obtained for G is of the 
same order of magnitude as the modulus of the hydrogel formed in PBS buffer as reported by 
Yang et.al.
218
. The instant separation of G and G and the dominating G observed in the 
time sweep obtained immediately after the addition of CIP shows immediate hydrogelation 
triggered by enzymatic conversion of the precursor.  
The stiffness of the hydrogel network appears to be concentration dependent. Both 
the storage and loss modulus of the hydrogel increased exponentially with increasing 
precursor concentration, leading to formation of stronger gel network. However, the tangent 
of phase angel (tan) is essentially unaffected with varying precursor concentration, 
demonstrating the viscoelastic properties of the hydrogel at precursor concentration as low as 
0.1% w/v. The tangent delta values are in the range of 0.1-0.2, which are comparable to those 
obtained from natural tissues (personal communication with Dr. Tong Jiao at department of 
mechanical engineering of Brown University).  
3.3.6.2 Rheological synergism of mucin and hydrogel mixture 
The rheological profiles of mucin solution (4% w/v) (mucin from bovine 
submaxillary glands), hydrogel precursor (0.6% w/v) and their mixtures in Tris buffer (with 
or without addition of CIP) were examined and compared to assess the mucoadhesive 
properties of the hydrogel. Frequency sweeps of the mucin solution displays a profile of G 
dominating G throughout the frequency range, indicating mostly liquid like (viscous) 
behavior (Figure 3.15-A). Similarly, the rheological profile for pure hydrogel precursor 
solution without addition of CIP showed little elastic behavior (Figure 3.13-A). While the 
mucin-hydrogel precursor mixture showed synergistic increase of G  and G, with elastic 
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modulus dominating the viscous parting signifying viscoelastic gel behavior (tan  = 0.24 at 
1.995 Hz) (Figure 3.13-B). Both G  and G were below 100 Pa suggesting the formation of 
a weak network. Most interestingly, when CIP was added to the mucin-hydrogel precursor 
mixture, a more pronounced synergism was observed, with nearly 10-fold increase of G  and 
Gcomparing to those observed with 0.6% w/v hydrogel alone (Figure 3.13-C, D) G= 
6113 Pa and G= 1087 Pa (Table 3.3). The appearance of “flat” plateau of G and G in the 
rheological profile of mucin-gel mixture suggests formation of a strong gel network, similar 
to those observed in a covalently-crosslinked gel
291
. This rheological synergism of mucin-
hydrogel mixture showed strong mucin hydrogel interactions, and mucoadhesive behavior of 
the hydrogel system is likely to occur in vivo upon enzymatic conversion.  
3.3.6.3 Temperature effect on rheological synergism 
Frequency sweeps at different temperatures (25°C and 37°Ce) did not induce any 
changes to the oscillatory behavior of 4% mucin solution, nor did it have any effect on the 
viscoelastic property of the hydrogel. However, higher temperature did reduce the G of 
mucin-gel mixture, which seems to become less stiff due to enhanced molecular mobility. 
The mucoadhesive behavior of the hydrogel is likely to be preserved at physiological 
temperature.  
3.3.7 In vivo evaluation of the in-situ formed hydrogel system for nasal delivery of 
rPA and C48/80. 
In-vivo nasal vaccinations in rabbits were carried out to evaluate the efficacy of this 
novel in-situ formed hydrogel formulation. Hydrogel precursor solution with 0.6% w/v 
concentration demonstrated enhanced gel stiffness while maintaining similar release profile 
compared to other lower gel concentration tested and sustaining solubilization of 
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reconstituted powder formulation concomitantly, therefore, this particular hydrogel was 
selected for preliminary testing in-vivo. Hydrogel vaccine formulations were prepared by 
addition of fresh rPA and C48/80 or by addition of reconstituted powder (2009) solution to 
obtain 30µg antigen rPA and 120µg adjuvant C48/80 in every 200µl hydrogel precursor 
solution (0.6% w/v). The mixture (100µl/nostril) was delivered using a handheld pipette 
fitted with a 200µl tip. Since this experiment was performed at the same time as the second 
animal study powder vaccine formulation, the results of the liquid groups (nasal and IM) 
reported here are adopted from those reported in previous sections.  
After initial immunization, no seroconversion was seen for rabbits in liquid groups 
and the gel group containing rPA and C48/80. Besides the liquid IM group, rabbits in the 
other IN gel group, containing reconstituted powder, showed seroposititve response as 
indicated by day 7 ELISA results (Figure 3.17-A). However, this positive initial response 
was completely negated following second and third immunizations as both gel groups 
showed significantly lower systemic responses compared to all of the liquid IN groups and 
liquid IM as indicated by anti-PA IgG ELISA titers (Figure 3.17-B, C). Furthermore, the 
serum antibodies elicited in the gel groups failed to carry out neutralization activity in-vitro. 
As shown in Figure 3.18-A and B, no functional titers were observed for the two gel groups 
and similarly, minimal functional titers were seen in the liquid group without adjuvant.  
An in-situ formed hydrogel formulation for nasal delivery of anthrax vaccine was 
proposed to increased the nasal residence time of vaccine components and thereby enhance 
the systemic immune response. However, results from this initial study (precursor 
concentration 0.6% w/v) suggest the opposite effect. Decreased or almost total abrogated 
systemic immune response occurred after second and third immunizations. This systemic 
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unresponsiveness suggests a potential mucosal tolerance was elicited. Mucosal tolerance has 
been demonstrated in human and animal models after nasal or oral immunizations
292
, which 
have been a condition indicated to be beneficial to the treatment of autoimmune diseases
293
. 
It‟s known that the schedule and amount of antigen administration determine the nature of 
tolerance. Either a single feeding of very high-dose antigen or repetitive administration of 
low-dose antigen can induce mucosal tolerance (Figure 3.19). In the current study, it is likely 
that the in vivo mixing and interaction of the hydrogel formulation with mucus has led to a 
slow release formulation that serves as a low-dose induction of mucosal tolerance. In 
addition, this increased mucoadhesiveness may have also limited antigen transport to the 
back of the nasal cavity where NALT is located, thus, preventing a systemic immune 
response. Although an active suppression mechanism tends to have an induction effect on 
Th2 response, immunoglobulin isotype switching to sIgA often occurs which can further 
limit antigen uptake at mucosal surfaces and lead to immune exclusion during future antigen 
encounters. Our current results seem to support the postulated mucosal tolerance. However, 
further investigations e.g. the mucosal IgA titers or production of regulatory cytokines, are 
required before any conclusions can be drawn.  
Conversely, in vivo, the hydrogel formulation could have led to rapid transit time of 
the antigen in the rabbit nasal cavity. In the current experiment, a relatively large volume of 
solution was administrated to both rabbit nostrils, and the viscosity of the solution was likely 
to increase in vivo provided successful enzymatic conversion occurred. Given that the rabbit 
is an obligated nose breather, the administration of the hydrogel formulation as a bulk 
solution would have interfere with normal breathing, leading to induction of innate defense 
mechanisms to increase the clearance. When a large amount of water is secreted upon nasal 
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stimulation, a dilution effect would occur, leading to formation of a slippage plane followed 
by rapid clearance by mechanical forces. This hypothesis can be examined by conducting a 
nasal residence time study using gamma scintigraphy. One solution adopted by PecSys
233
, an 
in situ gelling system for nasal drug delivery, would also be applicable to the current 
hydrogel formulation, that is to use a simple nasal pump to disperse the hydrogel precursor 
formulation into small droplets, which will likely be deposited as a thin layer on the nasal 
mucosal while eliminating the interference of the formulation with normal breathing. Figure 
3.19 shows that the solutions of reconstituted SFD powder in the presence of hydrogel 
precursor can be efficiently dispersed into a plume of droplets using a liquid spray device 
(PennCentury, Microsprayer
TM
, model IA-1B). Furthermore, an in vivo study with various 
hydrogel precursor concentrations would help to select formulation combinations for optimal 
immune responses. 
One positive result from the animal study is that no apparent toxicity was observed 
with rabbits vaccinated with hydrogel precursor formulation as all rabbits survived the three 
immunizations and maintained a steady weight again throughout the course of vaccination.  
3.4 Summary  
Previously powder formulations were prepared as an improvement to the less stable 
liquid vaccine formulation for increased shelf life, to potentially improved storage and 
shipping conditions. However, disadvantages to powder formulations have been reported 
such as poor patient compliance and device requirement. The unit cost of a powder device 
can be a limitation to its applications in developing countries or in the case of mass 
vaccination. An alternative in-situ formed hydrogel formulation is proposed that would allow 
vaccine formulation to be stored as powder, but can be delivered as a reconstituted liquid 
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using a simple liquid pump while maintaining sufficient retention in the nasal cavity for 
enhanced immune response.  
A hydrogel precursor that is a phosphatase substrate was developed by Yang et al. 
and was selected in current project to test the hypothesis. It is well known that endogenous 
phosphatase activity is prominent in human mucosal surfaces, such as in intestine and in 
nasal mucosa. In addition, alkaline phosphatase has been used as a toxicity marker in rabbit 
nasal cavity. A simple in vivo experiment was performed using a classical substrate p-NPP to 
confirm the phosphatase activity. After treating the rabbit nasal cavity with various amounts 
of p-NPP in PBS solution, nasal wash was collected and showed a significant increase in 
absorbance at 405nm compared to the absorbance of the substrate solution, indicating 
formation of p-NP thus, confirming the rabbit nasal phosphatase activity.  
The hydrogel precursor NapFFY(P) was prepared by manual solid phase synthesis. 
Resin type and coupling conditions were optimized for increase in yield and decrease 
coupling time. Crude peptide precursor product was purified by prep-HPLC, and 
characterized by MS with confirmed molecular weight.  
In-vitro studies showed the hydrogel precursor obtained from solid phase peptide 
synthesis can form a hydrogel in the presence of reconstituted SFD powder formulation. Gel 
formation was confirmed by visual examination using inverted tube method.  SEM and AFM 
imaging analyses of freeze-dried samples of hydrogel confirmed the formation of fibril 
structure and demonstrated the pores size in the range of 100-500nm which offered enough 
space for protein to transit, without disrupting gel structure. The steric hindrance from mesh 
spacing is not likely to limit protein diffusion. 
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Most encouragingly, this in-vitro hydrogel conversion can be carried out by either of 
the non-specific hydrolytic enzymes, CIP or BAP, suggesting in vivo conversion is likely to 
occur. NapFFY(P) seems to be a powerful hydrogelator, with  minimum concentration as low 
as 0.1% w/v.  
In addition to the visual examination, hydrogel formation was further characterized 
by rheological analysis using a cone and plate rheometer. The results of the time sweep 
analyses showed that the hydrogel can form instantly, and its viscoelastic properties were 
confirmed by dynamic frequency scan. The stiffness of the gel formed seems to be buffer and 
concentration dependent based on comparisons of G and G, and the tangent of the phase 
angle. 
In vitro release experiments were performed to determine whether the antigen can be 
released from the hydrogel and if they are still stable after release. PA released after 1.5 hr of 
interaction time with first the precursor and then the in-situ formed hydrogel were collected, 
and subjected to structural analyses and functionality testing. Results showed minimum 
structural perturbation of released rPA and BSA, with PA being also functional stable as 
determined by macrophage toxicity assay.  
Protein release profiles were examined using fluorescence labeled proteins. The 
release profiles were precursor concentration dependent. However, no significant difference 
was observed with each protein at early time points. At each gel concentration tested, rPA 
seems to have a faster release than BSA, and nearly complete release was observed after 24 
hrs for PA released from gel at 0.2% w/v concentration. In-vivo release was expected to be 
faster due to the presence of hydrolytic enzymes at mucosal surfaces that could cause 
degradation of the peptide and the gel structure. All in vitro result have demonstrated that the 
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in-situ formed hydrogel formulation was suitable for vaccine delivery, even with 
reconstituted powder formulation.  
The precursor concentration of 0.6% w/v was selected for an initial efficacy study in 
rabbits due to the formation of stronger gel in-vitro while maintaining solubility for 
reconstituted powder component. However, a decreased systemic immune response was 
observed as indicated by results from ELISA and toxin neutralization study. These results 
can be explained by proposing several mechanisms, namely, formation of a slow-release 
formulation and/or a rapid clearance mechanism. Further experiments are required before any 
conclusion can be drawn. Nonetheless, further optimization of the formulation and device is 
may lead to a successful of this hydrogel formulation.  
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Figure 3.1 Schematic illustration of the made up of mucin fiber. 
Three mucin monomers cross-linked by disulfide bonds, ionic interaction and non-covalent 
interaction. (Modified from Quraishi, M.S. et al., Clin. Otolaryngol. 1998, 23, 403-413) 
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Figure 3.2 Schematic depiction of nasal mucus double layers. 
(Modified from Quraishi, M.S. et al., Clin. Otolaryngol. 1998, 23, 403-413) 
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Figure 3.3 Stress and strain phase diagrams of pure solid and liquid material in oscillatory 
tests. 
Where: 0 = amplitude of stress; 0 = amplitude of strain;  = phase lag; G= storage modulus 
(elastic modulus) and; G = loss modulus (viscous modulus).  
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Figure 3.4 Purification of Nap-FFY(P).  
A-B). HPLC trace of crude product, C) Mass spectrum of the purified final product.  
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Figure 3.5 In-vitro examination of enzymatic hydrogel formation.  
A). In-vitro hydrogel formation in 200µl PBS containing Nap-FFY(P) 0.1% w/v , 40U CIP 
(left), 50U BAP (right).  
 
B). In-vitro hydrogel formation in 200µl 250mM Tris containing Nap-FFY(P) 0.1% w/v, 
40U CIP 
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Figure 3.6 Hydrogel formation with SFD formulations. 
i). Hydrogel formation in 200µl PBS, Nap precursor (added in 50µl DMSO): 0.2% w/v, 
BAP: 10µl@5U/µl.  
 
ii). Hydrogel formation in 200µl 250mM Tris, Nap precursor 0.2% w/v, CIP: 4µl @10U/µl. 
 
 
From left to right:  
A. Trehalose; B. C48/80 formulation; C. rPA formulation; D. precursor control no enzyme. 
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Figure 3.7 SEM images of dried hydrogel sample formed with SFD rPA formulation  
(see Figure 3.6, i-C) 
A). Fibril Structure of the Hydrogel. 
 
B). Trehalose precipitates during lyophilization 
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Figure 3.8 AFM image of the dried hydrogel.  
A) Height trace,  
 
B) 3D look of the gel. 
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Figure 3.9 Far-UV CD spectra of the control and released protein solutions (T=25°C). 
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Figure 3.10 Functional stability of rPA after release from hydrogel.  
A). Activity of PA released from PBS Gel*  
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B). Activity of PA released from Tris Gel*  
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*:   PA was collected from the released media of PBS or Tris based hydrogel 
 PA was collected from PBS or Tris buffer only solution 
▲ PA standard is used 
▼Release media collected from PBS or Tris based hydrogel without addition of PA 
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Figure 3.11 Release profiles for rPA and BSA at different hydrogel concentrations. Data 
shown: mean ± SD, n=3. 
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0.2% w/v Tris gel release 
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Figure 3.12 Rheometer with cone/plate geometries.  
(The tip of the cone is truncated and the gap corresponding to this truncation is set).   
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Figure 3.13 Rheology properties of the Tris-based hydrogel. 
A). 0.6% Frequency Sweep of Hydrogel Precursor w/o CIP. 
 
B). 0.6% Frequency Sweep of Hydrogel with addition of CIP. 
 
C). Time Sweep to examine gel formation at 2 rad s
-1
, 1.0% strain.  
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Figure 3.14 Concentration dependency of hydrogel rheological properties.  
Data shown: mean ± SD, n=3.  
A). Concentration dependence of storage and loss modulus at frequency of 1.995 Hz 
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B). Tangent delta values at different gel conc. 
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Figure 3.15 Rheological synergy of mucin and hydrogel mixture. 
A). Frequency Sweep of 4% Mucin.  
 
 
B). Frequency sweep of 4% mucin and 0.6% hydrogel precursor mixture without CIP. 
 
C). 4% mucin & 0.6% hydrogel mixture with addition of CIP. 
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D). Combined frequency sweeps demonstrating rheological synergism of 4% mucin and 
0.6% hydrogel mixture 25°C (including Figure 3.14-A,C and Figure 3.12-B).  
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Figure 3.16 The effect of temperature on mucin hydrogel interaction. 
A). Frequency sweep of 4% Mucin at 25°C or 37°C.  
 
B). Frequency sweep of 0.6% hydrogel precursor with CIP at 25°C or 37°C  
 
C). Frequency sweep of 0.6% hydrogel and 4% mucin mixture at 25°C or 37°C.  
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Figure 3.17 In vivo determination of hydrogel efficacy-serum ELISA results. 
A) day 7 seropositive results, B) day 35 serum anti-rPA IgG GMT titers, C) day 56 serum 
anti-rPA IgG GMT titers. A one-way ANOVA followed by Tukey‟s post test were performed 
on log2 transformed ELISA titer. A statistical significance was revealed between the gel 
groups and other liquid groups (n=4, *, p < 0.05). Data are presented as ELISA titers with 
geometric mean.  
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Figure 3.18 In vivo determination of hydrogel efficacy serum toxin neutralization results: A) 
day 35 serum LeTx NT50 titer, B) day 56 serum LeTx NT50 titer. 
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Figure 3.19 The solution of reconstituted SFD powder-hydrogel combined formulation can 
be dispersed into a plume of droplets using PennCentury Microsprayer
TM
.  
A). Image of spray plume produced by reconstituted SFD powder-hydrogel formulation 
(75mg/ml SFD powder containing 0.2% w/v hydrogel precursor).  
B). Particle size distribution of the spray.  
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Figure 3.20 Mucosal tolerance and immune exclusion are two major defense mechanisms in 
the mucosal membrane. 
(modified from Xiao, BG et al. Clin Immunol Immunopathol. 1997, 85(2), 119-28)  
 
  
193 
 
Table 3.1Qualitative determination of ALP activity in rabbit nasal cavity. 
Concentration of substrate 0mM 0.01mM 0.3mM 1mM 3mM 10mM 
Ratio of absorbance at 
405nm 
(Nasal Wash vs. p-NPP in 
PBS) 
1.2 1.2 1.3 1.3 1.0 2.5 
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Table 3.2 Buffer dependent hydrogel formation. 
Buffer type & concentration vs Gel Formation 
(Buffer volume 100 µl, Nap-FFY(P) 0.2% w/v, CIP 2µl @ 10U/µL) 
PBS (mM) 
   
75 150 300 750 
    
P G-P G G 
Tris (mM) 10 25 50 62.5 125 250 500 
 
P G-P G G G G G 
HEPES (mM) 
 
25 31 
 
125 
 
500 
  
P G-P 
 
G-P 
 
G-S 
 
P Precursor precipitates out  
G-P Transition from gel to precipitation  
G Hydrogel Formation  
G-S Transition from gel to solution phase  
 
 
  
Increase 
gel 
stiffness 
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Table 3.3 Examination of rheology synergism of mucin-precursor and mucin-gel mixture. 
 
mucin precursor 
mucin-
precursor mix Synergism) 
G' 0.16 0.0319 79.21 79.02 
G" -0.06 0.08 19.72 19.70 
 
 
2.64 0.25 
 
     
     
 
mucin hydrogel mucin-gel mix 
Synergism) 
G' 0.16 566 6679 6113 
G" -0.06 72 1159 1087 
 
 
0.13 0.17 
 
 
  
 
 
 
4 CONCLUSIONS AND FUTURE WORK 
  
4.1 Conclusions  
Anthrax has been a disease of herbivores, and rarely infects human. Current 
biodefense interest in inhalational anthrax has been the impetus for anthrax vaccine research, 
which arose from the incidence of the intentional release of anthrax spores in 2001 through 
the US postal system shortly after 9/11. Inhalational anthrax is difficult to diagnose and can 
be deadly (nearly 100% fatality) without prompt antibiotic intervention; therefore, 
prophylactic vaccination is critical to individuals at risk of exposure or in the case of 
intentional mass exposure. Due to the shortcomings that are associated with current licensed 
acellular culture supernatant human vaccines, efforts have been made to develop alternative 
vaccines in regards to improvement in dosing schedule, immunogenicity, safety and 
pharmaceutical consistency
33
. The non-toxic PA has been identified as the primary 
immunogenic molecule and is known for its ability to elicit a protective immune response. 
Second generation anthrax vaccine based on recombinant PA have shown promising results 
in rabbits and nonhuman primates and have been under clinical investigation for IM 
administration. Several phase I trials have demonstrated the safety and immunogenicity of 
PA based vaccines from a recombinant source
37, 38
. However, the optimal formulation, 
vaccination schedule and demonstration of non-inferiority with AVA remain to be 
established. Better adjuvant and delivery systems are still desired to improve the 
immunogenicity and efficacy of rPA based vaccines. CpG ODN has been added to AVA to 
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improve the immune response and was demonstrated to be an effective adjuvant in 
experimental animals. However, the use of CpG ODN in human is likely to be limited due to 
the increased adverse effects reported in a Phase I study in humans in spite of its ability to 
enhance the immune response. A novel mast cell activator C48/80 has been demonstrated to 
be an effective mucosal adjuvant for PA based vaccine in a mice model
294
, while this 
dissertation project involves the evaluation of its adjuvant activity in a larger animal model, 
in this case rabbits. Intranasal immunization is known to elicit mucosal immunity in the site 
of vaccination as well as in the lungs
295-297
, and has been demonstrated to be an effective 
route for administrating vaccines against pulmonary anthrax infection
39, 111
. Intranasal 
immunization not only offers the advantages of non-invasive administration with the 
possibility of self-administration, but also allows flexibility with the formulation of vaccine. 
In the present study, a dry powder, a novel in-situ formed hydrogel formulation and a 
combined formulation have been evaluated (i) for their compatibility with the proposed rPA 
and C48/80 vaccine components, (ii) their ability to facilitate nasal immunization, (iii) 
storage stability as an effort to develop best possible next generation anthrax vaccine.  
It was proposed that C48/80 would be compatible with rPA when formulated in a dry 
powder formulation and effective as a mucosal adjuvant for rabbit nasal vaccination. Dry 
powder formulation of rPA and C48/80 with trehalose would offer great stability of both the 
vaccine components.  In situ formed hydrogel formulation is suitable as delivery system for 
nasal delivery of the rPA-based vaccine. The dry powder and hydrogel combined formulation 
can be prepared and delivered via simple liquid delivering devices while maintaining 
sufficient residence time for desirable immune response. These hypotheses were addressed 
by the following specific aims. The outcomes are summarized below.  
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1. To prepare and evaluate the compatibility of adjuvant and rPA in a dry powder 
formulation with trehalose and demonstrate its effectiveness in eliciting immune response in 
rabbits after nasal vaccination.  
Trehalose was selected as a bulking agent and cryoprotectants. It is also known for its 
ability to stabilize proteins under temperature or drying induced stress conditions. In 
addition, its stabilizing effect has been reported in a dry powder formulation of rPA with 
CpG ODN. SFD process has been previously optimized with trehalose to produce particles in 
different size distributions. The present study adopted the SFD condition for produce 
particles with target a median diameter of 25µm for nasal vaccine delivery in rabbits. Particle 
size distributions of the SFD particles were examined by laser diffraction. Results showed 
that addition of varying amount of rPA (0, 0.067%, 0.2% wt/wt) and C48/80 (0.8%, 1%, 
1.2%, 2.4% wt/wt) to the bulk trehalose have lead to slight particle size deviation from the 
target size as indicated by the difference  in D50 which appears to be in the range of 
(20.15µm-28.32µm). The moisture content of these SFD particles was below 5%, which did 
not seem to affect the glass transition temperature of the bulking agent-trehalose very much 
(~100-120°C). The high Tg values of the SFD powders indicates the potential for room 
temperature storage, and would also allow for temperature fluctuation during transportation. 
Nearly complete delivery was observed when these low density porous spherical particles 
were delivered using Unitdose powder device (Pfeiffer GmbH, Germany), with or without 
the fitted tip. The similarity between the particle size distribution of the powder particles in 
air and in mineral oil suspension indicates good dispersion properties of the powders and 
dispersion efficiency of the device.   
199 
 
It is known that structural properties of proteins are closely correlated to their 
biological activity and stability. Two complimentary spectroscopic techniques, ATR-FTIR 
and CD, were used to monitor the possible protein secondary structure change due to the 
manufacturing process and storage, the results of which confirmed the structural stability of 
PA in the SFD formulation. Furthermore, the SDS and Native PAGE showed that rPA in the 
SFD formulation was keeping its integrity and free of aggregation.  
The biological functions of the adjuvant and antigen have allowed characterization of 
their functional stability in-vitro with cell-based assays. The SFD formulations containing 
C48/80 showed a highest mast cell degranulation activity of about 30% at 2.0 mg/ml. Their 
activities were comparable to C48/80 control before SFD process at other concentration 
dilutions. The macrophage toxicity assay has been a useful tool for us to monitor the 
functional stability of PA after formulation, manufacturing process and storage. The SFD 
rPA formulation prepared and stored for 2 years and the freshly prepared SFD rPA 
formulation were comparable to PA standards stored in -80°C refrigerator, all of which had 
LC50 values of PA/LF concentration between 0.0469 and 0.0938 µg/ml. These results suggest 
that the SFD process and subsequent storage did not affect the functional activity of the 
antigen and adjuvant which corresponds well with the physicochemical characterization of 
the powders.  
With confirmed in-vitro stability of the powder formulation, animal studies in rabbits 
were carried out to examine the in-vivo efficacy of the powder vaccines was tested. For the 
pilot study, three groups rabbits were vaccinated, with intranasal administration of liquid 
formulations containing rPA alone, rPA and adjuvant, and the SFD powder vaccines 
delivered as reconstituted liquid. No seroconversion was observed after a single 
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immunization. After the 2rd immunizations, serum ELISA of the adjuvanted liquid groups 
showed significant higher antibody titer than the liquid formulation containing rPA alone, 
while a significant functional titer was also observed in serum toxin neutralization assay after 
the 3
rd
 immunization, suggesting that the novel mast cell activator C48/80 is indeed an 
effective mucosal adjuvant in rabbit. In addition, results from the initial animal study 
suggested that the reconstituted powder formulation is comparable to freshly prepared liquid 
vaccines in eliciting systemic immune response. Although the two adjuvanted groups did not 
show significant difference between each other, the lower titer in the reconstituted powder 
group could be due to the interaction with trehalose, as slight depression of the PA activity 
was also observed in the in-vitro macrophage toxicity assay of the liquid groups containing 
rPA and C48/80 with addition of trehalose (Figure 2.13).  
A second animal study was performed to further examine the powder vaccine efficacy 
using a Unitdose powder device. Results with serum ELISA and toxin neutralization studies 
confirmed the effective adjuvant activity of C48/80. Similar to IM injection of rPA and 
C48/80, powder vaccines were effective for an early induction of antigen specific serum anti-
body response after only a single immunization. Additional, after the 2
nd
 and 3
rd
 
immunizations, the systemic immune responses elicited by freshly prepared powder vaccines 
and powders stored at room temperature for more than 2 years were comparable to the 
freshly prepared liquid formulation for IM injection in terms of the magnitude of the ELISA 
and functional titers. Positive results from this study not only agree with the current 
hypothesis that C48/80 is an effective mucosal adjuvant, but also support the use of mast cell 
activators as a new class of adjuvants. Dry powder formulation with trehalose seems to be 
suitable for the rPA and C48/80 combination, and is superior to liquid formulation in terms 
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of the immune response elicited and storage stability, which could have significant 
implication as a potential stable and affordable formulation alternative for other vaccines. 
This is the first report of a recombinant protein vaccine formulation to have significant in-
vivo efficacy after over 2 years of room temperature storage. 
Additional storage stability studies were performed with SFD rPA formulations at 
different temperatures and relative humidities. It has been reported in the literature that the 
storage stability of a protein formulation can be determined by the physical properties of a 
protein, for example size exclusion HPLC can be used to monitor the monomeric content of 
rPA upon storage
111
. In the present study, we attempted to monitor the functional stability of 
the vaccine by macrophage toxicity assay. The results demonstrated the improved vaccine 
storage stability provided by the powder formulation compared to liquid formulation. 
However, this stability is only made possible under conditions with limited moisture uptake. 
Elevated humidity levels for storage would lead to increased moisture uptake, which 
ultimately affect the rate of degradation. 
2. To evaluate the compatibility of the peptide-based in-situ hydrogel as a nasal vaccine 
delivery system. 
Dry powder formulation of anthrax vaccines have shown to be a great improvement 
to the liquid vaccine formulation. However the dry powder formulation is very moisture 
sensitive and requires a special powder device for effective and efficient delivery to the nasal 
cavity. As a consequence, the cost of powder device can be a drawback for the powder 
formulation in the developing world or in the case of an outbreak. A novel in-situ formed 
hydrogel formulation is proposed as a solution to the potential drawback of powder vaccines, 
which would not only allow the vaccines to be stored as dry powders, but also can be 
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delivered as reconstituted liquid using a simple liquid pump at the time of usage. Unlike the 
conventional simple liquid formulation, the addition of hydrogel precursor to the 
reconstituted liquid would facilitate instant formation of a hydrogel upon contact with nasal 
mucosa. As a result, this increase in viscoelastic property would ultimately increase the nasal 
residence time. A powerful hydrogel precursor that was a phosphatase substrate (Nap-
FFY(P)) was selected from the literature to test the current hypothesis of its potential 
application as a nasal delivery system. Alkaline phosphatase activity was confirmed in rabbit 
nasal cavity using a classical substrate p-NPP. The hydrogel precursor was successfully 
synthesized by manual solid phase peptide synthesis, which structure was confirmed by mass 
spectrometry. Results of in-vitro hydrogel formation experiment were encouraging. Non-
specific enzymes, either CIP or BAP, can be effective for the enzymatic conversion, 
suggesting the likelihood of precursor conversion by nonspecific alkaline phosphatases 
present in the human or rabbit airway mucosa, e.g. ecto 5′-nucleotidase and alkaline 
phosphatase
222
. The minimum precursor concentration for hydrogelation can be as low as 
0.1% in PBS or Tris buffer, suggesting a powerful hydrogelator. Gel formation appears to be 
buffer type and concentration dependent, as they govern the solubility of the precursor and 
formation of hydrogel or aggregate precipitation. Hydrogel can still form in the presence of 
reconstituted SFD powder formulation upon enzymatic conversion. Hydrogel formation was 
confirmed by visual examination with inverted vial method. SEM and AFM images of the 
freeze-dried hydrogel sample confirmed the fibril structure formation, and pore size (meshing 
spacing) appears to be in the range of 100-500nm which would allow free diffusion of the 
protein.  
203 
 
Dynamic mechanical analysis has allowed further characterization of the hydrogel 
using a cone and plate rheometer. Time sweep study showed an immediate separation of G 
and G suggesting hydrogel formation is instant. The storage modulus G  dominating loss 
modulus G viscoelastic property was observed in the dynamic frequency scan, confirming 
the viscoelastic properties of the hydrogel. The stiffness of the gel formed is concentration 
dependent, increasing concentration resulted in exponential increase in dynamic modulus.  
The tangent of the phase angel is between 0.1-0.2 for the gel precursor concentration tested 
which is similar to values obtained for natural tissue and is another illustration of viscoelastic 
properties of the enzyme converted hydrogel. 
Release studies from the hydrogel were performed to monitor the time profile of the 
protein release and the stability of the release protein. A maximum of ~90% cumulative 
release of rPA was observed from the gel formed by 0.2% w/v precursor concentration after 
24 hrs using fluorescence labeled protein. The total amount of protein released is inversely 
proportional to the hydrogel precursor concentration, which is likely due to the different 
density of hydrogel formed. However, this effect of different hydrogel concentration on 
protein release profile did not seem to be evident at early time points, yet the protein release 
profile seems to be rather dependent on properties of individual protein. Structure and 
functional stability of released PA was confirmed in the same manner as described 
previously by CD and macrophage toxicity assay. All the in vitro results confirmed the 
hypothesis that in-situ formed hydrogel formulation is a suitable for nasal vaccine delivery, 
even with reconstituted powder formulation.  
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3. To evaluate the in-vivo effectiveness of in-situ formed hydrogel as a vaccine delivery 
system in eliciting systemic immune responses after nasal vaccination of rPA and C48/80 in 
rabbits.  
Vaccine formulations containing either freshly prepared rPA and C48/80, or 
reconstituted from freshly prepared powder (stored > 6 months) were prepared in the 
presence of 0.6% hydrogel precursor in 250mM Tris buffer. The precursor concentration was 
selected to obtain a maximum mucoadhesive behavior while maintaining good solubility of 
all the components. The hydrogel formulations were delivered to rabbit nasal cavity by 
instillation with a handheld pipette. Blood sample were collected and examined for systemic 
anti-rPA IgG response, as well as functional antibody titer. Results were compared among 
different formulation groups including nasal liquid formulation controls and IM controls. 
However, a significant lower systemic immune response was observed after the 2
nd
 and 3
rd
 
immunizations, as indicated by results from ELISA and toxin neutralization study. The 
suppression of systemic immune response can be explained by several possible mechanisms, 
i.e. upon contact in the nasal cavity, a high density “super” gel is formed due to interaction 
between hydrogel and mucin mixture, resulting in limited diffusion or slow-release of the 
rPA, hence the antigen uptake and presentation was inadequate. Otherwise, a rapid clearance 
mechanism could be in play. Further experiments are required before any conclusion can be 
drawn. Nonetheless, the positive results from in-vitro experiments presented in this thesis 
research are promising, and grants further investigation in regards to the formulation and 
delivery device. The prospect of effective, stable, affordable powder and hydrogel combined 
formulation as an IN vaccine delivery system has the potential to expand the use of the IN 
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vaccination route and improve the outcomes in mass vaccination programs resulting in 
substantial health and economic benefits.  
4.2 Extensions, improvements and future work 
The results in this thesis provided further support to the novel vaccination approach 
combining the dry powder formulation and the IN delivery platform. This research has also 
explored an in-situ enzyme-triggered hydrogel formulation as a novel delivery system for 
nasal vaccine delivery, which also has the potential for its application to small molecule drug 
delivery to the nasal cavity. There are some natural extensions to this work that would help 
expand and strengthen the results, and some future works are needed to fully interpret the 
outcome of the in vitro and in vivo studies. 
4.2.1 Dry powder vaccine formulation 
Dry powder vaccine formulation was prepared by spray-freeze-drying. The frozen 
droplets were dried using a manifold style lyophilizer, which doesn‟t have the capability of 
controlling shelf or product temperature. The product volume and the size of the jar would 
affect heat transfer between the surrounding environment and the product. Depending on 
where the frozen droplets are positioned in the container, a difference in product temperature 
could occur. The temperature of the frozen droplets closer to the container wall would rise 
faster, which would result in the formation of a product in sticky a rubbery state instead of 
the desired glassy state. Powders in a rubbery state would have a high mobility which could 
affect protein stability, and the stickiness of the powders would affect its delivery efficiency. 
One solution would be utilization of a shelf lyophilizer which offers control over product 
temperature for primary and secondary drying. In general, for primary drying the condenser 
temperature should be held 20°C lower than the product. The product temperature depends 
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on the shelf temperature, the vacuum which ultimately determines the rate of sublimation, 
and should be carefully determined based on the Tg and Tcol of the protein solution (note the 
Tcol of a trehalose solution has been reported to be -29°C and -34°C)
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 in order to design a 
robust lyophilization cycle. However, such lyophilizer may not be available in the university 
setting, the volume of the frozen product and size of the container can be optimized in the 
future for better product consistency and property. In addition, insulation of the container or a 
temperature control systems can be utilized for better temperature control of the products.  
In the present thesis, the secondary structure and aggregation state of rPA after were 
only characterized in a qualitative way. It would be interesting to examine quantitatively to 
what extent the structural change/aggregation state might interfere with PA‟s functional 
activity, or vice versa. A forced degradation study accompanied with secondary structure 
examination and measurements of functional activity of PA using macrophage toxicity assay 
should be able to establish a correlation between protein physical property and its biological 
properties. The information obtained from the correlation profile should facilitate future 
stability monitoring using simple spectroscopic techniques and offer great benefit in terms of 
saving both resources and time. Similarly, the effect of moisture uptake on rPA stability in 
the SFD powder can be determined.  
The trehalose based SFD formulation is very moisture sensitive. Care must be taken 
throughout powder handling and packaging process to prevent moisture uptake. One solution 
is to coat the particle with the potential to enhance their stability, viability and flowability. 
Fluid bed dry coating is a new method for encapsulating water sensitive material, with the 
advantages of high coating yield and energy saving in addition to the non-wetting of the 
product in comparison with the classical aqueous coating system. Due to its beneficial 
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properties, this technology has been applied or has the potential to be applied to many 
industries, agriculture, chemical, pharmaceutical and food. There are three main mechanisms 
to dry coating (Figure 4.1). Hot melt coating involves the use of molten materials such as 
solid fats, waxes and some polymers to provide a shell with very good barrier properties 
against water vapor. This approach offers many benefits, but may not be practical for heat 
sensitive biological products, unless a wax with low melting point is used. Dry particle 
coating requires relative large host particle size and the bonding strength due to the 
mechanical forces can be weak between the guest and the host particles. Finally, dry coating 
can be achieved by fixing fine particles on the core using a non-aqueous binder or a 
plasticizer instead of the mechanical forces
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. The hot melt coating and the dry coating with 
plasticizer seem to be two reasonable approaches for the current SFD product, and can be 
explored in the future especially when mass vaccine production is desired.  
4.2.2 In-situ formed hydrogel formulation  
In the current thesis, the qualitative of alkaline phosphatase in-vivo in the rabbit nasal 
cavity, along with the in-vitro assessments of hydrogel formation of the Nap-FFY(P) 
precursor upon enzymatic conversion by phosphatases, offer strong implications of 
enzymatic hydrogel formation upon contact in nasal cavity in-vivo. However, the hydrogel 
formation in-vivo remains to be confirmed. Direct visual examination of hydrogel formation 
requires surgical incision of the nasal cavity, which can be invasive and difficult to perform 
due to the hardness of rabbit skull. A less invasive method for visual examination would be 
to perform a nasal endoscopy which is known for its application in rabbits in veterinary 
medicine. A nasal residence time study using gamma scintigraphy would not only provide an 
alternative way to assess the hydrogel formation in-vivo indirectly, but also facilitate explaining 
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the questions arose from the animal study: whether the decreased systemic immune response is a 
result a slow-release or a rapid clearance mechanism of the hydrogel formulation. 
On the other hand, the initial induction of serum anti-PA specific IgG titer after a 
single immunization suggests mucosal tolerance or immune exclusion could have occurred. 
Mucosal tolerance is a state of peripheral immunological tolerance which has been utilized to 
prevent and treat autoimmune diseases. It has been shown that mucosal tolerance is more 
effective after nasal compared to oral administration of antigens at the same dose
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. One 
way to confirm this hypothesis is to perform a systemic challenge of the antigen (e.g. IM 
administration of rPA) after the 3
rd
 nasal immunization, and study the systemic serum-
antibody response. Confirmation of mucosal tolerance will imply that hydrogel formulation 
is not suitable for vaccine delivery. However, if confirmed, the result would suggest that 
hydrogel delivery system might be still be useful for the treatment of autoimmune disease 
through nasal mucosa in which situation mucosal tolerance has been indicated to be 
beneficial. A nasal lavage study would also help to interpret the result, a positive mucosal 
IgA response, would support the mucosal tolerance or immune exclusion hypothesis.  
In the animal study described to evaluate the efficacy of hydrogel formulation in-vivo, 
only one hydrogel precursor concentration was tested. For future studies, different precursor 
concentration (0.1%, 0.2%, 0.4% w/v), and volume can be optimized for best in-vivo results. 
Furthermore, a correlation profile between the in-vitro release properties and the in-vivo 
results can be established, which will provide mechanistic insight in regards to the optimal 
absorption window for nasal vaccine delivery. Instead of bulk delivery of the precursor 
solution with a pipette, a liquid spray device should be used for better spreading and coating 
of the formulation within the nasal cavity. A single dose nasal pump/device that does not 
require priming, would be optimal for current vaccine delivery purposes.  
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As mentioned in previous chapters, the hydrogel precursor can be designed to be 
responsive for other enzymes. Since esterase is another common enzyme present on the nasal 
mucosa, hydrogel precursors that are substrate for esterase can also be examined for in-situ 
hydrogel formation in-vivo, providing an alternative plan to current specific aims. In 
addition, this in-situ form hydrogel delivery system provides a novel platform for other 
routes of vaccine delivery, such as tonsilar immunization, mucosal vaccination through the 
female reproductive tract as well as transdermal vaccination. Furthermore, present 
observations with the in-situ formed hydrogel formulation may be useful for developing 
mucoadhesive formulations for small molecular drug delivery.  
4.3 Summary of Significance and Achievements 
In summary, the work described in this thesis made the following contributions:  
A stable, effective dry powder formulation was prepared for nasal delivery of rPA-
based anthrax vaccine. It is the first time to demonstrate long term room temperature storage 
stability (over 2 years) with rPA-based vaccine products, which again reinforcing the 
advantage of dry powder preparation of subunit vaccine. The lab-scale SFD preparation of 
dry powder was able to preverve both the antigen and adjuvant activity at the same time, and 
was successfully used to produce dry powder particles for suitable for direct nasal 
application. Positive results from current animal study not only support the use of mast cell 
activator as mucosal adjuvants in a large animal model, in this case rabbit. It is further 
demonstrated that dry powder formulation of rPA and C48/80 was able to elicit a quick and 
effective immune response. In addition to its excellent room temperature stability, this dry 
powder formulation strategy would support its use for stock piling in case of the need for 
mass vaccination.  
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An in-situ formation of enzyme-responsive hydrogel was proposed and evaluated for 
the first time for nasal vaccine delivery. In vitro studies showed that the hydrogel formulation 
is suitable for antigen delivery of rPA, and suggested strong mucoadhesive behavior in vivo 
given successful enzymatic conversion. However, further experiement is required to identify 
the optimal conditions for desired application, for instance, different routes of application 
(nasal, tonsilar, female reproductive tract) or mucosal immunity vs. mucosal tolerance. The 
combination of dry powder and in-situ formed hydrogel formulation would allow the vaccine 
to be stored as a dry powder, but delivered as reconstituted liquid using a simple liquid pump. 
This combined formulation would be an improvement to the dry powder formulation, which 
would not only provide more dosing flexibilities but may also have better patient compliance 
than direct nasal application of dry powder. This powder-hydorgel combination seems to be 
feasible as a nasal product, and provides a new vaccination strategy for nasal delivery of 
soluble antigen. 
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Figure 4.1 Principles of different dry coating approaches. 
(Modified from Ivanova, E. J. Food Eng., 2005, 71(2), 223-230) 
A). Solvent and hot-melt, B). Dry particle coating, C). Use of plasticizer.  
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